Cover
Cover - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Feb. 16, 2024 | Jun. 30, 2023 | |
Cover [Abstract] | |||
Document Type | 10-K | ||
Document Annual Report | true | ||
Document Period End Date | Dec. 31, 2023 | ||
Current Fiscal Year End Date | --12-31 | ||
Document Transition Report | false | ||
Entity File Number | 1-16137 | ||
Entity Registrant Name | INTEGER HOLDINGS CORPORATION | ||
Entity Incorporation, State or Country Code | DE | ||
Entity Tax Identification Number | 16-1531026 | ||
Entity Address, Address Line One | 5830 Granite Parkway, | ||
Entity Address, Address Line Two | Suite 1150 | ||
Entity Address, City or Town | Plano, | ||
Entity Address, State or Province | TX | ||
Entity Address, Postal Zip Code | 75024 | ||
City Area Code | 214 | ||
Local Phone Number | 618-5243 | ||
Title of 12(b) Security | Common Stock, Par Value $0.001 Per Share | ||
Trading Symbol | ITGR | ||
Security Exchange Name | NYSE | ||
Entity Well-known Seasoned Issuer | Yes | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Interactive Data Current | Yes | ||
Entity Filer Category | Large Accelerated Filer | ||
Entity Small Business | false | ||
Entity Emerging Growth Company | false | ||
ICFR Auditor Attestation Flag | true | ||
Document Financial Statement Error Correction [Flag] | false | ||
Entity Shell Company | false | ||
Entity Public Float | $ 2,915 | ||
Entity Common Stock, Shares Outstanding (in shares) | 33,404,740 | ||
Documents Incorporated by Reference | Portions of the following document are specifically incorporated by reference into the indicated parts of this report: Document Part Proxy Statement for the 2024 Annual Meeting of Stockholders (which shall be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates) Part III, Item 10 “Directors, Executive Officers and Corporate Governance” Part III, Item 11 Part III, Item 12 Part III, Item 13 Part III, Item 14 | ||
Entity Central Index Key | 0001114483 | ||
Amendment Flag | false | ||
Document Fiscal Year Focus | 2023 | ||
Document Fiscal Period Focus | FY |
Audit Information
Audit Information | 12 Months Ended |
Dec. 31, 2023 | |
Auditor Information [Abstract] | |
Auditor Name | Deloitte & Touche LLP |
Auditor Location | Williamsville, New York |
Auditor Firm ID | 34 |
CONSOLIDATED BALANCE SHEETS
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Current assets: | ||
Cash and cash equivalents | $ 23,674 | $ 24,272 |
Accounts receivable, net of provision for credit losses of $0.4 million and $0.3 million as of December 31, 2023 and 2022, respectively | 238,277 | 224,325 |
Inventories | 239,716 | 208,766 |
Refundable income taxes | 1,998 | 2,003 |
Contract assets | 85,871 | 71,927 |
Prepaid expenses and other current assets | 28,132 | 27,005 |
Total current assets | 617,668 | 558,298 |
Property, plant and equipment, net | 407,954 | 317,243 |
Goodwill | 1,011,007 | 982,192 |
Other intangible assets, net | 783,146 | 819,889 |
Deferred income taxes | 7,001 | 6,247 |
Operating lease assets | 81,632 | 74,809 |
Financing lease assets | 11,828 | 8,852 |
Other long-term assets | 22,417 | 26,856 |
Total assets | 2,942,653 | 2,794,386 |
Current liabilities: | ||
Current portion of long-term debt | 0 | 18,188 |
Accounts payable | 120,293 | 110,780 |
Income taxes payable | 3,896 | 10,923 |
Operating lease liabilities | 8,692 | 10,362 |
Accrued expenses and other current liabilities | 88,088 | 73,499 |
Total current liabilities | 220,969 | 223,752 |
Long-term debt | 959,925 | 907,073 |
Deferred income taxes | 145,625 | 160,671 |
Operating lease liabilities | 72,339 | 64,049 |
Financing lease liabilities | 10,388 | 8,006 |
Other long-term liabilities | 14,365 | 13,379 |
Total liabilities | 1,423,611 | 1,376,930 |
Commitments and contingencies (Note 13) | ||
Stockholders’ equity: | ||
Preferred stock, $0.001 par value, authorized 100,000,000 shares; no shares issued or outstanding as of December 31, 2023 and 2022 | 0 | 0 |
Common stock, $0.001 par value; 100,000,000 shares authorized; 33,329,648 and 33,169,778 shares issued and outstanding as of December 31, 2023 and 2022, respectively | 33 | 33 |
Additional paid-in capital | 727,435 | 731,393 |
Retained earnings | 771,351 | 680,701 |
Accumulated other comprehensive income | 20,223 | 5,329 |
Total stockholders’ equity | 1,519,042 | 1,417,456 |
Total liabilities and stockholders’ equity | $ 2,942,653 | $ 2,794,386 |
CONSOLIDATED BALANCE SHEETS (Pa
CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Millions | Dec. 31, 2023 | Dec. 31, 2022 |
Current assets: | ||
Allowance for doubtful accounts | $ 0.4 | $ 0.3 |
Stockholders’ equity: | ||
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized (in shares) | 100,000,000 | 100,000,000 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, shares authorized (in shares) | 100,000,000 | 100,000,000 |
Common stock, shares issued (in shares) | 33,329,648 | 33,169,778 |
Common stock, shares outstanding (in shares) | 33,329,648 | 33,169,778 |
CONSOLIDATED STATEMENTS OF OPER
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Income Statement [Abstract] | |||
Sales | $ 1,596,673 | $ 1,376,096 | $ 1,221,079 |
Cost of sales | 1,178,384 | 1,017,090 | 884,109 |
Gross profit | 418,289 | 359,006 | 336,970 |
Operating expenses: | |||
Selling, general and administrative | 175,619 | 160,578 | 141,418 |
Research, development and engineering | 63,771 | 60,918 | 51,985 |
Restructuring and other charges | 11,569 | 16,183 | 7,856 |
Total operating expenses | 250,959 | 237,679 | 201,259 |
Operating income | 167,330 | 121,327 | 135,711 |
Interest expense | 53,370 | 38,632 | 31,628 |
Loss on equity investments, net | 5,691 | 7,636 | 3,143 |
Other (income) loss, net | 975 | (899) | (123) |
Income from continuing operations before income taxes | 107,294 | 75,958 | 101,063 |
Provision for income taxes | 16,644 | 10,608 | 8,043 |
Income from continuing operations | 90,650 | 65,350 | 93,020 |
Discontinued operations: | |||
Income from discontinued operations before income taxes | 0 | 1,323 | 4,931 |
Provision for income taxes | 0 | 296 | 1,143 |
Income from discontinued operations | 0 | 1,027 | 3,788 |
Net income | $ 90,650 | $ 66,377 | $ 96,808 |
Basic earnings per share: | |||
Income from continuing operations (in dollars per share) | $ 2.72 | $ 1.97 | $ 2.82 |
Income from discontinued operations (in dollars per share) | 0 | 0.03 | 0.11 |
Basic earnings per share (in dollars per share) | 2.72 | 2 | 2.93 |
Diluted earnings per share: | |||
Income from continuing operations (in dollars per share) | 2.69 | 1.96 | 2.80 |
Income from discontinued operations (in dollars per share) | 0 | 0.03 | 0.11 |
Diluted earnings per share (in dollars per share) | $ 2.69 | $ 1.99 | $ 2.91 |
Weighted average shares outstanding: | |||
Basic (in shares) | 33,320 | 33,127 | 32,993 |
Diluted (in shares) | 33,758 | 33,357 | 33,258 |
CONSOLIDATED STATEMENTS OF COMP
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Comprehensive Income | |||
Net income | $ 90,650 | $ 66,377 | $ 96,808 |
Other comprehensive income (loss): | |||
Foreign currency translation gain (loss) | 14,379 | (25,570) | (27,826) |
Net change in cash flow hedges, net of tax | 310 | 3,200 | 2,105 |
Defined benefit plan liability adjustment, net of tax | 205 | 509 | 219 |
Other comprehensive income (loss), net | 14,894 | (21,861) | (25,502) |
Comprehensive income | $ 105,544 | $ 44,516 | $ 71,306 |
CONSOLIDATED STATEMENTS OF CASH
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Cash flows from operating activities: | |||
Net income | $ 90,650 | $ 66,377 | $ 96,808 |
Adjustments to reconcile net income to net cash provided by operating activities: | |||
Depreciation and amortization | 98,841 | 91,991 | 81,369 |
Debt related charges included in interest expense | 8,054 | 2,036 | 6,954 |
Inventory step-up amortization | 590 | 798 | 301 |
Stock-based compensation | 23,283 | 21,023 | 16,185 |
Non-cash lease expense | 11,248 | 10,914 | 8,235 |
Non-cash loss on equity investments | 5,691 | 7,636 | 3,143 |
Contingent consideration fair value adjustment | (736) | 3,097 | 133 |
Other non-cash losses | 4,379 | 5,854 | 1,553 |
Deferred income taxes | (9,490) | (17,498) | (10,270) |
Changes in operating assets and liabilities, net of acquisitions: | |||
Accounts receivable | (7,437) | (41,380) | (17,539) |
Inventories | (30,178) | (56,721) | 4,700 |
Prepaid expenses and other assets | (930) | 764 | (2,409) |
Contract assets | (13,646) | (7,543) | (24,923) |
Accounts payable | (520) | 26,038 | 19,525 |
Accrued expenses and other liabilities | 7,908 | (9,529) | (22,984) |
Income taxes payable | (7,494) | 12,524 | (4,115) |
Net cash provided by operating activities | 180,213 | 116,381 | 156,666 |
Cash flows from investing activities: | |||
Acquisition of property, plant and equipment | (119,938) | (74,728) | (53,463) |
Proceeds from sale of property, plant and equipment | 173 | 639 | 443 |
Proceeds from return of capital from equity investments | 0 | 304 | 0 |
Acquisitions, net of cash acquired | (43,602) | (126,636) | (217,978) |
Net cash used in investing activities | (163,367) | (200,421) | (270,998) |
Cash flows from financing activities: | |||
Principal payments of term loans | (415,938) | (25,249) | (741,786) |
Proceeds from issuance of term loans | 0 | 0 | 818,250 |
Proceeds from issuance of convertible notes, net of discount | 486,250 | 0 | 0 |
Proceeds from revolving credit facility | 383,103 | 166,000 | 82,300 |
Payments of revolving credit facility | (424,801) | (45,000) | (63,000) |
Purchase of capped calls | (35,000) | 0 | 0 |
Payment of debt issuance costs | (2,181) | 0 | (8,139) |
Proceeds from the exercise of stock options | 2,303 | 150 | 743 |
Tax withholdings related to net share settlements of restricted stock units | (3,098) | (2,929) | (4,592) |
Proceeds from contingent consideration | 0 | 1,319 | 0 |
Payment of contingent consideration | (7,660) | (972) | (1,621) |
Principal payments on finance leases | (992) | (843) | (169) |
Net cash provided by (used in) financing activities | (18,014) | 92,476 | 81,986 |
Effect of foreign currency exchange rates on cash and cash equivalents | 570 | (2,049) | 1,025 |
Net increase (decrease) in cash and cash equivalents | (598) | 6,387 | (31,321) |
Cash and cash equivalents, beginning of year | 24,272 | 17,885 | 49,206 |
Cash and cash equivalents, end of year | $ 23,674 | $ 24,272 | $ 17,885 |
CONSOLIDATED STATEMENT OF STOCK
CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands | Total | Common stock and additional paid-in capital | Retained earnings | Accumulated other comprehensive income | Additional Paid-in Capital |
Total stockholders’ equity, beginning balance at Dec. 31, 2020 | $ 1,271,055 | $ 700,847 | $ 517,516 | $ 52,692 | |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||
Stock awards exercised or vested | (3,849) | ||||
Stock-based compensation | 16,185 | ||||
Capped calls related to the issuance of convertible notes, net of tax | $ 0 | ||||
Net income | 96,808 | 96,808 | |||
Other comprehensive income (loss) | (25,502) | ||||
Total stockholders’ equity, ending balance at Dec. 31, 2021 | 1,354,697 | 713,183 | 614,324 | 27,190 | |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||
Stock awards exercised or vested | (2,780) | ||||
Stock-based compensation | 21,023 | ||||
Capped calls related to the issuance of convertible notes, net of tax | 0 | ||||
Net income | 66,377 | 66,377 | |||
Other comprehensive income (loss) | (21,861) | ||||
Total stockholders’ equity, ending balance at Dec. 31, 2022 | 1,417,456 | 731,426 | 680,701 | 5,329 | |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||
Stock awards exercised or vested | (991) | ||||
Stock-based compensation | 23,283 | ||||
Capped calls related to the issuance of convertible notes, net of tax | $ (26,250) | ||||
Net income | 90,650 | 90,650 | |||
Other comprehensive income (loss) | 14,894 | ||||
Total stockholders’ equity, ending balance at Dec. 31, 2023 | $ 1,519,042 | $ 727,468 | $ 771,351 | $ 20,223 |
SUMMARY OF SIGNIFICANT ACCOUNTI
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 12 Months Ended |
Dec. 31, 2023 | |
Accounting Policies [Abstract] | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Integer Holdings Corporation (together with its consolidated subsidiaries, “Integer” or the “Company”) is a publicly traded corporation listed on the New York Stock Exchange under the symbol “ITGR.” Integer is one of the largest medical device outsource manufacturers in the world serving the cardiac rhythm management, neuromodulation, orthopedics, vascular, advanced surgical and portable medical markets. The Company provides innovative, high-quality medical technologies that enhance the lives of patients worldwide. In addition to medical technologies, the Company develops batteries for high-end niche applications in the energy, military, and environmental markets. The Company’s customers include large multi-national original equipment manufacturers (“OEMs”) and their affiliated subsidiaries. Basis of Presentation and Principles of Consolidation The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and include the accounts of Integer Holdings Corporation and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. In July 2018, the Company completed the sale of its Advanced Surgical and Orthopedic product lines (the “AS&O Product Line”) within its Medical segment. For all periods presented, financial results reported as discontinued operations in the Consolidated Statements of Operations relate to the divested AS&O Product Line. The Consolidated Statements of Cash Flows includes cash flows related to the discontinued operations due to Integer’s (parent) centralized treasury and cash management processes. See Note 20, “Discontinued Operations,” for the financial results and cash flow amounts for discontinued operations. All results and information in the consolidated financial statements are presented as continuing operations and exclude the AS&O Product Line unless otherwise noted specifically as discontinued operations. The Company organizes its business into two reportable segments: (1) Medical and (2) Non-Medical. The discontinued operations of the AS&O Product Line were reported in the Medical segment. Refer to Note 18, “Segment and Geographic Information,” for additional information on the Company’s reportable segments. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of sales and expenses during the reporting periods. Actual results could differ materially from those estimates. Cash and Cash Equivalents Cash and cash equivalents consist of cash and highly liquid, short-term investments with maturities at the time of purchase of three months or less. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist principally of accounts receivable. A significant portion of the Company’s sales and accounts receivable are to three customers, all in the medical device industry, and, as such, the Company is directly affected by the condition of those customers and that industry. However, the credit risk associated with trade receivables is partially mitigated due to the stability of those customers. The Company performs on-going credit evaluations of its customers. Note 19, “Revenue from Contracts with Customers,” contains information on sales and accounts receivable for these customers. The Company maintains cash deposits with major banks, which from time to time may exceed insured limits. The Company performs on-going credit evaluations of its banks. (1.) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) Trade Accounts Receivable and Provision for Current Expected Credit Losses The Company provides credit, in the normal course of business, to its customers in the form of trade receivables. Credit is extended based on evaluation of a customer’s financial condition and collateral is not required. The Company maintains a provision for those customer receivables that it does not expect to collect. In accordance with Accounting Standards Codification (“ASC”) Topic 326, the Company accrues its estimated losses from uncollectable accounts receivable to the provision based upon recent historical experience, the length of time the receivable has been outstanding, other specific information as it becomes available, and reasonable and supportable forecasts not already reflected in the historical loss information. Provisions for current expected credit losses are charged to current operating expenses. Actual losses are charged against the provision when incurred. Factoring Arrangements The Company enters into receivable factoring arrangements, pursuant to which certain receivables may be sold to financial institutions without recourse in exchange for cash. Transactions under the receivables factoring arrangements are accounted for as sales under ASC 860, Transfers and Servicing, with the sold receivables removed from the Company’s Consolidated Balance Sheet. Under these arrangements, the Company does not maintain any beneficial interest in the receivables sold. Once sold, the receivables are no longer available to satisfy creditors in the event of bankruptcy. Sale proceeds are reflected in Cash flows from operating activities on the Consolidated Statements of Cash Flows. Factoring fees are recorded in Selling, general, and administrative expenses in the Company’s Consolidated Statements of Operations. During the year ended December 31, 2023, the Company sold, without recourse, accounts receivable of $144.4 million and recorded factoring fees of $1.1 million . The Company did not utilize receivable factoring arrangements prior to 2023. Supplier Financing Arrangements The Company utilizes supplier financing arrangements with financial institutions to sell certain accounts receivable on a non-recourse basis. These transactions are treated as a sale of, and are accounted for as a reduction to, accounts receivable. The agreements transfer control and risk related to the receivables to the financial institutions. The Company has no continuing involvement in the transferred receivables subsequent to the sale. Fees for supplier financing arrangements are recorded in Selling, general, and administrative expenses in the Company’s Consolidated Statements of Operations. During the years ended December 31, 2023 and 2022, the Company sold and de-recognized accounts receivable and collected cash of $139.4 million and $120.7 million, respectively, and recorded costs associated with the supplier financing arrangements of $1.8 million and $0.9 million, respectively. Inventories Inventories are stated at the lower of cost, determined using the first-in first-out method, or net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Write-downs for excess, obsolete or expired inventory are based primarily on how long the inventory has been held, historical sales volume, and estimates of forecasted net sales of that product. A significant change in the timing or level of demand for products may result in recording additional write-downs for excess, obsolete or expired inventory in the future. Note 4, “Inventories,” contains additional information on the Company’s inventory. Leases The Company determines if an arrangement is, or contains, a lease at inception and classifies it at as finance or operating. The Company has operating and finance leases for office and manufacturing facilities, machinery, computer hardware, office equipment, and vehicles. Short-term finance lease liabilities are included in Accrued expenses and other current liabilities on the Consolidated Balance Sheets. Lease right-of-use (“ROU”) assets and corresponding liabilities are recognized based on the present value of the lease payments over the lease term at commencement date. When discount rates implicit in leases cannot be readily determined, the Company uses its incremental borrowing rate based on information available at commencement date in determining the present value of future payments. The incremental borrowing rate is determined based on the Company’s recent debt issuances, the Company’s specific credit rating, lease term and the currency in which lease payments are made. (1.) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such option. Costs associated with operating leases are recognized within operating expenses on a straight-line basis over the lease term. Finance lease assets are amortized within operating expenses on a straight-line basis over the shorter of the estimated useful lives of the assets or, in the instance where title does not transfer at the end of the lease term, the lease term. The interest component of a finance lease is included in Interest expense and recognized using the effective interest method over the lease term. The Company combines lease and non-lease components for all asset classes. For certain leases where rent escalates based upon a change in a financial index, such as the Consumer Price Index, the difference between the rate at lease inception and the subsequent fluctuations in that rate are included in variable lease costs. Additionally, because the Company does not separate lease and non-lease components, variable costs also include payments to the landlord for common area maintenance, real estate taxes, insurance and other operating expenses. The Company does not apply the recognition requirements to leases with lease terms of 12 months or less. Note 14, “Leases,” contains additional information on the Company’s leases. Property, Plant and Equipment (“PP&E”) PP&E is carried at cost less accumulated depreciation. Depreciation is computed by the straight-line method over the estimated useful lives of the assets, as follows: buildings and building improvements 12-30 years; machinery and equipment 3-10 years; office equipment 3-10 years; and leasehold improvements over the remaining lives of the improvements or the lease term, whichever is shorter. The costs of repairs and maintenance are expensed as incurred; renewals and betterments are capitalized. Upon retirement or sale of an asset, its cost and related accumulated depreciation or amortization is removed from the accounts and any gain or loss is recorded in operating income or expense. The Company also reviews its PP&E for impairment when impairment indicators exist. When impairment indicators exist, the Company determines if the carrying value of its fixed assets exceeds the related undiscounted future cash flows. In cases where the carrying value of the Company's long-lived assets or asset groups (excluding goodwill and indefinite-lived intangible assets) exceeds the related undiscounted cash flows, the carrying value is written down to fair value. Fair value is generally determined using a discounted cash flow analysis. Note 5, “Property, Plant and Equipment, Net,” contains additional information on the Company’s PP&E. Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e . the “exit price”) in an orderly transaction between market participants at the measurement date. ASC 820, Fair Value Measurements, establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the reliability of inputs as follows: Level 1 – Valuation is based on quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Level 1 valuations do not entail a significant degree of judgment. Level 2 – Valuation is determined from quoted prices for similar assets or liabilities in active markets, quoted prices for identical instruments in markets that are not active or by model-based techniques in which all significant inputs are observable in the market. Level 3 – Valuation is based on unobservable inputs that are significant to the overall fair value measurement. The degree of judgment in determining fair value is greatest for Level 3 valuations. Fair value is a market-based measure considered from the perspective of a market participant rather than an entity-specific measure. Therefore, even when market assumptions are not readily available, assumptions are required to reflect those that market participants would use in pricing the asset or liability at the measurement date. Note 17, “Financial Instruments and Fair Value Measurements,” contains additional information on assets and liabilities recorded at fair value in the consolidated financial statements. (1.) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) Acquisitions The Company accounts for acquisitions under the acquisition method of accounting for business combinations. Results of operations of acquired companies are included in the Company’s results of operations as of the respective acquisition dates. The purchase price of each acquisition is allocated to the net assets acquired based on estimates of their fair values at the date of the acquisition. Any purchase price in excess of these net assets is recorded as goodwill. All direct acquisition-related costs are expensed as incurred and are recognized as a component of Restructuring and other charges. The allocation of purchase price in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date. Contingent Consideration In circumstances where an acquisition involves a contingent consideration arrangement, the Company recognizes a liability equal to the fair value of the contingent payments it expects to make as of the acquisition date. Increases or decreases in the fair value of the contingent consideration liability can result from changes in discount periods and rates, as well as changes in the timing, amount of, or the likelihood of achieving the applicable performance target. Increases in projected revenues, estimated cash flows and probabilities of payment may result in significantly higher fair value measurements; decreases in these items may have the opposite effect. Increases in the discount rates in periods prior to payment may result in significantly lower fair value measurements and decreases in the discount rates may have the opposite effect. The contingent consideration fair value measurement is based on significant inputs not observable in the market and therefore constitute Level 3 inputs within the fair value hierarchy. The Company determines the initial fair value of contingent consideration liabilities using a Monte Carlo (“Monte Carlo”) valuation model, which involves a simulation of future revenues during the earn out-period using management’s best estimates, or a probability-weighted discounted cash flow analysis. In periods subsequent to the initial measurement, contingent consideration liabilities are remeasured to fair value each reporting period until the contingent consideration is settled using various assumptions including estimated revenues (based on internal operational budgets and long-range strategic plans), discount rates, revenue volatility and projected payment dates. The current portion of contingent consideration liabilities is included in Accrued expenses and other current liabilities and the non-current portion is included in Other long-term liabilities on the Consolidated Balance Sheets. Adjustments to the fair value of contingent consideration liabilities are included in Restructuring and other charges in the Consolidated Statements of Operations, and cash flows from operating activities in the Consolidated Statements of Cash Flows. Note 17, “Financial Instruments and Fair Value Measurements,” contains additional information on contingent consideration recorded at fair value in the consolidated financial statements. Goodwill Goodwill represents the excess of cost over the fair value of identifiable net assets of a business acquired and is assigned to one or more reporting units. The Company’s reporting units are the same as its reportable segments, Medical and Non-Medical. The Company tests each reporting unit’s goodwill for impairment at least annually as of the last day of the fiscal year and between annual tests if an event occurs or circumstances change that would more-likely-than-not reduce the fair value of a reporting unit below its carrying amount. In conducting its goodwill test, the Company either performs a qualitative assessment or a quantitative assessment. A qualitative assessment requires that the Company consider events or circumstances including, but not limited to, macro-economic conditions, market and industry conditions, cost factors, competitive environment, changes in strategy, changes in customers, changes in the Company’s stock price, results of the last impairment test, and the operational stability and the overall financial performance of the reporting units. If, after assessing the totality of events or circumstances, the Company determines that it is more likely than not that the fair values of its reporting units are greater than the carrying amounts, then the quantitative goodwill impairment test is not performed. The Company may elect to bypass the qualitative analysis and perform a quantitative analysis. If the qualitative assessment indicates that the quantitative analysis should be performed or if management elects to bypass a qualitative analysis to perform a quantitative analysis, the Company then evaluates goodwill for impairment by comparing the fair value of each of its reporting units to its carrying value, including the associated goodwill. To determine the fair values, the Company uses a combination of the income approach based on estimated discounted future cash flows and the market approach based on comparable publicly traded companies. The cash flow assumptions consider historical and forecasted revenue, operating costs and other relevant factors. (1.) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) The Company completed its annual goodwill impairment test as of December 31, 2023 and determined, after performing a qualitative review of its Medical reporting unit, that it is more likely than not that the fair value of the Medical reporting unit exceeds its carrying amount. Accordingly, there was no indication of impairment and the quantitative goodwill impairment test was not performed for the Medical reporting unit. The Company bypassed the qualitative analysis for its Non-Medical reporting unit and performed a quantitative analysis. The fair value of the Non-Medical reporting unit exceeded its carrying amount as of December 31, 2023. Other Intangible Assets Other intangible assets consist of purchased technology and patents, customer lists and trademarks. Definite-lived intangible assets are amortized on an accelerated or straight-line basis, which approximates the projected cash flows used to determine the fair value of those definite-lived intangible assets at the time of acquisition, as follows: purchased technology and patents 5-20 years; customer lists 7-20 years and other intangible assets 1-20 years. Certain trademark assets are considered indefinite-lived intangible assets and are not amortized. The Company expenses the costs incurred to renew or extend the term of intangible assets. The Company reviews its definite-lived intangible assets for impairment when impairment indicators exist. When impairment indicators exist, the Company determines if the carrying value of its definite-lived intangible assets or asset groups exceeds the related undiscounted future cash flows. In cases where the carrying value exceeds the undiscounted future cash flows, the carrying value is written down to fair value. Fair value is generally determined using a discounted cash flow analysis. The Company assesses its indefinite-lived intangible assets for impairment periodically to determine if any adverse conditions exist that would indicate impairment or when impairment indicators exist. The Company assesses its indefinite-lived intangible assets for impairment at least annually by comparing the fair value of the indefinite-lived intangible asset to its carrying value. The fair value is determined using the relief from royalty method. Refer to Note 6, “Goodwill and Other Intangible Assets, Net,” for further details of the Company’s goodwill and other intangible assets. Equity Investments The Company holds long-term, strategic investments in companies to promote business and strategic objectives. These investments are included in Other long-term assets on the Consolidated Balance Sheets. Equity investments are measured and recorded as follows: • Non-marketable equity securities are equity securities without readily determinable fair value that are measured and recorded at fair value with changes in fair value recognized within net income. The Company measures the securities at cost minus impairment, if any, plus or minus changes resulting from qualifying observable price changes. If an impairment is recognized on the Company’s non-marketable equity securities during the period, these assets are classified as Level 3 within the fair value hierarchy based on the nature of the fair value inputs. • Equity method investments are equity securities in investees the Company does not control but over which it has the ability to exercise influence. Equity method investments are recorded at cost and are adjusted to recognize (1) the Company’s share, based on percentage ownership or other contractual basis, of the investee’s income or loss, (2) additional contributions made and dividends or other distributions received, and (3) impairments resulting from other-than-temporary declines in fair value. Realized and unrealized gains and losses resulting from changes in fair value or the sale of these equity investments are recorded through (Gain) loss on equity investments, net. For some investments, the Company records its share of the investee’s income or loss one quarter in arrears due to the timing of its receipt of such information. The carrying value of the Company’s non-marketable equity securities is adjusted for qualifying observable price changes resulting from the issuance of similar or identical securities by the same issuer. Determining whether an observed transaction is similar to a security within the Company’s portfolio requires judgment based on the rights and preferences of the securities. Recording upward and downward adjustments to the carrying value of the Company’s equity securities as a result of observable price changes requires quantitative assessments of the fair value of these securities using various valuation methodologies and involves the use of estimates. (1.) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) Non-marketable equity securities and equity method investments (collectively referred to as non-marketable equity investments) are also subject to periodic impairment reviews. The Company’s quarterly impairment analysis considers both qualitative and quantitative factors that may have a significant impact on the investee’s fair value. Qualitative factors considered include the investee’s financial condition and business outlook, market for technology, operational and financing cash flow activities, technology and regulatory approval progress, and other relevant events and factors affecting the investee. When indicators of impairment exist, quantitative assessments of the fair value of the Company’s non-marketable equity investments are prepared. To determine the fair value of these investments, the Company uses all pertinent financial information available related to the investees, including financial statements, market participant valuations from recent and proposed equity offerings, and other third-party data. Non-marketable equity securities are tested for impairment using a qualitative model similar to the model used for goodwill and long-lived assets. Upon determining that an impairment may exist, the security’s fair value is calculated and compared to its carrying value and an impairment is recognized immediately if the carrying value exceeds the fair value. Equity method investments are subject to periodic impairment reviews using the other-than-temporary impairment model, which considers the severity and duration of a decline in fair value below cost and the Company’s ability and intent to hold the investment for a sufficient period of time to allow for recovery. The Company has determined that its investments are not considered variable interest entities. The Company’s exposure related to these entities is limited to its recorded investment. These investments are in start-up research and development companies whose fair value is highly subjective in nature and subject to future fluctuations, which could be significant. Refer to Note 17, “Financial Instruments and Fair Value Measurements,” for additional information on the Company’s equity investments. Debt Issuance Costs and Discounts Debt issuance costs and discounts associated with the issuance of debt by the Company are deferred and amortized over the lives of the related debt. Debt issuance costs incurred in connection with the Company’s issuance of its revolving credit facility are classified within Other long-term assets and amortized to Interest expense on a straight-line basis over the contractual term of the revolving credit facility. Debt issuance costs and discounts related to the Company’s term-debt are recorded as a reduction of the carrying value of the related debt and are amortized to Interest expense using the effective interest method over the period from the date of issuance to the maturity date. Upon prepayment of the related debt, the Company also recognizes a proportionate amount of the costs as extinguishment of debt. Costs treated as extinguishment of debt are expensed and included in Interest expense in the accompanying Consolidated Statements of Operations. The amortization of debt issuance costs and discounts, and debt extinguishment charges are included in Debt related charges included in interest expense in the Consolidated Statements of Cash Flows. Note 8, “Debt,” contains additional information on the Company’s debt issuance costs and discounts. Income Taxes The consolidated financial statements of the Company have been prepared using the asset and liability approach to account for income taxes, which requires the recognition of deferred income taxes for the expected future tax consequences of net operating losses, credits, and temporary differences between the financial statement carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided on deferred tax assets if it is determined, within each taxing jurisdiction, that it is more likely than not that the asset will not be realized. The Company accounts for uncertain tax positions using a more likely than not recognition threshold. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. These tax positions are evaluated on a quarterly basis. The Company recognizes interest expense related to uncertain tax positions as Provision for income taxes. Penalties, if incurred, are recognized as a component of Selling, general and administrative (“SG&A”) expenses. The Company and its subsidiaries file a consolidated United States (“U.S.”) federal income tax return. State tax returns are filed on a combined or separate basis depending on the applicable laws in the jurisdictions where the tax returns are filed. The Company also files foreign tax returns on a separate company basis in the countries in which it operates. (1.) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) Derivative Financial Instruments The Company recognizes all derivative financial instruments in its consolidated financial statements at fair value . The accounting for changes in the fair value of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and, if so, the reason for holding it. The Company’s use of derivative instruments is generally limited to cash flow hedges of certain interest rate risks and minimizing foreign currency exposure on foreign currency transactions, which are typically designated in hedging relationships, and intercompany balances, which are not designated as hedging instruments. Under master agreements with the respective counterparties to the Company’s derivative contracts, subject to applicable requirements, it has the right of set-off and is allowed to net settle transactions of the same type with a single net amount payable by one party to the other. Gains and losses on cash flow hedges are recorded in Accumulated other comprehensive income (“AOCI”) in the Consolidated Balance Sheets until the underlying transaction is recorded in earnings. When the hedged item is realized, gains or losses are reclassified from AOCI to the Consolidated Statement of Operations on the same line item as the underlying transaction. In the event the forecasted transactions do not occur, or it becomes probable that they will not occur, the Company reclassifies any gain or loss on the related cash flow hedge to earnings in the respective period. Cash flows related to these derivative financial instruments are included in cash flows from operating activities. Foreign currency contracts not designated as hedging relationships are recorded at fair value in Accrued expenses and other current liabilities in the Consolidated Balance Sheets with resulting gains or losses are recorded in the Consolidated Statement of Operations. Revenue Recognition The majority of the Company’s revenues consist of sales of various medical devices and products to large, multinational OEMs and their affiliated subsidiaries. The Company considers the customer’s purchase order, which in some cases is governed by a long-term agreement, and the Company’s corresponding sales order acknowledgment as the contract with the customer. The majority of contracts have an original expected duration of one year or less. Consideration payable to customers is included in the transaction price. In accordance with ASC 340-40-25-4, the Company expenses incremental costs of obtaining a contract when incurred because the amortization period is less than one year. The Company recognizes revenue from contracts with customers as performance obligations are satisfied when the customer obtains control of the products. Control is defined as the ability to direct the use of and obtain substantially all of the remaining benefits from the products. The customer obtains control of the products when title and risk of ownership transfers to them, which is primarily based upon shipping terms. Most of the Company’s revenues are recognized at the point in time when the products are shipped to customers. When a contract with a customer relates to products with no alternative use and the Company has an enforceable right to payment, including reasonable profit, for performance completed to date throughout the duration of the contract, revenue is recognized over time as control is transferred to the customer. When revenue is recognized over time, the Company uses an input measure to determine progress towards completion and total estimated costs at completion. Und |
BUSINESS ACQUISITIONS
BUSINESS ACQUISITIONS | 12 Months Ended |
Dec. 31, 2023 | |
Business Combination and Asset Acquisition [Abstract] | |
BUSINESS ACQUISITIONS | BUSINESS ACQUISITIONS 2023 Acquisition Effective as of October 1, 2023, the Company acquired substantially all of the assets and assumed certain liabilities of InNeuroCo, Inc. (“InNeuroCo”), a privately-held company based in Florida. InNeuroCo is a recognized leader in neurovascular catheter innovation with strong development and manufacturing capabilities. InNeuroCo’s expertise and highly differentiated neurovascular catheter innovation complements the Company’s existing capabilities and market focus. Consistent with the Company’s strategy, the addition of InNeuroCo further increases Integer’s ability to provide enhanced solutions to its customers in the neurovascular catheter space. The Company funded the purchase price with borrowings under its Revolving Credit Facility. The total consideration transferred was $44.5 million, which includes an initial cash payment of $43.6 million and $0.9 million in estimated fair value of contingent consideration. The contingent consideration represents the estimated fair value of the Company’s obligation, under the purchase agreement, to make additional payments of up to $13.5 million based on specified annual revenue growth milestones being met through 2027, and a one-time contingent payment to be made based on cumulative revenue amounts through 2027 exceeding a specified revenue target. The Company has preliminarily estimated fair values for the assets purchased and liabilities assumed as of the date of the acquisition. The determination of estimated fair value required management to make significant estimates and assumptions based on information that was available at the time the Consolidated Financial Statements were prepared. The amounts reported are considered preliminary as the Company is completing the valuations that are required to allocate the purchase price in areas such as property and equipment, intangible assets, liabilities and goodwill. As a result, the allocation of the preliminary purchase price may change in the future, which could be material. During the fourth quarter of 2023, the Company updated the allocation of the purchase price to certain current assets and, based on analysis of information as of the acquisition date, reduced goodwill by $2.2 million. The following table summarizes the preliminary fair values of the assets acquired and liabilities assumed (in thousands): Fair value of net assets acquired Current assets $ 6,924 Inventory 5,376 Property, plant and equipment 3,436 Goodwill 20,989 Definite-lived intangible assets 9,200 Operating lease assets 2,072 Current liabilities (2,331) Operating lease liabilities (1,157) Fair value of net assets acquired $ 44,509 The preliminary fair values of the assets acquired were determined using one of three valuation approaches: market, income or cost. The selection of a particular method for a given asset depended on the reliability of available data and the nature of the asset, among other considerations. The market approach estimates the value for a subject asset based on available market pricing for comparable assets. The income approach estimates the value for a subject asset based on the present value of cash flows projected to be generated by the asset. The projected cash flows were discounted at a required rate of return that reflects the relative risk of the asset and the time value of money. The projected cash flows for each asset considered multiple factors from the perspective of a marketplace participant including revenue projections from existing customers, attrition trends, technology life-cycle assumptions, marginal tax rates and expected profit margins giving consideration to historical and expected margins. The cost approach estimates the value for a subject asset based on the cost to replace the asset and reflects the estimated reproduction or replacement cost for the asset, less an allowance for loss in value due to depreciation or obsolescence, with specific consideration given to economic obsolescence if indicated. These fair value measurement approaches are based on significant unobservable inputs, including management estimates and assumptions. (2.) BUSINESS ACQUISITIONS (Continued) Current Assets and Liabilities The fair value of current assets and liabilities, excluding inventory, was assumed to approximate their carrying value as of the acquisition date due to the short-term nature of these assets and liabilities. The fair value of in-process and finished goods inventory acquired was estimated by applying a version of the income approach called the comparable sales method. This approach estimates the fair value of the assets by calculating the potential revenue generated from selling the inventory and subtracting from it the costs related to the completion and sale of that inventory and a reasonable profit allowance for these remaining efforts. Net book value was deemed to be a reasonable proxy for the fair value of raw materials. Based upon this methodology, the Company recorded the inventory acquired at fair value resulting in an increase in inventory of $0.6 million. Property, Plant and Equipment The fair value of PP&E acquired was estimated by applying the cost approach for personal property and leasehold improvements. The cost approach was applied by developing a replacement cost and adjusting for economic depreciation and obsolescence. Leases The Company recognized an operating lease liability and operating lease right-of-use asset for a manufacturing facility in accordance with ASC 842, Leases. Additionally, the Company recorded favorable lease terms associated with the operating lease of $0.7 million. The favorable lease terms were recorded as an increase to the ROU lease asset. Goodwill The excess of the purchase price over the fair value of net tangible and intangible assets acquired and liabilities assumed was allocated to goodwill. The goodwill resulting from the transaction is primarily attributable to future customer relationships and the assembled workforce of the acquired business. The goodwill acquired in connection with the InNeuroCo acquisition was allocated to the Medical segment and is deductible for tax purposes. Intangible Assets The purchase price was allocated to intangible assets as follows (dollars in thousands): Definite-lived Intangible Assets Fair Value Assigned Weighted Average Amortization Period Weighted Average Discount Rate Customer lists $ 4,000 20.0 14.5% Technology 5,200 10.0 14.5% $ 9,200 Customer Lists - Customer lists represent the estimated fair value of contractual and non-contractual customer relationships InNeuroCo had as of the acquisition date. The primary customers of InNeuroCo include large original equipment manufacturers. InNeuroCo had long-term recurring relationships with customers in both the design services and original design manufacturing segments. These relationships were valued separately from goodwill at the amount that an independent third party would be willing to pay for these relationships. The fair value of customer lists was determined using the multi-period excess-earnings method, a form of the income approach. The estimated useful life of the existing customer base was based upon the historical customer annual attrition rate of 5.0%, as well as management’s understanding of the industry and product life cycles. Technology - Technology consists of technical processes, patented and unpatented technology, manufacturing know-how, trade secrets and the understanding with respect to products or processes that have been developed by InNeuroCo and that will be leveraged in current and future products. The fair value of technology acquired was determined utilizing the relief from royalty method, a form of the income approach, with a royalty rate of 5.0% . The estimated useful life of the technology is based upon management’s estimate of the product life cycle associated with the technology before they will be replaced by new technologies. (2.) BUSINESS ACQUISITIONS (Continued) Contingent Consideration - As part of the InNeuroCo acquisition, the Company may be required to pay additional consideration based on achievement of specified annual revenue growth milestones being met through 2027, and a one-time contingent payment to be made based on cumulative revenue amounts through 2027 exceeding a specified revenue target. Any amounts earned will be payable in 2025 through 2028. The contingent consideration is classified as Level 3 in the fair value hierarchy and the fair value is measured based on a Monte Carlo simulation utilizing projections about future performance. Significant inputs include revenue volatility of 15%, a discount rate of 14% and projected financial information. See Note 17, “Financial Instruments and Fair Value Measurements,” for additional information related to the fair value measurement of the contingent consideration. 2022 Acquisition On April 6, 2022, the Company acquired 100% of the outstanding equity interests of Connemara Biomedical Holdings Teoranta, including its operating subsidiaries Aran Biomedical and Proxy Biomedical (collectively “Aran”), a recognized leader in proprietary medical textiles, high precision biomaterial coverings and coatings as well as advanced metal and polymer braiding. Aran delivers development and manufacturing solutions for implantable medical devices. Consistent with the Company’s strategy, the acquisition of Aran further increases Integer’s ability to offer complete solutions for complex delivery and therapeutic devices in high growth cardiovascular markets such as structural heart, neurovascular, peripheral vascular, and endovascular as well as general surgery. The Company funded the purchase price with borrowings under its Revolving Credit Facility. Aran is included in the Company’s Medical segment. The total consideration transferred was $141.3 million, which includes an initial cash payment of $133.9 million ($129.3 million net of cash acquired) and $7.4 million in estimated fair value of contingent consideration. The contingent consideration represents the estimated fair value of the Company’s obligation, under the purchase agreement, to make additional payments of up to €10 million ($10.9 million at the exchange rate as of April 6, 2022) based on Aran’s achievement of 2022 revenue growth milestones. The earn-out period ended on December 31, 2022 and full payment was made, in accordance with the terms of the share purchase agreement, in April 2023. See Note 17, “Financial Instruments and Fair Value Measurements,” for additional information related to the fair value measurement of the contingent consideration. There were no measurement period adjustments compared to the preliminary purchase price allocation as of December 31, 2022. The final purchase price allocation was as follows (in thousands): Fair value of net assets acquired Current assets $ 9,319 Property, plant and equipment 4,151 Goodwill 68,460 Definite-lived intangible assets 71,485 Operating lease assets 3,505 Other noncurrent assets 1,354 Current liabilities (4,370) Operating lease liabilities (3,258) Other noncurrent liabilities (9,377) Fair value of net assets acquired $ 141,269 (2.) BUSINESS ACQUISITIONS (Continued) Intangible Assets The purchase price was allocated to intangible assets as follows (dollars in thousands): Definite-lived Intangible Assets Fair Value Assigned Weighted Average Amortization Period Customer lists $ 53,395 26.0 Technology 17,435 12.0 Tradenames 655 1.5 $ 71,485 2021 Acquisition On December 1, 2021, the Company acquired 100% of the equity interests of Oscor Inc., Oscor Caribe, LLC and Oscor Europe GmbH (collectively “Oscor”), privately-held companies with operations in Florida, the Dominican Republic and Germany that design, develop, manufacture and market a comprehensive portfolio of highly specialized medical devices, venous access systems and diagnostic catheters and implantable devices. Serving the Company’s current markets, Oscor broadens the Company’s product portfolio, expands its research and development capabilities, and adds low-cost manufacturing capacity. The Company used proceeds from its Senior Secured Credit Facilities to fund the acquisition. See Note 8, “Debt,” for additional information on the Company’s Senior Secured Credit Facilities. Oscor is included in the Company’s Medical segment. The Oscor acquisition was structured as a stock purchase, however the parties agreed to coordinate the election of Section 338(h)(10) of the Internal Revenue Code relative to this transaction for tax purposes. Therefore, the excess purchase price over the fair value of net assets acquired was recorded as goodwill, which will be amortized over 15 years for income tax filing purposes. The goodwill was primarily associated with future customer relationships and an acquired assembled work force. During 2022, the Company recorded final measurement period adjustments, inclusive of working capital and other closing adjustments, resulting in increases to goodwill and current liabilities of $0.5 million and $2.3 million, respectively, and decreases to current assets (excluding inventory) and inventory of $2.5 million and $0.9 million, respectively. The final purchase price, including working capital and other closing adjustments of $5.2 million, was $215.2 million. The final purchase price allocation was as follows (in thousands): Fair value of net assets acquired Current assets (excluding inventory) $ 9,621 Inventory 11,270 Property, plant and equipment 17,977 Goodwill 78,392 Intangible assets 105,300 Operating lease assets 15,142 Other noncurrent assets 695 Current liabilities (11,143) Operating lease liabilities (12,044) Fair value of net assets acquired $ 215,210 (2.) BUSINESS ACQUISITIONS (Continued) Intangible Assets The purchase price was allocated to intangible assets as follows (dollars in thousands): Definite-lived Intangible Assets Fair Value Assigned Weighted Average Amortization Period Customer lists $ 73,800 20.0 Technology 15,200 15.0 Tradenames 16,300 20.0 $ 105,300 Contingent Receivable – The Company recorded a contingent receivable related to the Oscor acquisition related to retentive RSU awards issued to certain Oscor associates. The estimated fair value of the contingent consideration receivable at the acquisition date and as of December 31, 2021 was $1.4 million. During 2022, the Company recorded a $0.1 million reduction in the estimated fair value of the contingent receivable due to voluntary resignation of one Oscor associate. The remaining contingent receivable related to the acquisition date fair value of $1.3 million was received during 2022 and is reported as a financing activity in the Consolidated Statements of Cash Flows. Actual and Pro Forma (unaudited) disclosures For segment reporting purposes, the results of operations and assets from the InNeuroCo, Aran and Oscor acquisitions have been included in the Company’s Medical segment since the respective acquisition dates. From the date of acquisition through the year ended December 31, 2023, sales related to InNeuroCo were $5.2 million and earnings were not material. From the date of acquisition through the year ended December 31, 2022, sales related to Aran were $15.1 million and earnings were not material. From the date of acquisition through the year ended December 31, 2021, sales related to Oscor were $4.7 million and earnings were not material. The following table presents (in thousands) unaudited pro forma financial information, for the years shown, as if InNeuroCo, Aran and Oscor had been included in the Company’s financial results as of the beginning of fiscal year 2022, 2021 and 2020, respectively, through the date of acquisition (in thousands): 2023 2022 2021 Sales $ 1,615,606 $ 1,402,584 $ 1,291,600 Income from continuing operations 93,148 68,153 87,439 The unaudited pro forma results are presented for illustrative purposes only and do not reflect the realization of potential cost savings, and any related integration costs. Certain costs savings may result from the acquisition; however, there can be no assurance that these cost savings will be achieved. These unaudited pro forma results do not purport to be indicative of the results that would have been obtained, or to be a projection of results that may be obtained in the future. These unaudited pro forma results include certain adjustments, primarily due to increases in amortization expense due to the fair value adjustments of intangible assets, the increases to interest expense reflecting the amount borrowed in connection with the acquisition, acquisition related costs and the impact of income taxes on the pro forma adjustments. Acquisition costs During the years ended December 31, 2023, 2022 and 2021, direct costs of these acquisitions of $0.7 million, $6.9 million and $2.0 million, respectively, were expensed as incurred and included in Restructuring and other charges in the Consolidated Statements of Operations. |
SUPPLEMENTAL CASH FLOW INFORMAT
SUPPLEMENTAL CASH FLOW INFORMATION | 12 Months Ended |
Dec. 31, 2023 | |
Supplemental Cash Flow Elements [Abstract] | |
SUPPLEMENTAL CASH FLOW INFORMATION | SUPPLEMENTAL CASH FLOW INFORMATION The following represents supplemental cash flow information for the years ended December 31, 2023, 2022 and 2021 (in thousands): 2023 2022 2021 Non-cash investing and financing activities: Property, plant and equipment purchases included in accounts payable $ 21,044 $ 13,592 $ 5,556 Cash paid during the year for: Interest 37,701 35,804 24,740 Income taxes 30,351 11,165 19,649 |
INVENTORIES
INVENTORIES | 12 Months Ended |
Dec. 31, 2023 | |
Inventory Disclosure [Abstract] | |
INVENTORIES | INVENTORIES Inventories comprise the following (in thousands): December 31, 2023 2022 Raw materials $ 115,887 $ 98,640 Work-in-process 106,032 98,188 Finished goods 17,797 11,938 Total $ 239,716 $ 208,766 |
PROPERTY, PLANT AND EQUIPMENT,
PROPERTY, PLANT AND EQUIPMENT, NET | 12 Months Ended |
Dec. 31, 2023 | |
Property, Plant and Equipment [Abstract] | |
PROPERTY, PLANT AND EQUIPMENT, NET | PROPERTY, PLANT AND EQUIPMENT, NET PP&E comprises the following (in thousands): December 31, 2023 2022 Manufacturing machinery and equipment $ 436,834 $ 392,109 Buildings and building improvements 105,733 101,445 Information technology hardware and software 72,241 68,205 Leasehold improvements 90,510 87,616 Furniture and fixtures 18,089 17,614 Land and land improvements 13,358 13,173 Construction work in process 148,342 73,632 Other 1,537 1,478 886,644 755,272 Accumulated depreciation (478,690) (438,029) Total $ 407,954 $ 317,243 Depreciation expense for PP&E was as follows for the years ended December 31, 2023, 2022 and 2021 (in thousands): 2023 2022 2021 Depreciation expense $ 44,306 $ 42,617 $ 39,772 |
GOODWILL AND OTHER INTANGIBLE A
GOODWILL AND OTHER INTANGIBLE ASSETS, NET | 12 Months Ended |
Dec. 31, 2023 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
GOODWILL AND OTHER INTANGIBLE ASSETS, NET | GOODWILL AND OTHER INTANGIBLE ASSETS, NET Goodwill The changes in the carrying amount of goodwill by reportable segment during the years ended December 31, 2023 and 2022 was as follows (in thousands): Medical Non-Medical Total December 31, 2021 $ 907,704 $ 17,000 $ 924,704 Aran acquisition (Note 2) 68,460 — 68,460 Acquisition-related adjustments (Note 2) 505 — 505 Foreign currency translation (11,477) — (11,477) December 31, 2022 965,192 17,000 982,192 InNeuroCo acquisition (Note 2) 20,989 — 20,989 Foreign currency translation 7,826 — 7,826 December 31, 2023 $ 994,007 $ 17,000 $ 1,011,007 As of December 31, 2023, no accumulated impairment loss has been recognized for the goodwill allocated to the Company’s Medical or Non-Medical segments. Intangible Assets Intangible assets comprise the following (in thousands): Gross Accumulated Net December 31, 2023 Definite-lived: Purchased technology and patents $ 291,142 $ (196,388) $ 94,754 Customer lists 837,453 (253,267) 584,186 Amortizing tradenames and other 21,035 (7,117) 13,918 Total amortizing intangible assets $ 1,149,630 $ (456,772) $ 692,858 Indefinite-lived: Trademarks and tradenames $ 90,288 December 31, 2022 Definite-lived: Purchased technology and patents $ 283,929 $ (178,844) $ 105,085 Customer lists 825,634 (216,546) 609,088 Amortizing tradenames and other 21,028 (5,600) 15,428 Total amortizing intangible assets $ 1,130,591 $ (400,990) $ 729,601 Indefinite-lived: Trademarks and tradenames $ 90,288 See Note 2, “Business Acquisitions,” for additional details regarding intangible assets acquired during 2023 and 2022. Included in the Company’s indefinite-lived intangible assets are the Lake Region Medical and Greatbatch Medical tradenames with carrying values of $70.0 million and $20.3 million, respectively. (6. ) GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Continued) Aggregate intangible asset amortization expense comprises the following for the years ended December 31, 2023, 2022 and 2021 (in thousands): 2023 2022 2021 Cost of sales $ 16,260 $ 15,701 $ 13,090 SG&A 36,270 32,612 28,507 Restructuring and other charges 638 — — Total intangible asset amortization expense $ 53,168 $ 48,313 $ 41,597 Estimated future intangible asset amortization expense based upon the carrying value as of December 31, 2023 is as follows (in thousands): 2024 2025 2026 2027 2028 After 2028 Amortization expense $ 52,298 $ 51,525 $ 49,844 $ 47,047 $ 44,246 $ 447,898 |
ACCRUED EXPENSES AND OTHER CURR
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES | 12 Months Ended |
Dec. 31, 2023 | |
Accounts Payable and Accrued Liabilities [Abstract] | |
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES | ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accrued expenses and other current liabilities comprise the following (in thousands): December 31, 2023 2022 Salaries and benefits $ 30,544 $ 33,084 Profit sharing and bonuses 36,114 15,800 Contingent consideration — 11,201 Contract liabilities 6,142 5,616 Short-term finance lease liabilities 1,894 1,093 Product warranties 84 77 Accrued interest 4,578 472 Other 8,732 6,156 Total $ 88,088 $ 73,499 |
DEBT
DEBT | 12 Months Ended |
Dec. 31, 2023 | |
Debt Disclosure [Abstract] | |
DEBT | DEBT Long-term debt comprises the following (in thousands): December 31, 2023 December 31, 2022 Principal Amount Discounts and Deferred Issuance Costs Net Carrying Amount Principal Amount Discounts and Deferred Issuance Costs Net Carrying Amount Senior Secured Credit Facilities: Revolving credit facilities $ 99,000 $ — $ 99,000 $ 140,300 $ — $ 140,300 Term loan A 375,000 (1,687) 373,313 455,313 (2,172) 453,141 Term loan B — — — 335,625 (3,805) 331,820 Convertible Senior Notes due 2028 500,000 (12,388) 487,612 — — — Total $ 974,000 $ (14,075) $ 959,925 $ 931,238 $ (5,977) $ 925,261 Current portion of long-term debt — (18,188) Long-term debt $ 959,925 $ 907,073 Senior Secured Credit Facilities On September 2, 2021, the Company entered into a credit agreement (the “2021 Credit Agreement”), governing the Company’s senior secured credit facilities (the “Senior Secured Credit Facilities”). As of December 31, 2022, the Senior Secured Credit Facilities consisted of a five-year $400 million revolving credit facility (the “Revolving Credit Facility”), a five-year “term A” loan (the “TLA Facility”) and a seven-year “term B” loan (the “TLB Facility” and, together with the TLA Facility, the “Term Loan Facilities”). The TLB Facility was issued at a 0.50% discount. Amendments to the 2021 Credit Agreement On January 30, 2023, the Company entered into a first amendment (the “First Amendment”) to the 2021 Credit Agreement to, among other things: (i) permit the Company to issue the notes (described below under 2028 Convertible Senior Note s and Related Capped Call Transactions) and incur indebtedness thereunder in an aggregate principal amount of up to $600 million at any time outstanding; (ii) permit the Company to enter into bond hedge and capped call transactions; and (iii) permit the Company to issue call options, warrants or purchase rights relating to the Company’s common stock; provided, in each case, that the terms of any such transaction are customary for transactions of such type. On February 15, 2023, the Company entered into a second amendment (the “Second Amendment”) to the 2021 Credit Agreement to, among other things: (i) increase the maximum borrowing capacity under the Revolving Credit Facility by $100 million from $400 million to $500 million, (ii) extend the maturity date for both the Revolving Credit Facility and the TLA Facility to February 15 , 2028, (iii) allow for borrowings by the Company under the Revolving Credit Facility denominated in Euros, subject to a sublimit equal to 50% of the maximum borrowing capacity under the Revolving Credit Facility, (iv) replace the London Interbank Offered Rate (“LIBOR”) based reference interest rate option with a forward-looking term rate based on the secured overnight financing rate (“SOFR”) for the applicable interest period plus an adjustment of 0.10% per annum (“Adjusted Term SOFR”), and (v) add carveouts to certain negative covenants included within the 2021 Credit Agreement to permit the expansion of capacity in Ireland by the Company and incur indebtedness related thereto. The information provided below reflects the First Amendment and Second Amendment (collectively the “2023 Amendments”) described above. Revolving Credit Facility The Revolving Credit Facility matures on February 15 , 2028 . As of December 31, 2023, the Company had available borrowing capacity on the Revolving Credit Facility of $397.5 million after giving effect to $99.0 million of outstanding borrowings and $3.5 million of outstanding standby letters of credit. Borrowings under the Revolving Credit Facility will bear interest at a rate of Adjusted Term SOFR, in relation to any loan in U.S. dollars, and the Euro Interbank Offered Rate (“EURIBOR”), in relation to any loan in Euros, plus a margin based on the Company’s Secured Net Leverage Ratio (as defined in the Senior Secured Credit Facilities agreement). In addition, the Company is required to pay a commitment fee on the unused portion of the Revolving Credit Facility, which will range between 0.15% and 0.25%, depending on the Company’s Secured Net Leverage Ratio. As of December 31, 2023, the weighted average interest rate on outstanding borrowings under the Revolving Credit Facility was 7.08% and the commitment fee on the unused portion of the Revolving Credit Facility was 0.18%. (8.) DEBT (Continued) Term Loan Facilities The TLA Facility matures on February 15 , 2028 , and requires quarterly installments. The quarterly principal installments under the TLA Facility increase over the term of the loan. The interest rate terms for the TLA Facility are the same as those above for the Revolving Credit Facility borrowings in U.S. dollars. As of December 31, 2023, the interest rate on the TLA Facility was 6.96% . In February 2023, the Company used a portion of the proceeds from its notes offering (see 2028 Convertible Senior Notes and Related Capped Call Transactions ) to settle the full principal and related accrued interest due under the TLB Facility. Deferred Debt Issuance Costs and Discounts Debt issuance costs are either deferred and amortized over the term of the associated debt or expensed as incurred. In connection with the 2023 Amendments , the Company incurred and capitalized an aggregate of $1.0 million of debt issuance costs. In connection with the 2023 Amendments, for each separate debt instrument on a lender by lender basis, in accordance with ASC 470-50, Debt Modifications and Extinguishment , the Company performed an assessment of whether the transaction was deemed to be new debt, a modification of existing debt, or an extinguishment of existing debt. Based on this assessment, $3.8 million of unamortized deferred debt issuance costs related to the Revolving Credit Facility and TLA Facility were deemed to be related to the issuance of new debt, or the modification of existing debt, and therefore will continue to be deferred and amortized over the term of the associated debt. The remaining $0.6 million of unamortized deferred debt issuance costs related to the Revolving Credit Facility and TLA Facility were deemed to be related to the extinguishment of debt and were expensed and included in Interest expense during the year ended December 31, 2023. Additionally, i n connection with the full repayment of the TLB Facility and prepayments of portions of the TLA Facility, the Company incurred a $3.9 million loss on extinguishment of debt from the write-off of the remaining deferred debt issuance costs and original issue discount, which were expensed and included in Interest expense during the year ended December 31, 2023. Covenants The Senior Secured Credit Facilities agreement contains customary terms and conditions, including representations and warranties and affirmative and negative covenants, as well as financial covenants for the benefit of the lenders under the Revolving Credit Facility and the TLA Facility, which require that (i) the Company maintain a Total Net Leverage Ratio not to exceed 5.00:1.00, subject to increase in certain circumstances following qualified acquisitions, but shall not exceed 5.50:1.00 and (ii) the Company maintain an interest coverage ratio of at least 2.50:1.00. As of December 31, 2023, the Company was in compliance with these financial covenants. Contractual maturities under the Senior Secured Credit Facilities as of December 31, 2023 are as follows (in thousands): 2024 2025 2026 2027 2028 Future minimum principal payments $ — $ 10,000 $ 27,500 $ 30,000 $ 406,500 2028 Convertible Senior Notes and Related Capped Call Transactions In February of 2023, the Company issued $500 million aggregate principal amount of Convertible Senior Notes due in 2028 (“2028 Convertible Notes”) in a private offering, which aggregate principal amount included the exercise in full of the initial purchasers’ option to purchase up to an additional $65 million principal amount of the 2028 Convertible Notes. The 2028 Convertible Notes mature on February 15, 2028 and bear interest at a fixed rate of 2.125% per annum, payable semiannually in arrears on February 15 and August 15 of each year, beginning on August 15, 2023. The total net proceeds from the issuance of the 2028 Convertible Notes (which includes the additional proceeds from the purchasers’ option), after deducting initial purchasers' discounts and commissions and debt issuance costs, were approximately $485 million. Conversion and Redemption Terms of the 2028 Convertible Notes Each $1,000 principal amount of the 2028 Convertible Notes is initially convertible into 11.4681 shares of the Company’s common stock (the “2028 Conversion Option”), which is equivalent to an initial conversion price of approximately $87.20 per share of common stock, subject to standard anti-dilutive adjustments and adjustments upon the occurrence of specified events. The initial conversion price represents a premium of approximately 32.5% to the $65.81 per share closing price of the Company’s common stock on January 31, 2023. (8.) DEBT (Continued) The 2028 Convertible Notes are convertible, in multiples of $1,000 principal amount, at the option of the holders prior to the close of business on the business day immediately preceding November 15, 2027, only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on March 31, 2023 (and only during such calendar quarter), if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (2) during the five business day period after any ten consecutive trading day period (the “Measurement Period”) in which the trading price (as defined in the Indenture governing the 2028 Convertible Notes) per $1,000 principal amount of the 2028 Convertible Notes for each trading day of the Measurement Period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate in effect on each such trading day; (3) if the Company calls any or all of the 2028 Convertible Notes for redemption, at any time prior to the close of business on the second scheduled trading day immediately preceding the redemption date; or (4) upon the occurrence of specified corporate events. On or after November 15, 2027 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their 2028 Convertible Notes, in multiples of $1,000 principal amount, at the option of the holder regardless of the foregoing circumstances. Upon conversion, the 2028 Convertible Notes will be settled in cash up to the aggregate principal amount of the 2028 Convertible Notes to be converted, and in cash, shares of the Company’s common stock or a combination thereof, at the Company’s option, in respect of the remainder, if any, of the Company’s conversion obligation in excess of the aggregate principal amount of the 2028 Convertible Notes being converted. If the Company undergoes a fundamental change (as defined in the indenture governing the 2028 Notes), subject to certain conditions, holders may require the Company to repurchase for cash all or any portion of their 2028 Convertible Notes, in principal amounts of $1,000 or a multiple thereof, at a fundamental change repurchase price equal to 100% of the principal amount of the 2028 Convertible Notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change repurchase date. In addition, following certain corporate events or if the Company issues a notice of redemption, it will, under certain circumstances, increase the conversion rate for holders who elect to convert their notes in connection with such corporate event or during the relevant redemption period. As of December 31, 2023, the conditions allowing holders of the 2028 Convertible Notes to convert had not been met and, therefore, the 2028 Convertible Notes are classified as a long-term liability on the Consolidated Balance Sheets at December 31, 2023. The Company may not redeem the 2028 Convertible Notes prior to February 20, 2026. The Company may redeem for cash all or any portion of the 2028 Convertible Notes, at its option, on or after February 20, 2026 and prior to February 15, 2028, if the last reported sale price of its common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending not more than two Seniority of the 2028 Convertible Notes The 2028 Convertible Notes are the Company’s senior unsecured obligations and rank senior in right of payment to any of the Company’s indebtedness that is expressly subordinated in right of payment to the 2028 Convertible Notes; equal in right of payment to any of the Company’s unsecured indebtedness that is not so subordinated; effectively junior in right of payment to any of the Company’s secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables) of the Company’s subsidiaries. Covenants The 2028 Convertible Notes do not contain financial maintenance covenants. Deferred Debt Issuance Costs and Discounts The 2028 Convertible Notes are accounted for as a single liability measured at amortized cost. The discount and issuance costs related to the 2028 Convertible Notes are being amortized to interest expense over the contractual term of the 2028 Convertible Notes at an effective interest rate of 2.76%. (8.) DEBT (Continued) Indenture The Company issued the 2028 Convertible Notes pursuant to an indenture dated as of February 3, 2023 (the “Indenture”) by and between the Company and Wilmington Trust, National Association, as trustee. The Indenture provides for customary events of default, which include (subject in certain cases to grace and cure periods), among others: nonpayment of principal or interest; failure by the Company to comply with its conversion obligations upon exercise of a holder’s conversion right under the Indenture; breach of covenants or other agreements in the Indenture; defaults by the Company or any significant subsidiary (as defined in the Indenture) with respect to other indebtedness in excess of a threshold amount; failure by the Company or any significant subsidiary to pay final judgments in excess of a threshold amount; and the occurrence of certain events of bankruptcy, insolvency or reorganization with respect to the Company or any significant subsidiary. Generally, if an event of default occurs and is continuing under the Indenture, either the Indenture trustee or the holders of at least 25% in aggregate principal amount of the 2028 Convertible Notes then outstanding may declare the principal amount plus accrued and unpaid interest on the 2028 Convertible Notes to be immediately due and payable. Capped Call Transactions In connection with the issuance of the 2028 Convertible Notes, the Company entered into privately negotiated capped call transactions (the “Capped Calls”) with certain financial institutions. The Capped Calls are expected generally to reduce the potential dilution to the Company’s common stock in connection with any conversion of the 2028 Convertible Notes and/or offset any cash payments the Company is required to make in excess of the principal amount of converted 2028 Convertible Notes, as the case may be, with such reduction and/or offset subject to a cap based on strike price of written warrants. The initial upper strike price of the Capped Calls is $108.59 per share and is subject to certain adjustments under the terms of the Capped Calls. The Capped Calls cover, subject to anti-dilution adjustments, approximately 5.7 million shares of the Company’s common stock, the same number of shares initially underlying the 2028 Convertible Notes. For accounting purposes, the Capped Calls are separate transactions, and not integrated with the issuance of the 2028 Convertible Notes. As these transactions meet certain accounting criteria, the Capped Calls are recorded in stockholders’ equity and are not accounted for as derivatives. The 2028 Convertible Notes and the Capped Calls will be integrated for tax purposes. The accounting impact of this tax treatment results in the Capped Calls being deductible as original issue discount for tax purposes over the term of the 2028 Notes, which generates an $8.8 million deferred tax asset recognized through equity. The cost to the Company of the Capped Calls was $35 million, which was recorded, net of tax, as a reduction to additional paid-in capital. Deferred Debt Issuance Costs and Discounts The change in deferred debt issuance costs related to the Company’s Revolving Credit Facility is as follows (in thousands): December 31, 2022 2,387 Financing costs incurred 579 Write-off of deferred debt issuance costs (260) Amortization during the period (540) December 31, 2023 $ 2,166 The change in debt discount and deferred debt issuance costs related to the Term Loan Facilities and 2028 Convertible Notes is as follows (in thousands): Deferred Debt Issuance Costs Debt Discount Total December 31, 2022 4,569 1,408 5,977 Financing costs incurred 1,602 13,750 15,352 Write-off of deferred debt issuance costs and unamortized discount (2,867) (1,391) (4,258) Amortization during the period (637) (2,359) (2,996) December 31, 2023 $ 2,667 $ 11,408 $ 14,075 |
BENEFIT PLANS
BENEFIT PLANS | 12 Months Ended |
Dec. 31, 2023 | |
Retirement Benefits [Abstract] | |
BENEFIT PLANS | BENEFIT PLANS Savings Plan The Company sponsors a defined contribution 401(k) plan (the “Plan”) for its U.S. based employees. The Plan provides for the deferral of employee compensation under Internal Revenue Code §401(k) and a Company match. The Company matches $0.50 per dollar of each participant’s deferral made to the Plan up to 6% of their compensation, subject to Internal Revenue Service guidelines. Contributions from employees, as well as those matched by the Company, vest immediately. Net costs related to defined contribution plans for 2023, 2022 and 2021 were $9.9 million , $8.8 million and $7.9 million, respectively. Defined Benefit Plans The Company is required to provide its employees located in Switzerland and Mexico certain statutorily mandated defined benefits. Under these plans, benefits accrue to employees based upon years of service, position, age and compensation. The defined benefit pension plan provided to the Company’s employees located in Switzerland is a funded contributory plan, while the plans that provide benefits to the Company’s employees located in Mexico are unfunded and noncontributory. The assets of the Switzerland plan are held at an AA- rated insurance carrier who bears the pension risk and longevity risk, and will be used to cover the pension liability for the remaining retirees of the Swiss plan, as well as the remaining employees at that location. The liability and corresponding expense related to these benefit plans is based on actuarial computations of current and future benefits for employees. The aggregated projected benefit obligation for these plans was $2.9 million and $2.5 million as of December 31, 2023 and December 31, 2022, respectively. Net periodic pension cost for 2023, 2022 and 2021 was $0.6 million, $0.1 million and $0.5 million, respectively. Over the next ten years, the Company expects gross benefit payments to be $1.3 million in total for the years 2024 through 2028, and $2.7 million in total for the years 2029 through 2033. |
STOCK-BASED COMPENSATION
STOCK-BASED COMPENSATION | 12 Months Ended |
Dec. 31, 2023 | |
Share-Based Payment Arrangement [Abstract] | |
STOCK-BASED COMPENSATION | STOCK-BASED COMPENSATION Stock-based Compensation Plans The Company maintains certain stock-based compensation plans that were approved by the Company’s stockholders and are administered by the Board of Directors (the “Board”) or the Compensation and Organization Committee of the Board. The stock-based compensation plans provide for the granting of stock options, restricted stock awards, RSUs, performance awards, stock appreciation rights and stock bonuses to employees, non-employee directors, consultants, and service providers. As of December 31, 2023, the Company’s outstanding stock-based compensation plans and agreements include the 2021 Omnibus Incentive Plan (the “2021 Plan”), 2016 Stock Incentive Plan (the “2016 Plan”), 2011 Stock Incentive Plan (the “2011 Plan”), the 2009 Stock Incentive Plan (the “2009 Plan”). The 2021 Plan replaced the 2016 Plan and the Company ceased granting any new awards under the 2016 Plan. The number of shares initially reserved for issuance under the 2021 Plan is (i) 1,450,000 plus (ii) the total number of shares of common stock available for issuance under the 2016 Plan, plus (iii) any shares of common stock that are subject to awards forfeited, cancelled, expired, terminated or otherwise lapsed or settled in cash, in whole or in part, without the delivery of shares under the 2016 Plan. The 2011 Plan and 2009 Stock Plan have expired and no awards are available for issuance under these expired plans. As of December 31, 2023, there were 1,088,383 shares available for future grants under the 2021 Plan. Stock-based Compensation Expense The classification of stock-based compensation expense in the accompanying Consolidated Statements of Operations was as follows (in thousands): Year Ended December 31, 2023 2022 2021 Cost of sales $ 3,709 $ 3,240 $ 3,365 SG&A 18,224 15,234 11,579 RD&E 1,237 1,099 969 Restructuring and other charges 113 1,450 272 Total stock-based compensation expense $ 23,283 $ 21,023 $ 16,185 Income tax benefit recognized for stock-based compensation arrangements $ 3,692 $ 2,908 $ 4,188 (10.) STOCK-BASED COMPENSATION (Continued) Stock Options There were no stock options granted during 2023, 2022 or 2021. The following table summarizes stock option activity during the year ended December 31, 2023: Number of Weighted Weighted Aggregate Outstanding at December 31, 2022 240,622 $ 38.51 Exercised (82,533) 35.00 Outstanding at December 31, 2023 158,089 $ 40.35 2.9 $ 9.3 Vested and exercisable at December 31, 2023 158,089 $ 40.35 2.9 $ 9.3 Intrinsic value is calculated for in-the-money options (exercise price less than market price) as the difference between the market price of the Company’s common stock as of December 31, 2023 ($99.08) and the weighted average exercise price of the underlying stock options, multiplied by the number of options outstanding and/or exercisable. Shares are distributed from the Company’s authorized but unissued reserve upon the exercise of stock options. As of December 31, 2023, there was no unrecognized compensation cost related to stock options. The following table provides certain information relating to the exercise of stock options during 2023, 2022 and 2021 (in thousands): 2023 2022 2021 Intrinsic value $ 3,670 $ 370 $ 2,370 Cash received 2,303 150 743 Actual tax benefit for the tax deductions from the exercise of options 881 89 569 Restricted Stock Units The following table summarizes RSU activity during the year ended December 31, 2023: Time-Vested Weighted Nonvested at December 31, 2022 291,929 $ 77.58 Granted 231,604 75.77 Vested (117,587) 79.03 Forfeited (56,191) 72.98 Nonvested at December 31, 2023 349,755 $ 76.63 As of December 31, 2023, there was $15.0 million of total unrecognized compensation cost related to RSUs, which is expected to be recognized over a weighted-average period of approximately 1.8 years. The fair value of RSU shares that vested during 2023, 2022 and 2021 was $9.1 million, $10.7 million and $12.9 million, respectively. The weighted average grant date fair value of RSUs granted during 2023, 2022 and 2021 was $79.03, $75.87 and $81.98, respectively. (10.) STOCK-BASED COMPENSATION (Continued) Performance Restricted Stock Units The following table summarizes PRSU activity during the year ended December 31, 2023: Performance- Weighted Nonvested at December 31, 2022 263,906 $ 90.29 Granted 105,757 74.32 Vested (24,427) 107.26 Forfeited (69,733) 82.72 Nonvested at December 31, 2023 275,503 $ 84.57 For the Company’s PRSUs, in addition to service conditions, the ultimate number of shares earned depends on the achievement of financial or market-based performance conditions. The financial performance condition is based on the Company’s sales. The market conditions are based on the Company’s achievement of a relative total shareholder return (“TSR”) performance requirement, on a percentile basis, compared to a defined group of peer companies over three year performance periods, or contingent upon achieving specified stock price milestones over a five year performance period. At December 31, 2023, there was $10.2 million of total unrecognized compensation cost related to unvested PRSUs, which is expected to be recognized over a weighted-average period of approximately 1.6 years. The fair value of PRSU shares vested during 2023 and 2021 was $1.8 million and $3.1 million, respectively. There were no PRSU shares vested during 2022. The weighted average grant date fair value of PRSUs granted during 2023, 2022 and 2021 was $74.32, $90.84 and $85.16, respectively. The grant-date fair values of the market-based portion of the PRSUs granted during 2023, 2022 and 2021 were determined using the Monte Carlo valuation model on the date of grant. The weighted average fair value and assumptions used to value the TSR portion of the PRSUs granted are as follows: 2023 2022 2021 Weighted average fair value $ 74.29 $ 97.58 $ 85.16 Risk-free interest rate 3.79 % 1.58 % 0.19 % Expected volatility 46 % 42 % 41 % Expected life (in years) 3.0 3.9 3.0 Expected dividend yield — % — % — % The valuation of the TSR portion of the PRSUs granted during 2023, 2022 and 2021 also reflects a weighted average illiquidity discount of 11.23%, 9.25% and 8.19%, respectively, related to the six-month period that recipients are restricted from selling, transferring, pledging or assigning the underlying shares, in the event of vesting. |
RESTRUCTURING AND OTHER CHARGES
RESTRUCTURING AND OTHER CHARGES | 12 Months Ended |
Dec. 31, 2023 | |
Restructuring and Related Activities [Abstract] | |
RESTRUCTURING AND OTHER CHARGES | RESTRUCTURING AND OTHER CHARGES Restructuring and other charges comprise the following (in thousands): 2023 2022 2021 Restructuring charges $ 6,015 $ 4,920 $ 4,804 Acquisition and integration costs 3,444 10,075 2,544 Other general expenses 2,110 1,188 508 Total restructuring and other charges $ 11,569 $ 16,183 $ 7,856 Restructuring programs Operational excellence The Company’s operational excellence (“OE”) initiatives mainly consist of costs associated with executing on its sales force, manufacturing, business process and performance excellence operational strategic imperatives. These projects focus on changing the Company’s organizational structure to match product line growth strategies and customer needs, transitioning its manufacturing process into a competitive advantage and standardizing and optimizing its business processes. 2022 OE Initiatives - Costs related to the Company’s 2022 OE initiatives are primarily recorded within the Medical segment or unallocated operating expenses and mainly include termination benefits. The Company estimates that it will incur aggregate pre-tax charges in connection with the 2022 OE initiatives of between approximately $10 million and $12 million, the majority of which are expected to be cash expenditures. As of December 31, 2023, total restructuring and restructuring-related charges incurred since inception were $7.1 million. These actions are expected to be substantially complete by the end of 2025. 2021 OE Initiatives - Costs related to the Company’s 2021 OE initiatives are primarily recorded within the Medical segment or unallocated operating expenses and mainly include termination benefits. As of December 31, 2023, total restructuring and restructuring-related charges incurred since inception were $4.9 million. These actions were complete in 2023. Strategic reorganization and alignment The Company’s strategic reorganization and alignment (“SRA”) initiatives primarily include those that align resources with market conditions and the Company’s strategic direction in order to enhance the profitability of its portfolio of products. 2021 SRA Initiatives - During the fourth quarter of 2021, the Company initiated plans to exit certain markets served in its Medical segment to enhance profitability and reallocate manufacturing capacity needed to support the Company’s overall growth plans. The Company estimates that it will incur a range of pre-tax charges in connection with the 2021 SRA initiatives of approximately $6 million and $7 million, the majority of which are expected to be cash expenditures. Costs related to the Company’s 2021 SRA Initiatives are primarily recorded within the Medical segment and mainly include termination benefits. As of December 31, 2023, total charges incurred since inception were $5.7 million. These actions are expected to be completed by the end of 2025. Cost Reduction Initiatives - During 2022, the Company recorded $1.5 million in restructuring charges related to cost reduction actions taken in response to higher manufacturing and direct labor costs. These charges consisted of employee termination benefits and are recorded within the Medical segment. As of December 31, 2023, total restructuring and restructuring-related charges incurred since inception were $1.7 million. These actions were complete in 2023. Manufacturing alignment to support growth The Company’s manufacturing alignment to support growth (“MASG”) initiatives are designed to reduce costs, improve operating efficiencies or increase capacity to accommodate growth, which may involve relocation or consolidation of manufacturing operations. Research and Product Development Alignment – In 2023, the Company commenced an initiative to consolidate certain research and product development operations to more efficiently meet customer needs. The Company will be consolidating existing facilities in Israel and Ireland primarily to a new facility in Ireland. The Company estimates that it will incur aggregate pre-tax charges in connection with this initiative of between approximately $6 million and $8 million, the majority of which are expected to be cash expenditures. Costs related to the Company’s Research and Product Development Alignment initiative are primarily recorded within the Medical segment and mainly include asset disposal and impairment charges and termination benefits. As of December 31, 2023, total restructuring and restructuring-related charges incurred since inception were $3.6 million. These actions are expected to be substantially complete by the end of 2026. (11.) RESTRUCTURING AND OTHER CHARGES (Continued) 2022 MASG - In 2022, the Company initiated plans to relocate manufacturing of certain products. The Company estimates that it will incur aggregate pre-tax charges in connection with the 2022 MASG initiatives of between approximately $2 million and $3 million, the majority of which are expected to be cash expenditures. As of December 31, 2023, total restructuring and restructuring-related charges incurred since inception were $1.2 million. These actions are expected to be substantially complete by the end of 2025. The following table comprises restructuring and restructuring-related charges by classification in the accompanying Consolidated Statements of Operations (in thousands): 2023 2022 Restructuring charges: Restructuring and other charges $ 6,015 $ 4,920 Restructuring-related expenses (a) : Cost of sales 1,669 1,148 Selling, general and administrative 2,093 1,966 Research, development and engineering 667 1,231 Total restructuring and restructuring-related charges $ 10,444 $ 9,265 __________ (a) Restructuring-related expenses primarily include retention bonuses, consulting expenses and professional fees. Restructuring related expenses for 2021 were not material. The following table summarizes the activity for restructuring reserves (in thousands): Operational Strategic reorganization and alignment Manufacturing alignment to support growth Total December 31, 2022 $ 232 $ 2,134 $ — $ 2,366 Charges incurred, net of reversals 844 1,259 3,912 6,015 Cash payments (1,055) (3,268) (687) (5,010) Non-cash adjustments — — (1,935) (1,935) December 31, 2023 $ 21 $ 125 $ 1,290 $ 1,436 Acquisition and integration costs Acquisition and integration costs primarily consist of professional fees and other costs related to business acquisitions. During 2023, acquisition and integration costs of $3.4 million included expenses primarily related to the acquisition of InNeuroCo and the integration of Oscor and Aran. During 2022, acquisition and integration costs included $10.1 million of expenses primarily related to the acquisitions of Oscor and Aran, including a net $3.1 million adjustment to increase the fair value of acquisition-related contingent consideration liabilities. During 2021, acquisition and integration costs included $2.4 million of expenses primarily related to the acquisition of Oscor, and a net $0.1 million adjustment to increase the fair value of acquisition-related contingent consideration liabilities. See Note 17, “Financial Instruments and Fair Value Measurements,” for additional information related to the fair value measurement of the contingent consideration. Other general expenses During 2023, 2022 and 2021, the Company recorded gains and losses in connection with the disposal of property, plant and equipment. In addition, during 2023 the Company recorded $2.0 million of property loss and related expenses resulting from a fire which occurred in the fourth quarter of 2023 at one of its manufacturing facilities. |
INCOME TAXES
INCOME TAXES | 12 Months Ended |
Dec. 31, 2023 | |
Income Tax Disclosure [Abstract] | |
INCOME TAXES | INCOME TAXES Income from continuing operations before income taxes for fiscal years 2023, 2022 and 2021 consisted of the following (in thousands): 2023 2022 2021 U.S. $ 31,001 $ 14,446 $ 48,293 International 76,293 61,512 52,770 Total income from continuing operations before income taxes $ 107,294 $ 75,958 $ 101,063 The provision for income taxes from continuing operations for fiscal years 2023, 2022 and 2021 comprises the following (in thousands): 2023 2022 2021 Current: Federal $ 11,590 $ 20,455 $ 9,511 State 1,404 780 1,553 International 13,140 6,871 8,459 26,134 28,106 19,523 Deferred: Federal (7,451) (16,300) (8,665) State (168) 26 (393) International (1,871) (1,224) (2,422) (9,490) (17,498) (11,480) Total provision for income taxes $ 16,644 $ 10,608 $ 8,043 The provision for income taxes from continuing operations differs from the U.S. statutory rate for fiscal years 2023, 2022 and 2021 due to the following: 2023 2022 2021 Statutory rate $ 22,531 21.0 % $ 15,951 21.0 % $ 21,223 21.0 % Federal tax credits (including R&D) (11,113) (10.4) (9,399) (12.4) (11,929) (11.8) Foreign rate differential (5,513) (5.1) (7,693) (10.1) (5,165) (5.1) Stock-based compensation 1,862 1.7 2,009 2.6 (1,084) (1.1) Uncertain tax positions (1,170) (1.1) 2,469 3.3 18 — State taxes, net of federal benefit 1,185 1.1 978 1.3 1,183 1.2 U.S. tax on foreign earnings, net of §250 deduction 6,090 5.7 5,225 6.9 1,913 1.9 Valuation allowance 1,737 1.6 (194) (0.3) 524 0.5 Other 1,035 1.0 1,262 1.7 1,360 1.4 Effective tax rate $ 16,644 15.5 % $ 10,608 14.0 % $ 8,043 8.0 % The difference between the Company’s effective tax rate and the U.S. federal statutory income tax rate in the current year is primarily attributable to the availability of Foreign Tax Credits, R&D Credits, the impact of the Company’s earnings realized in foreign jurisdictions with statutory rates that are different than the U.S. federal statutory rate, and the provision for Global Intangible Low Taxed income (“GILTI”), net of the statutory deduction of 50% of the GILTI inclusion and the Foreign Derived Intangible Income (“FDII”) deduction (collectively “Section 250 deduction”). The Company’s foreign earnings are primarily derived from Switzerland, Mexico, Uruguay, Ireland and Malaysia. The Company has previously operated under a tax holiday in Malaysia. The Company met the conditions of the Malaysian tax holiday and the holiday expired in accordance with its original terms on April 30, 2023. The Company’s manufacturing operations in the Dominican Republic operate under a free trade zone agreement through March 2034. (12.) INCOME TAXES (Continued) Difference Attributable to Foreign Investment: Certain foreign subsidiary earnings are subject to U.S. taxation under the Tax Cuts and Jobs Act of 2017 (the “Tax Reform Act”) . The Company intends to permanently reinvest substantially all of its foreign subsidiary earnings, as well as its capital in those foreign subsidiaries, with the exception of planned distributions made out of current year earnings and profits (“E&P”) and E&P previously taxed as of and for the year ended December 29, 2017, including E&P subject to the toll charge under the Tax Reform Act. The Company accrues for withholding taxes on distributions in the year associated with earnings that are intended to be distributed. As of December 31, 2023 and December 31, 2022, the Company had a net deferred tax liability consisting of the following (in thousands): December 31, December 31, Research and development $ 27,957 $ 15,168 Operating lease liabilities 20,726 18,781 Tax credit carryforwards 8,989 10,110 Net operating loss carryforwards 7,814 9,121 Accrued expenses 7,516 7,113 Original issue discount from capped calls 7,288 — Stock-based compensation 5,154 4,230 Inventories 3,131 13,103 Gross deferred tax assets 88,575 77,626 Less valuation allowance (15,741) (16,649) Net deferred tax assets 72,834 60,977 Intangible assets (181,737) (188,976) Operating lease assets (20,851) (18,846) Property, plant and equipment (7,290) (6,789) Other (1,580) (790) Gross deferred tax liabilities (211,458) (215,401) Net deferred tax liability $ (138,624) $ (154,424) Presented as follows: Noncurrent deferred tax asset $ 7,001 $ 6,247 Noncurrent deferred tax liability (145,625) (160,671) Net deferred tax liability $ (138,624) $ (154,424) As of December 31, 2023, the Company has the following carryforwards available (in millions): Jurisdiction Tax Gross Amount Deferred Tax Asset Valuation Allowance Begin to Expire U.S. State Net operating losses (a)(b) $ 89.6 $ 3.5 $ (3.3) 2024 International Net operating losses (a) 18.1 4.3 (4.1) 2024 U.S. Federal Foreign tax credits 4.9 4.9 (4.9) 2024 U.S. State R&D tax credits (b) 1.0 0.8 — 2035 U.S. State State tax credits (b) 3.8 3.0 (3.0) 2024 International R&D tax credits 0.3 0.3 — Indefinite __________ (a) Net operating losses (“NOLs”) are presented as pre-tax amounts. (b) U.S. State deferred tax assets and valuation allowance are presented net of federal benefit. (12.) INCOME TAXES (Continued) In assessing the realizability of deferred tax assets, management considers, within each taxing jurisdiction, whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on the consideration of the weight of both positive and negative evidence, management has determined it is more likely than not that a portion of the deferred tax assets as of December 31, 2023 and December 31, 2022 related to certain foreign tax credits, state investment tax credits, and foreign and state net operating losses will not be realized. The Company files annual income tax returns in the U.S., various state and local jurisdictions, and in various foreign jurisdictions. A number of years may elapse before an uncertain tax position, for which the Company has unrecognized tax benefits, is examined and finally settled. While it is often difficult to predict the final outcome or the timing of resolution of any particular uncertain tax position, the Company believes that its unrecognized tax benefits reflect the most probable outcome. The Company adjusts these unrecognized tax benefits, as well as the related interest, in light of changing facts and circumstances. The resolution of an uncertain tax position, if recognized, would be recorded as an adjustment to the provision for income taxes and the effective tax rate in the period of resolution. Below is a summary of changes to the unrecognized tax benefit for the years ended December 31, 2023, 2022 and 2021 (in thousands): 2023 2022 2021 Balance, beginning of year $ 7,739 $ 5,537 $ 5,484 Additions based upon tax positions related to the current year 356 1,364 3,324 Additions (reductions) related to prior period tax returns (18) 838 (3,271) Reductions as a result of a lapse of applicable statute of limitations (1,607) — — Balance, end of year $ 6,470 $ 7,739 $ 5,537 The tax years that remain open and subject to tax audits vary depending on the tax jurisdiction. The Company is no longer subject to tax authority examinations in the U.S. for tax years prior to 2020 and is generally no longer subject to tax authority examinations in other major foreign, or state tax jurisdictions for years prior to fiscal year 2019. It is reasonably possible that a reduction of approximately $0.6 million of the balance of unrecognized tax benefits may occur within the next twelve months as a result of the lapse of the statute of limitations and/or audit settlements. As of December 31, 2023, approximately $6.4 million of unrecognized tax benefits would favorably impact the effective tax rate (net of federal impact on state issues), if recognized. The Company recognizes interest related to unrecognized tax benefits as a component of Provision for income taxes on the Consolidated Statements of Operations. The Company accrued interest of $0.3 million and no penalties during 2023 and recognized an aggregate liability related to interest and penalties on unrecognized tax benefits of $0.8 million as of December 31, 2023. The Company accrued interest of $0.4 million and no penalties during 2022 and recognized an aggregate liability related to interest and penalties on unrecognized tax benefits of $0.5 million as of December 31, 2022. During 2021, the recorded amounts for interest and penalties were not significant. On December 15, 2022, the European Union (EU) Member States formally adopted the EU’s Pillar Two Directive, which generally provides for a minimum effective tax rate of 15%, as established by the Organization for Economic Co-operation and Development (OECD) Pillar Two Framework. The EU effective dates are January 1, 2024, and January 1, 2025, for different aspects of the directive. A significant number of other countries are expected to also implement similar legislation with varying effective dates in the future. The Company is continuing to evaluate the potential impact on future periods of the Pillar Two Framework, pending legislative adoption by additional individual countries. See Note 20, “Discontinued Operations,” for additional information pertaining to income taxes from discontinued operations. |
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES | 12 Months Ended |
Dec. 31, 2023 | |
Commitments and Contingencies Disclosure [Abstract] | |
COMMITMENTS AND CONTINGENCIES | COMMITMENTS AND CONTINGENCIES Contingent Consideration Arrangements The Company records contingent consideration liabilities related to the earn-out provisions for certain acquisitions. See Note 17, “Financial Instruments and Fair Value Measurements,” for additional information. Litigation The Company is subject to litigation arising from time to time in the ordinary course of its business. The Company does not expect that the ultimate resolution of any pending legal actions will have a material effect on its consolidated results of operations, financial position, or cash flows. However, litigation is subject to inherent uncertainties. As such, there can be no assurance that any pending legal action will not become material in the future. Environmental Matters The Company acquired Lake Region Medical Holdings, Inc. (“LRM”) in 2015. At the direction of the New Jersey Department of Environmental Protection (“NJDEP”), LRM has been performing, and has agreed to fund approximately $0.3 million for, environmental investigations of a manufacturing facility LRM owned in South Plainfield, New Jersey from 1971 to 2004, and where it conducted operations from 1971 to 2007. NJDEP required LRM to perform and fund these environmental investigations due to concerns that prior investigations by LRM at the property were inadequate and because NJDEP concluded that the property was a source of local ground water contamination during LRM’s operations, including the Franklin Street Regional Groundwater Contamination Area, which has been designated as an immediate environmental concern by NJDEP. LRM funded the environmental investigation undertaken by NJDEP’s contractor by placing approximately $0.3 million in escrow for the environmental investigation. As of December 31, 2023, approximately $0.2 million had been drawn down from the escrow account by NJDEP to pay for the environmental investigation, and approximately $0.1 million remains in escrow for anticipated future costs associated with the environmental investigation. These environmental investigations may conclude that remediation of the property by LRM, and the reimbursement of costs and damages, including natural resource damages, associated with the groundwater immediate environmental concern, are necessary. Further, the current owner of the property claims to have been financially impacted by LRM’s inadequate environmental investigations. While the Company does not expect this environmental matter will have a material effect on its consolidated results of operations, financial position or cash flows, there can be no assurance that this environmental matter will not become material in the future. As of December 31, 2023, there was $0.1 million recorded in Accrued expenses and other current liabilities License Agreements The Company is a party to various license agreements for technology that is utilized in certain of its products. The most significant of these agreements are the licenses for basic technology used in the production of wet tantalum capacitors, filtered feedthroughs and MRI compatible lead systems. Expenses related to license agreements were $1.8 million, $1.7 million, and $1.3 million, for 2023, 2022 and 2021, respectively, and are primarily included in Cost of Sales. Self-Insurance Liabilities |
LEASES
LEASES | 12 Months Ended |
Dec. 31, 2023 | |
Leases [Abstract] | |
LEASES | LEASES The components and classification of lease cost for the years ended December 31, 2023, 2022 and 2021 are as follows (in thousands): 2023 2022 2021 Finance lease cost: Amortization of lease assets $ 1,367 $ 1,080 $ 223 Interest on lease liabilities 321 317 59 Finance lease cost 1,688 1,397 282 Operating lease cost 14,057 13,927 10,729 Short-term lease cost (leases with initial term of 12 months or less) 324 342 137 Variable lease cost 3,041 3,026 2,619 Sublease income (904) (1,294) (1,392) Total lease cost $ 18,206 $ 17,398 $ 12,375 Cost of sales $ 13,542 $ 13,111 $ 9,642 SG&A 3,028 2,864 1,817 RD&E 929 1,106 857 Restructuring and other charges 386 — — Interest expense $ 321 $ 317 $ 59 Total lease cost $ 18,206 $ 17,398 $ 12,375 The Company’s sublease income is derived primarily from certain real estate leases to several non-affiliated tenants under operating sublease arrangements. Supplemental cash flow information related to leases for the years ended December 31, 2023, 2022 and 2021 is as follows (in thousands): 2023 2022 2021 Cash paid for operating leases $ 13,892 $ 13,519 $ 10,808 Cash paid for interest on finance leases 321 317 59 Assets acquired under operating leases 17,911 15,777 32,466 Assets acquired under finance leases 4,210 1,882 8,154 At December 31, 2023, the maturities of operating and finance lease liabilities were as follows (in thousands): Operating Leases Finance Leases 2024 $ 12,744 $ 2,411 2025 12,639 2,449 2026 12,580 2,011 2027 12,386 1,681 2028 11,851 1,296 Thereafter 42,683 4,516 Gross lease liabilities 104,883 14,364 Less: imputed interest (23,852) (2,082) Present value of lease liabilities 81,031 12,282 Less: current portion of lease liabilities (8,692) (1,894) Total long-term lease liabilities $ 72,339 $ 10,388 As of December 31, 2023, the Company did not have any leases that have not yet commenced. (14.) LEASES (Continued) The following table presents the weighted average remaining lease term and discount rate. December 31, December 31, Weighted-average remaining lease term - operating leases (in years) 9.2 7.5 Weighted-average remaining lease term - finance leases (in years) 7.7 10.0 Weighted-average discount rate - operating leases 5.5 % 3.9 % Weighted-average discount rate - finance leases 4.4 % 3.4 % |
EARNINGS PER SHARE
EARNINGS PER SHARE | 12 Months Ended |
Dec. 31, 2023 | |
Earnings Per Share [Abstract] | |
EARNINGS PER SHARE | EARNINGS PER SHARE The following table sets forth a reconciliation of the information used in computing basic and diluted EPS for the years ended December 31, 2023, 2022 and 2021 (in thousands, except per share amounts): 2023 2022 2021 Numerator for basic and diluted EPS: Income from continuing operations $ 90,650 $ 65,350 $ 93,020 Income from discontinued operations — 1,027 3,788 Net income $ 90,650 $ 66,377 $ 96,808 Denominator for basic EPS: Weighted average shares outstanding 33,320 33,127 32,993 Effect of dilutive securities: Stock options, restricted stock and restricted stock units 438 230 265 Denominator for diluted EPS 33,758 33,357 33,258 Basic earnings per share: Income from continuing operations $ 2.72 $ 1.97 $ 2.82 Income from discontinued operations — 0.03 0.11 Basic earnings per share 2.72 2.00 2.93 Diluted earnings per share: Income from continuing operations $ 2.69 $ 1.96 $ 2.80 Income from discontinued operations — 0.03 0.11 Diluted earnings per share 2.69 1.99 2.91 The diluted weighted average share calculations do not include the following securities for the years ended December 31, 2023, 2022 and 2021, which are not dilutive to the EPS calculations or the performance criteria have not been met (in thousands): 2023 2022 2021 Time-vested stock options, restricted stock and restricted stock units 1 15 4 Performance-vested restricted stock units 84 152 92 (15.) EARNINGS PER SHARE (Continued) The dilutive effect for the Company's 2028 Convertible Notes is calculated using the if-converted method. The Company is required, pursuant to the Indenture governing the 2028 Convertible Notes, to settle the principal amount of the 2028 Convertible Notes in cash and may elect to settle the remaining conversion obligation (i.e., the stock price in excess of the conversion price) in cash, shares of the Company's common stock, or a combination thereof. Under the if-converted method, the Company includes the number of shares required to satisfy the conversion obligation, assuming all the 2028 Convertible Notes are converted. During the year ended December 31, 2023, the 2028 Convertible Notes were not included in the diluted EPS calculation because all associated shares were antidilutive. In connection with the issuance of the 2028 Convertible Notes, the Company entered into privately negotiated capped call transactions with certain financial institutions. The Capped Calls cover, subject to anti-dilution adjustments substantially similar to those in the 2028 Convertible Notes, approximately 5.7 million shares of the Company's common stock, the same number of shares initially underlying the 2028 Convertible Notes, at a strike price of approximately $108.59, subject to certain adjustments under the terms of the Capped Calls. The Capped Calls will expire upon the maturity of the 2028 Convertible Notes, subject to earlier exercise or termination. Exercise of the Capped Calls would reduce the number of shares of the Company's common stock outstanding, and therefore would be antidilutive. See Note 8 “Debt” for additional information related to 2028 Convertible Notes and Capped Calls. |
STOCKHOLDERS' EQUITY
STOCKHOLDERS' EQUITY | 12 Months Ended |
Dec. 31, 2023 | |
Equity [Abstract] | |
STOCKHOLDERS' EQUITY | STOCKHOLDERS’ EQUITY Common Stock The following table sets forth the changes in the number of shares of common stock for the years ended December 31: 2023 2022 Shares issued and outstanding at beginning of period 33,169,778 33,063,336 Stock options exercised, net of shares exchanged for payment 72,125 7,018 Vesting of RSUs, net of shares withheld to cover taxes 87,745 99,424 Shares issued and outstanding at end of period 33,329,648 33,169,778 Accumulated Other Comprehensive Income Accumulated other comprehensive income comprises the following (in thousands): Defined Cash Foreign Total Tax Net-of-Tax December 31, 2021 $ (890) $ (2,291) $ 29,720 $ 26,539 $ 651 $ 27,190 Unrealized gain on cash flow hedges — 3,649 — 3,649 (766) 2,883 Realized gain on foreign currency hedges — (516) — (516) 108 (408) Realized loss on interest rate swap hedge — 918 — 918 (193) 725 Net defined benefit plan adjustments 544 — — 544 (35) 509 Foreign currency translation loss — — (25,570) (25,570) — (25,570) December 31, 2022 $ (346) $ 1,760 $ 4,150 $ 5,564 $ (235) $ 5,329 Unrealized gain on cash flow hedges — 7,008 — 7,008 (1,472) 5,536 Realized gain on foreign currency hedges — (5,353) — (5,353) 1,124 (4,229) Realized gain on interest rate swap hedge — (1,262) — (1,262) 265 (997) Net defined benefit plan adjustments 318 — — 318 (113) 205 Foreign currency translation gain — — 14,379 14,379 — 14,379 December 31, 2023 $ (28) $ 2,153 $ 18,529 $ 20,654 $ (431) $ 20,223 |
FINANCIAL INSTRUMENTS AND FAIR
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS | 12 Months Ended |
Dec. 31, 2023 | |
Fair Value Disclosures [Abstract] | |
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS | FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS Assets and Liabilities Measured at Fair Value on a Recurring Basis Fair value measurement standards apply to certain financial assets and liabilities that are measured at fair value on a recurring basis (each reporting period). For the Company, these financial assets and liabilities include its derivative instruments and contingent consideration. The Company does not have any nonfinancial assets or liabilities that are measured at fair value on a recurring basis. The Company is exposed to global market risks, including the effect of changes in interest rates and foreign currency exchange rates, and uses derivatives to manage these exposures that occur in the normal course of business. The Company does not hold or issue derivatives for trading or speculative purposes. All derivatives are recorded at fair value on the balance sheet. The following tables provide information regarding assets and liabilities recorded at fair value on a recurring basis (in thousands): Fair Value Quoted Significant Significant December 31, 2023 Assets: Foreign currency hedging contracts $ 2,153 $ — $ 2,153 $ — Liabilities: Contingent consideration 876 — — 876 December 31, 2022 Assets: Interest rate swaps $ 1,262 $ — $ 1,262 $ — Assets: Foreign currency hedging contracts 521 — 521 — Liabilities: Foreign currency contracts 23 — 23 — Liabilities: Contingent consideration 11,756 — — 11,756 Derivatives Designated as Hedging Instruments Interest Rate Swaps The Company may periodically enter into interest rate swap agreements in order to reduce the cash flow risk caused by interest rate changes on its outstanding floating rate borrowings. Under these swap agreements, the Company pays a fixed rate of interest and receives a floating rate. The Company had no outstanding interest rate swaps as of December 31, 2023. Information regarding the Company’s outstanding interest rate swap, designated as a cash flow hedge, as of December 31, 2022 is as follows (dollars in thousands): Notional Amount Maturity Pay Fixed Rate Receive Current Floating Rate Fair Value Balance Sheet Location $ 100,000 Jun 2023 2.1785 % 4.3869 % $ 1,262 Prepaid expenses and other current assets Foreign Currency Contracts The Company periodically enters into foreign currency forward contracts to hedge its exposure to foreign currency exchange rate fluctuations in its international operations. The Company has designated these foreign currency forward contracts as cash flow hedges. The Company receives fair value estimates from the foreign currency contract counterparties. The fair value of foreign currency contracts is determined through the use of cash flow models that utilize observable market data inputs to estimate fair value. These observable market data inputs include foreign exchange rate and credit spread curves. The Company’s foreign currency contracts are categorized in Level 2 of the fair value hierarchy. The fair value of the Company’s foreign currency contracts will be realized as Sales or Cost of Sales as the inventory, which the contracts are hedging, is sold. (17.) FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued) Information regarding outstanding foreign currency forward contracts designated as cash flow hedges as of December 31, 2023 is as follows (dollars in thousands): Notional Amount Maturity $/Foreign Currency Fair Value Balance Sheet Location $ 51,389 Dec 2024 1.0831 Euro $ 1,389 Prepaid expenses and other current assets 19,392 Dec 2024 0.0566 MXN Peso 182 Prepaid expenses and other current assets 19,201 Dec 2024 0.0248 UYU Peso 582 Prepaid expenses and other current assets Information regarding outstanding foreign currency forward contracts designated as cash flow hedges as of December 31, 2022 is as follows (dollars in thousands): Notional Amount Maturity $/Foreign Currency Fair Value Balance Sheet Location $ 37,175 Dec 2023 0.0489 MXN Peso $ 504 Prepaid expenses and other current assets 2,685 Mar 2023 0.0249 UYU Peso 17 Prepaid expenses and other current assets 17,309 Mar 2023 1.0751 Euro (23) Accrued expenses and other current liabilities The following table presents the impact of cash flow hedge derivative instruments on the Company’s Consolidated Statements of Operations and Consolidated Statements of Comprehensive Income for fiscal years 2023, 2022 and 2021 (in thousands): Gain (Loss) Recognized in OCI Gain (Loss) Reclassified from AOCI Derivative 2023 2022 2021 Location in Statement of Operations 2023 2022 2021 Interest rate swaps $ — $ 3,322 $ 642 Interest expense $ 1,262 $ (918) $ (3,406) Foreign exchange contracts 1,171 (2,226) (943) Sales (241) (2,073) (674) Foreign exchange contracts 5,666 2,225 399 Cost of sales 5,611 2,205 1,437 Foreign exchange contracts 171 328 (7) Operating expenses (17) 384 69 The Company expects to reclassify net gains totaling $2.2 million related to its cash flow hedges from AOCI into earnings during the next twelve months. Derivatives Not Designated as Hedging Instruments The Company also has foreign currency exposure on balances, primarily intercompany, that are denominated in a foreign currency and are adjusted to current values using period-end exchange rates. To minimize foreign currency exposure, the Company enters into foreign currency contracts with a one month maturity. At December 31, 2023 and December 31, 2022, the Company had total gross notional amounts of $23.0 million and $12.0 million, respectively, of foreign currency contracts outstanding that were not designated as hedges. The fair value of derivatives not designated as hedges was not material for any period presented. The Company recorded net gains on foreign currency contracts not designated as hedging instruments of $0.4 million, $2.6 million and $0.4 million for 2023, 2022 and 2021, respectively, which are included in Other (income) loss, net. Each of the foreign currency contracts not designated as hedging instruments will have approximately offsetting effects from the underlying intercompany loans subject to foreign exchange remeasurement. (17.) FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued) Contingent Consideration Liabilities The following table presents the changes in the estimated fair values of the Company’s liabilities for contingent consideration measured using significant unobservable inputs (Level 3) for fiscal years 2023 and 2022 (in thousands): December 31, 2021 $ 2,415 Amount recorded for current year acquisitions 7,375 Fair value measurement adjustment 3,097 Payments (972) Foreign currency translation (159) December 31, 2022 11,756 Amount recorded for current year acquisition 876 Fair value measurement adjustment (736) Payments (11,177) Foreign currency translation 157 December 31, 2023 $ 876 The contingent consideration at December 31, 2023 is the estimated fair value of the Company’s remaining obligations, under the asset purchase agreements for InNeuroCo and InoMec Ltd. (“InoMec”), to make additional payments if certain revenue goals are met. As of December 31, 2023, the contingent consideration liability of $0.9 million was non-current. As of December 31, 2022, the current and non-current portions of contingent consideration liabilities were $11.2 million and $0.6 million, respectively. Effective as of October 1, 2023, the Company acquired certain assets and assumed certain liabilities of InNeuroCo. The fair value of the contingent consideration liability relating to the acquisition of InNeuroCo was $0.9 million at the date of acquisition and at December 31, 2023. See Note 2, “Business Acquisitions,” for additional information about the InNeuroCo acquisition and related contingent consideration. On April 6, 2022, the Company acquired Aran. The fair value of the contingent consideration liability relating to the acquisition of Aran was $7.4 million at the date of acquisition and $10.7 million at December 31, 2022. During 2023, the Company made the final earnout payment of $10.9 million, adjusted for currency exchange, resulting from achievement of the maximum revenue-based goals for the year ended December 31, 2022. During 2022, the Company recorded an adjustment of $3.4 million to increase the fair value of the contingent consideration liability. See Note 2, “Business Acquisitions,” for additional information about the Aran acquisition and related contingent consideration. On February 19, 2020, the Company acquired certain assets and liabilities of InoMec, a privately-held company specializing in the research, development and manufacturing of medical devices. As of December 31, 2023 and December 31, 2022, the fair value of the contingent consideration liability relating to the acquisition of InoMec was calculated using projected revenue for the remaining earnout periods and determined to be zero and $1.1 million, respectively. During 2023, the Company recorded adjustments of $0.7 million to reduce the fair value of the contingent consideration liability. During 2022, the Company recorded adjustments of $0.3 million to increase the fair value of the contingent consideration liability. The maximum potential undiscounted payout for the final earnout period ending February 29, 2024 relating to the acquisition of InoMec is $0.9 million. During 2023 and 2022, the Company made payments of $0.3 million and $0.5 million, respectively, associated with the InoMec acquisition, resulting from achievement of revenue-based goals for the period from March 1, 2022 to February 28, 2023 and March 1, 2021 to February 28, 2022. On October 7, 2019, the Company acquired certain assets and liabilities of USB, a privately-held developer and manufacturer of complex braided biomedical structures for disposable and implantable medical devices. As of December 31, 2023 and December 31, 2022, the Company assessed the probability of meeting the required revenue thresholds for the remaining earnout periods as unlikely and determined the fair value of the contingent consideration liability relating to the acquisition of USB was zero. During 2022, the Company recorded an adjustment of $0.6 million to reduce the fair value of the contingent consideration liability. During 2022, the Company made a payment of $0.5 million associated with the USB acquisition, resulting from achievement of revenue-based goals for the year ended December 31, 2021. (17.) FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued) Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis Fair value standards also apply to certain assets and liabilities that are measured at fair value on a nonrecurring basis. The carrying amounts of cash, accounts receivable, contract assets, accounts payable and accrued expenses approximate fair value due to the short-term nature of these items. Borrowings under the Company’s Revolving Credit Facility and TLA Facility accrue interest at a floating rate tied to a standard short-term borrowing index, selected at the Company’s option, plus an applicable margin. The carrying amount of this floating rate debt approximates fair value based upon the respective interest rates adjusting with market rate adjustments. The estimated fair value of the 2028 Convertible Notes was approximately $635 million as of December 31, 2023. The estimated fair value of the 2028 Convertible Notes was determined through consideration of quoted market prices. The fair value of the 2028 Convertible Notes are categorized in Level 2 of the fair value hierarchy. Equity Investments Equity investments comprise the following (in thousands): December 31, December 31, Equity method investment $ 7,771 $ 8,252 Non-marketable equity securities 427 5,637 Total equity investments $ 8,198 $ 13,889 The components of Loss on equity investments, net for each period were as follows (in thousands): 2023 2022 2021 Equity method investment loss $ 481 $ 7,636 $ 3,057 Impairment charges 5,210 — 86 Total loss on equity investments, net $ 5,691 $ 7,636 $ 3,143 During 2023 and 2021, the Company determined that certain non-marketable equity securities were impaired and recorded impairment charges of $5.2 million and $0.1 million, respectively, to reduce the carrying value of these non-marketable equity securities to their estimated fair value of $0.2 million and zero, respectively. In 2023, new equity financings by two of the Company’s non-marketable equity securities indicated new values for the investments. These assessments were based on qualitative indications of impairment which are considered to be a Level 3 fair value measurement, as the fair value was determined based on significant inputs not observable in the market. Factors that significantly influenced the determination of the impairment loss included priority claims to the equity security, distributions rights and preferences, and the investee’s financial condition, operational and financing cash flow activities. In 2021, new equity financings by one of the Company’s non-marketable equity securities indicated a new value for the investments. The fair values of this investment was derived from observable price changes of similar securities of the investee. There were no cash distributions received during 2023. During 2022, the Company received a cash distribution representing a return of capital on our equity method investments of $0.3 million. During 2021, the Company received cash distributions representing a return on equity method investments of $2.2 million. The Company’s equity method investment is in a venture capital fund focused on investing in life sciences companies. As of December 31, 2023, the Company owned 7.5% of this fund. |
SEGMENT AND GEOGRAPHIC INFORMAT
SEGMENT AND GEOGRAPHIC INFORMATION | 12 Months Ended |
Dec. 31, 2023 | |
Segment Reporting [Abstract] | |
SEGMENT AND GEOGRAPHIC INFORMATION | SEGMENT AND GEOGRAPHIC INFORMATION The Company organizes its business into two reportable segments: (1) Medical and (2) Non-Medical. This segment structure reflects the financial information and reports used by the Company’s management, specifically its Chief Operating Decision Maker, to make decisions regarding the Company’s business, including resource allocations and performance assessments. This segment structure reflects the Company’s current operating focus in compliance with ASC 280, Segment Reporting . The Company defines segment income from operations as sales less cost of sales including amortization and expenses attributable to segment-specific selling, general, administrative, research, development, engineering and other operating activities. The remaining unallocated operating and other expenses are primarily administrative corporate headquarter expenses and capital costs that are not allocated to reportable segments. Transactions between the two segments are not significant. The following table presents sales by product line for the years ended December 31, 2023, 2022 and 2021 (in thousands): 2023 2022 2021 Segment sales by product line: Medical Cardio & Vascular $ 836,342 $ 699,469 $ 593,117 Cardiac Rhythm Management & Neuromodulation 610,577 532,580 502,288 Advanced Surgical, Orthopedics & Portable Medical 106,421 97,502 87,221 Total Medical 1,553,340 1,329,551 1,182,626 Non-Medical 43,333 46,545 38,453 Total sales $ 1,596,673 $ 1,376,096 $ 1,221,079 Geographic Area Information The following table presents sales by significant country for the years ended December 31, 2023, 2022 and 2021. In these tables, sales are allocated based on where the products are shipped (in thousands). 2023 2022 2021 Sales by geographic area: United States $ 897,429 $ 762,134 $ 671,502 Non-Domestic locations: Puerto Rico 108,421 114,078 110,162 Costa Rica 89,573 76,140 66,975 Rest of world 501,250 423,744 372,440 Total sales $ 1,596,673 $ 1,376,096 $ 1,221,079 The following table presents revenues by significant customers, which are defined as any customer who individually represents 10% or more of a segment’s total revenues for the years ended December 31, 2023 and 2022. 2023 2022 Customer Medical Non-Medical Medical Non-Medical Customer A 17% * 17% * Customer B 16% * 17% * Customer C 13% * 13% * Customer D * 19% * 30% All other customers 54% 81% 53% 70% __________ * Less than 10% of segment’s total revenues for the period. (18.) SEGMENT AND GEOGRAPHIC INFORMATION (Continued) The following table presents revenues by significant ship to location, which is defined as any country where 10% or more of a segment’s total revenues are shipped for the years ended December 31, 2023 and 2022. 2023 2022 Ship to Location Medical Non-Medical Medical Non-Medical United States 56% 62% 55% 67% Canada * 10% * * United Kingdom * * * 10% Rest of world 44% 28% 45% 23% The following table presents income from continuing operations for the Company’s reportable segments for the years ended December 31, 2023, 2022 and 2021 (in thousands). 2023 2022 2021 Segment income from continuing operations: Medical $ 269,513 $ 205,877 $ 213,600 Non-Medical 3,182 7,571 8,022 Total segment income from continuing operations 272,695 213,448 221,622 Unallocated operating expenses (105,365) (92,121) (85,911) Operating income 167,330 121,327 135,711 Unallocated expenses, net (60,036) (45,369) (34,648) Income from continuing operations before income taxes $ 107,294 $ 75,958 $ 101,063 The following table presents depreciation and amortization expense for the Company’s reportable segments for the years ended December 31, 2023, 2022 and 2021 (in thousands). 2023 2022 2021 Segment depreciation and amortization: Medical $ 93,242 $ 86,825 $ 75,366 Non-Medical 1,211 1,096 1,167 Total depreciation and amortization included in segment income from continuing operations 94,453 87,921 76,533 Unallocated depreciation and amortization 4,388 4,070 4,836 Total depreciation and amortization $ 98,841 $ 91,991 $ 81,369 The following table presents total assets for the Company’s reportable segments as of December 31, 2023 and December 31, 2022 (in thousands). December 31, December 31, Identifiable assets: Medical $ 2,807,249 $ 2,652,357 Non-Medical 53,985 57,385 Total reportable segments 2,861,234 2,709,742 Unallocated assets 81,419 84,644 Total assets $ 2,942,653 $ 2,794,386 (18.) SEGMENT AND GEOGRAPHIC INFORMATION (Continued) The following table presents capital expenditures for the Company’s reportable segments for the years ended December 31, 2023, 2022 and 2021 (in thousands). 2023 2022 2021 Expenditures for tangible long-lived assets: Medical $ 114,886 $ 69,687 $ 48,364 Non-Medical 707 360 628 Total reportable segments 115,593 70,047 48,992 Unallocated long-lived tangible assets 4,345 4,681 4,471 Total expenditures $ 119,938 $ 74,728 $ 53,463 The following table presents PP&E by geographic area as of December 31, 2023 and December 31, 2022. In these tables, PP&E is aggregated based on the physical location of the tangible long-lived assets (in thousands). December 31, December 31, Long-lived tangible assets by geographic area: United States $ 234,246 $ 203,578 Ireland 118,965 61,356 Mexico 34,785 32,360 Rest of world 19,958 19,949 Total $ 407,954 $ 317,243 |
REVENUE FROM CONTRACTS WITH CUS
REVENUE FROM CONTRACTS WITH CUSTOMERS | 12 Months Ended |
Dec. 31, 2023 | |
Revenue from Contract with Customer [Abstract] | |
REVENUE FROM CONTRACTS WITH CUSTOMERS | REVENUE FROM CONTRACTS WITH CUSTOMERS Disaggregated Revenue In general, the Company’s business segmentation is aligned according to the nature and economic characteristics of its products and customer relationships and provides meaningful disaggregation of each business segment's results of operations. For a summary by disaggregated product line sales for each segment, refer to Note 18, “Segment and Geographic Information.” A significant portion of the Company’s sales for the years ended December 31, 2023, 2022 and 2021 and accounts receivable at December 31, 2023 and December 31, 2022 were to three customers as follows: Sales Accounts Receivable 2023 2022 2021 December 31, December 31, Customer A 17% 17% 18% 11% 14% Customer B 15% 16% 16% 8% 19% Customer C 13% 13% 13% 10% 11% 45% 46% 47% 29% 44% Revenue recognized from products and services transferred to customers over time during 2023 and 2022 represented 31% and 30%, respectively, of total revenue. Substantially all of the revenue recognized from products and services transferred to customers over time during 2023 and 2022 was within the Medical segment. Contract Balances The opening and closing balances of the Company’s contract assets and contract liabilities are as follows (in thousands): December 31, December 31, Contract assets $ 85,871 $ 71,927 Contract liabilities 6,142 5,616 Contract assets at December 31, 2023 increased $13.9 million from December 31, 2022 primarily due to a contract modification to add existing products. During 2023, the Company recognized $3.6 million of revenue that was included in the contract liability balance as of December 31, 2022. During 2022, the Company recognized $2.7 million of revenue that was included in the contract liability balance as of December 31, 2021. |
DISCONTINUED OPERATIONS
DISCONTINUED OPERATIONS | 12 Months Ended |
Dec. 31, 2023 | |
Discontinued Operations and Disposal Groups [Abstract] | |
DISCONTINUED OPERATIONS | DISCONTINUED OPERATIONS Divestiture of AS&O Product Line In July 2018, the Company completed the sale of its AS&O Product Line within its Medical segment. For all periods presented, financial results reported as discontinued operations in the Consolidated Statements of Operations relate to the divested AS&O Product Line. There were no income or cash flows from discontinued operations for the year ended December 31, 2023. During the years ended December 31, 2022 and 2021, the Company recognized other income Income from discontinued operations for the years ended December 31, 2022 and 2021 was as follows (in thousands): 2022 2021 Other income, net $ (1,323) $ (4,931) Provision for income taxes 296 1,143 Income from discontinued operations $ 1,027 $ 3,788 Cash flow information from discontinued operations for the years ended December 31, 2022 and 2021 was as follows (in thousands): 2022 2021 Income from discontinued operations $ 1,027 $ 3,788 Changes in operating assets and liabilities, net of acquisitions: Accrued expenses and other liabilities (1,323) (4,931) Income taxes payable 296 1,143 Net cash provided by operating activities $ — $ — |
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS | 12 Months Ended |
Dec. 31, 2023 | |
Subsequent Events [Abstract] | |
SUBSEQUENT EVENTS | SUBSEQUENT EVENTS On January 5, 2024, the Company acquired 100% of the equity interests of Pulse Technologies, Inc. (“Pulse”), in an all cash transaction for $138.2 million, subject to customary post-closing adjustments, with up to $20.0 million of contingent consideration payable based on specified revenue growth milestones being met through 2025. The Company funded the purchase price with borrowings under its Revolving Credit Facility during the first quarter of 2024. Prior to the acquisition, Pulse was a privately-held technology, engineering and contract manufacturing company focused on complex micro machining of medical device components for high growth structural heart, heart pump, electrophysiology, leadless pacing, and neuromodulation markets. Based in Pennsylvania, Pulse also provides proprietary advanced technologies, including Hierarchical Surface Restructuring (HSR TM ), Scratch-Free Surface Finishes, and Titanium Nitride Coatings. Consistent with the Company’s tuck-in acquisition strategy, the acquisition of Pulse further increases Company’s end-to-end development capabilities and manufacturing footprint in targeted growth markets and provides customers with expanded capabilities, capacity and resources to accelerate products time to market. For segment reporting purposes, the results of operations and assets from this acquisition will be included in the Company’s Medical segment. In addition to assets acquired and liabilities assumed, the Company expects to allocate the purchase price to identifiable intangible assets such as developed technology and customer relationships. The Company expects to determine the preliminary purchase price allocation prior to the end of the first quarter of 2024. Goodwill arising from the acquisition is tax deductible. |
Schedule II - Valuation and Qua
Schedule II - Valuation and Qualifying Accounts | 12 Months Ended |
Dec. 31, 2023 | |
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract] | |
Schedule II - Valuation and Qualifying Accounts | Schedule II—Valuation and Qualifying Accounts Col. C—Additions Column A Col. B Balance at Beginning Charged to Costs & Charged to Other Accounts- Describe Col. D Deductions Col. E Balance at End of December 31, 2023 Provision for credit losses $ 338 $ 74 $ 1 (1) $ (42) (4) $ 371 Valuation allowance for deferred tax assets $ 16,649 $ 3,267 (2) $ (14) (3) $ (4,161) (2) $ 15,741 December 31, 2022 Provision for credit losses $ 132 $ 48 $ 163 (1) $ (5) (4) $ 338 Valuation allowance for deferred tax assets $ 19,456 $ (684) (2) $ (131) (3) $ (1,992) (2) $ 16,649 December 31, 2021 Provision for credit losses $ 155 $ 20 $ — $ (43) (4) $ 132 Valuation allowance for deferred tax assets $ 20,739 $ (941) (2) $ 26 (3) $ (368) (2) $ 19,456 (1) Amount reclassified from deferred revenue. (2) Valuation allowance recorded in the provision for income taxes for certain net operating losses and tax credits. Deductions include the expiration of certain net operating losses and tax credits. (3) Includes foreign currency translation effect. (4) Accounts written off and reductions to allowances existing at the beginning of the year. Schedules not listed above have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto. (3) See exhibits listed under Part (b) below. |
SUMMARY OF SIGNIFICANT ACCOUN_2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) | 12 Months Ended |
Dec. 31, 2023 | |
Accounting Policies [Abstract] | |
Basis of Presentation and Principles of Consolidation | Basis of Presentation and Principles of Consolidation The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and include the accounts of Integer Holdings Corporation and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. In July 2018, the Company completed the sale of its Advanced Surgical and Orthopedic product lines (the “AS&O Product Line”) within its Medical segment. For all periods presented, financial results reported as discontinued operations in the Consolidated Statements of Operations relate to the divested AS&O Product Line. The Consolidated Statements of Cash Flows includes cash flows related to the discontinued operations due to Integer’s (parent) centralized treasury and cash management processes. See Note 20, “Discontinued Operations,” for the financial results and cash flow amounts for discontinued operations. All results and information in the consolidated financial statements are presented as continuing operations and exclude the AS&O Product Line unless otherwise noted specifically as discontinued operations. The Company organizes its business into two reportable segments: (1) Medical and (2) Non-Medical. The discontinued operations of the AS&O Product Line were reported in the Medical segment. Refer to Note 18, “Segment and Geographic Information,” for additional information on the Company’s reportable segments. |
Use of Estimates | Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of sales and expenses during the reporting periods. Actual results could differ materially from those estimates. |
Cash and Cash Equivalents | Cash and Cash Equivalents |
Concentration of Credit Risk | Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist principally of accounts receivable. A significant portion of the Company’s sales and accounts receivable are to three customers, all in the medical device industry, and, as such, the Company is directly affected by the condition of those customers and that industry. However, the credit risk associated with trade receivables is partially mitigated due to the stability of those customers. The Company performs on-going credit evaluations of its customers. Note 19, “Revenue from Contracts with Customers,” contains information on sales and accounts receivable for these customers. The Company maintains cash deposits with major banks, which from time to time may exceed insured limits. The Company performs on-going credit evaluations of its banks. |
Trade Accounts Receivable and Provision for Current Expected Credit Losses | Trade Accounts Receivable and Provision for Current Expected Credit Losses The Company provides credit, in the normal course of business, to its customers in the form of trade receivables. Credit is extended based on evaluation of a customer’s financial condition and collateral is not required. The Company maintains a provision for those customer receivables that it does not expect to collect. In accordance with Accounting Standards Codification (“ASC”) Topic 326, the Company accrues its estimated losses from uncollectable accounts receivable to the provision based upon recent historical experience, the length of time the receivable has been outstanding, other specific information as it becomes available, and reasonable and supportable forecasts not already reflected in the historical loss information. Provisions for current expected credit losses are charged to current operating expenses. Actual losses are charged against the provision when incurred. |
Factoring Arrangements | Factoring Arrangements |
Supplier Financing Arrangements | Supplier Financing Arrangements |
Inventories | Inventories Inventories are stated at the lower of cost, determined using the first-in first-out method, or net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Write-downs for excess, obsolete or expired inventory are based primarily on how long the inventory has been held, historical sales volume, and estimates of forecasted net sales of that product. A significant change in the timing or level of demand for products may result in recording additional write-downs for excess, obsolete or expired inventory in the future. Note 4, “Inventories,” contains additional information on the Company’s inventory. |
Leases | Leases The Company determines if an arrangement is, or contains, a lease at inception and classifies it at as finance or operating. The Company has operating and finance leases for office and manufacturing facilities, machinery, computer hardware, office equipment, and vehicles. Short-term finance lease liabilities are included in Accrued expenses and other current liabilities on the Consolidated Balance Sheets. Lease right-of-use (“ROU”) assets and corresponding liabilities are recognized based on the present value of the lease payments over the lease term at commencement date. When discount rates implicit in leases cannot be readily determined, the Company uses its incremental borrowing rate based on information available at commencement date in determining the present value of future payments. The incremental borrowing rate is determined based on the Company’s recent debt issuances, the Company’s specific credit rating, lease term and the currency in which lease payments are made. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such option. Costs associated with operating leases are recognized within operating expenses on a straight-line basis over the lease term. Finance lease assets are amortized within operating expenses on a straight-line basis over the shorter of the estimated useful lives of the assets or, in the instance where title does not transfer at the end of the lease term, the lease term. The interest component of a finance lease is included in Interest expense and recognized using the effective interest method over the lease term. The Company combines lease and non-lease components for all asset classes. For certain leases where rent escalates based upon a change in a financial index, such as the Consumer Price Index, the difference between the rate at lease inception and the subsequent fluctuations in that rate are included in variable lease costs. Additionally, because the Company does not separate lease and non-lease components, variable costs also include payments to the landlord for common area maintenance, real estate taxes, insurance and other operating expenses. The Company does not apply the recognition requirements to leases with lease terms of 12 months or less. Note 14, “Leases,” contains additional information on the Company’s leases. |
Property, Plant and Equipment (PP&E) | Property, Plant and Equipment (“PP&E”) PP&E is carried at cost less accumulated depreciation. Depreciation is computed by the straight-line method over the estimated useful lives of the assets, as follows: buildings and building improvements 12-30 years; machinery and equipment 3-10 years; office equipment 3-10 years; and leasehold improvements over the remaining lives of the improvements or the lease term, whichever is shorter. The costs of repairs and maintenance are expensed as incurred; renewals and betterments are capitalized. Upon retirement or sale of an asset, its cost and related accumulated depreciation or amortization is removed from the accounts and any gain or loss is recorded in operating income or expense. The Company also reviews its PP&E for impairment when impairment indicators exist. When impairment indicators exist, the Company determines if the carrying value of its fixed assets exceeds the related undiscounted future cash flows. In cases where the carrying value of the Company's long-lived assets or asset groups (excluding goodwill and indefinite-lived intangible assets) exceeds the related undiscounted cash flows, the carrying value is written down to fair value. Fair value is generally determined using a discounted cash flow analysis. Note 5, “Property, Plant and Equipment, Net,” contains additional information on the Company’s PP&E. |
Fair Value Measurements | Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e . the “exit price”) in an orderly transaction between market participants at the measurement date. ASC 820, Fair Value Measurements, establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the reliability of inputs as follows: Level 1 – Valuation is based on quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Level 1 valuations do not entail a significant degree of judgment. Level 2 – Valuation is determined from quoted prices for similar assets or liabilities in active markets, quoted prices for identical instruments in markets that are not active or by model-based techniques in which all significant inputs are observable in the market. Level 3 – Valuation is based on unobservable inputs that are significant to the overall fair value measurement. The degree of judgment in determining fair value is greatest for Level 3 valuations. Fair value is a market-based measure considered from the perspective of a market participant rather than an entity-specific measure. Therefore, even when market assumptions are not readily available, assumptions are required to reflect those that market participants would use in pricing the asset or liability at the measurement date. Note 17, “Financial Instruments and Fair Value Measurements,” contains additional information on assets and liabilities recorded at fair value in the consolidated financial statements. |
Acquisitions and Contingent Consideration | Acquisitions The Company accounts for acquisitions under the acquisition method of accounting for business combinations. Results of operations of acquired companies are included in the Company’s results of operations as of the respective acquisition dates. The purchase price of each acquisition is allocated to the net assets acquired based on estimates of their fair values at the date of the acquisition. Any purchase price in excess of these net assets is recorded as goodwill. All direct acquisition-related costs are expensed as incurred and are recognized as a component of Restructuring and other charges. The allocation of purchase price in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date. Contingent Consideration In circumstances where an acquisition involves a contingent consideration arrangement, the Company recognizes a liability equal to the fair value of the contingent payments it expects to make as of the acquisition date. Increases or decreases in the fair value of the contingent consideration liability can result from changes in discount periods and rates, as well as changes in the timing, amount of, or the likelihood of achieving the applicable performance target. Increases in projected revenues, estimated cash flows and probabilities of payment may result in significantly higher fair value measurements; decreases in these items may have the opposite effect. Increases in the discount rates in periods prior to payment may result in significantly lower fair value measurements and decreases in the discount rates may have the opposite effect. The contingent consideration fair value measurement is based on significant inputs not observable in the market and therefore constitute Level 3 inputs within the fair value hierarchy. The Company determines the initial fair value of contingent consideration liabilities using a Monte Carlo (“Monte Carlo”) valuation model, which involves a simulation of future revenues during the earn out-period using management’s best estimates, or a probability-weighted discounted cash flow analysis. In periods subsequent to the initial measurement, contingent consideration liabilities are remeasured to fair value each reporting period until the contingent consideration is settled using various assumptions including estimated revenues (based on internal operational budgets and long-range strategic plans), discount rates, revenue volatility and projected payment dates. The current portion of contingent consideration liabilities is included in Accrued expenses and other current liabilities and the non-current portion is included in Other long-term liabilities on the Consolidated Balance Sheets. Adjustments to the fair value of contingent consideration liabilities are included in Restructuring and other charges in the Consolidated Statements of Operations, and cash flows from operating activities in the Consolidated Statements of Cash Flows. Note 17, “Financial Instruments and Fair Value Measurements,” contains additional information on contingent consideration recorded at fair value in the consolidated financial statements. |
Goodwill | Goodwill Goodwill represents the excess of cost over the fair value of identifiable net assets of a business acquired and is assigned to one or more reporting units. The Company’s reporting units are the same as its reportable segments, Medical and Non-Medical. The Company tests each reporting unit’s goodwill for impairment at least annually as of the last day of the fiscal year and between annual tests if an event occurs or circumstances change that would more-likely-than-not reduce the fair value of a reporting unit below its carrying amount. In conducting its goodwill test, the Company either performs a qualitative assessment or a quantitative assessment. A qualitative assessment requires that the Company consider events or circumstances including, but not limited to, macro-economic conditions, market and industry conditions, cost factors, competitive environment, changes in strategy, changes in customers, changes in the Company’s stock price, results of the last impairment test, and the operational stability and the overall financial performance of the reporting units. If, after assessing the totality of events or circumstances, the Company determines that it is more likely than not that the fair values of its reporting units are greater than the carrying amounts, then the quantitative goodwill impairment test is not performed. The Company may elect to bypass the qualitative analysis and perform a quantitative analysis. If the qualitative assessment indicates that the quantitative analysis should be performed or if management elects to bypass a qualitative analysis to perform a quantitative analysis, the Company then evaluates goodwill for impairment by comparing the fair value of each of its reporting units to its carrying value, including the associated goodwill. To determine the fair values, the Company uses a combination of the income approach based on estimated discounted future cash flows and the market approach based on comparable publicly traded companies. The cash flow assumptions consider historical and forecasted revenue, operating costs and other relevant factors. |
Other Intangible Assets | Other Intangible Assets Other intangible assets consist of purchased technology and patents, customer lists and trademarks. Definite-lived intangible assets are amortized on an accelerated or straight-line basis, which approximates the projected cash flows used to determine the fair value of those definite-lived intangible assets at the time of acquisition, as follows: purchased technology and patents 5-20 years; customer lists 7-20 years and other intangible assets 1-20 years. Certain trademark assets are considered indefinite-lived intangible assets and are not amortized. The Company expenses the costs incurred to renew or extend the term of intangible assets. The Company reviews its definite-lived intangible assets for impairment when impairment indicators exist. When impairment indicators exist, the Company determines if the carrying value of its definite-lived intangible assets or asset groups exceeds the related undiscounted future cash flows. In cases where the carrying value exceeds the undiscounted future cash flows, the carrying value is written down to fair value. Fair value is generally determined using a discounted cash flow analysis. The Company assesses its indefinite-lived intangible assets for impairment periodically to determine if any adverse conditions exist that would indicate impairment or when impairment indicators exist. The Company assesses its indefinite-lived intangible assets for impairment at least annually by comparing the fair value of the indefinite-lived intangible asset to its carrying value. The fair value is determined using the relief from royalty method. Refer to Note 6, “Goodwill and Other Intangible Assets, Net,” for further details of the Company’s goodwill and other intangible assets. |
Equity Investments | Equity Investments The Company holds long-term, strategic investments in companies to promote business and strategic objectives. These investments are included in Other long-term assets on the Consolidated Balance Sheets. Equity investments are measured and recorded as follows: • Non-marketable equity securities are equity securities without readily determinable fair value that are measured and recorded at fair value with changes in fair value recognized within net income. The Company measures the securities at cost minus impairment, if any, plus or minus changes resulting from qualifying observable price changes. If an impairment is recognized on the Company’s non-marketable equity securities during the period, these assets are classified as Level 3 within the fair value hierarchy based on the nature of the fair value inputs. • Equity method investments are equity securities in investees the Company does not control but over which it has the ability to exercise influence. Equity method investments are recorded at cost and are adjusted to recognize (1) the Company’s share, based on percentage ownership or other contractual basis, of the investee’s income or loss, (2) additional contributions made and dividends or other distributions received, and (3) impairments resulting from other-than-temporary declines in fair value. Realized and unrealized gains and losses resulting from changes in fair value or the sale of these equity investments are recorded through (Gain) loss on equity investments, net. For some investments, the Company records its share of the investee’s income or loss one quarter in arrears due to the timing of its receipt of such information. The carrying value of the Company’s non-marketable equity securities is adjusted for qualifying observable price changes resulting from the issuance of similar or identical securities by the same issuer. Determining whether an observed transaction is similar to a security within the Company’s portfolio requires judgment based on the rights and preferences of the securities. Recording upward and downward adjustments to the carrying value of the Company’s equity securities as a result of observable price changes requires quantitative assessments of the fair value of these securities using various valuation methodologies and involves the use of estimates. Non-marketable equity securities and equity method investments (collectively referred to as non-marketable equity investments) are also subject to periodic impairment reviews. The Company’s quarterly impairment analysis considers both qualitative and quantitative factors that may have a significant impact on the investee’s fair value. Qualitative factors considered include the investee’s financial condition and business outlook, market for technology, operational and financing cash flow activities, technology and regulatory approval progress, and other relevant events and factors affecting the investee. When indicators of impairment exist, quantitative assessments of the fair value of the Company’s non-marketable equity investments are prepared. To determine the fair value of these investments, the Company uses all pertinent financial information available related to the investees, including financial statements, market participant valuations from recent and proposed equity offerings, and other third-party data. Non-marketable equity securities are tested for impairment using a qualitative model similar to the model used for goodwill and long-lived assets. Upon determining that an impairment may exist, the security’s fair value is calculated and compared to its carrying value and an impairment is recognized immediately if the carrying value exceeds the fair value. Equity method investments are subject to periodic impairment reviews using the other-than-temporary impairment model, which considers the severity and duration of a decline in fair value below cost and the Company’s ability and intent to hold the investment for a sufficient period of time to allow for recovery. The Company has determined that its investments are not considered variable interest entities. The Company’s exposure related to these entities is limited to its recorded investment. These investments are in start-up research and development companies whose fair value is highly subjective in nature and subject to future fluctuations, which could be significant. Refer to Note 17, “Financial Instruments and Fair Value Measurements,” for additional information on the Company’s equity investments. |
Debt Issuance Costs and Discounts | Debt Issuance Costs and Discounts Debt issuance costs and discounts associated with the issuance of debt by the Company are deferred and amortized over the lives of the related debt. Debt issuance costs incurred in connection with the Company’s issuance of its revolving credit facility are classified within Other long-term assets and amortized to Interest expense on a straight-line basis over the contractual term of the revolving credit facility. Debt issuance costs and discounts related to the Company’s term-debt are recorded as a reduction of the carrying value of the related debt and are amortized to Interest expense using the effective interest method over the period from the date of issuance to the maturity date. Upon prepayment of the related debt, the Company also recognizes a proportionate amount of the costs as extinguishment of debt. Costs treated as extinguishment of debt are expensed and included in Interest expense in the accompanying Consolidated Statements of Operations. The amortization of debt issuance costs and discounts, and debt extinguishment charges are included in Debt related charges included in interest expense in the Consolidated Statements of Cash Flows. Note 8, “Debt,” contains additional information on the Company’s debt issuance costs and discounts. |
Income Taxes | Income Taxes The consolidated financial statements of the Company have been prepared using the asset and liability approach to account for income taxes, which requires the recognition of deferred income taxes for the expected future tax consequences of net operating losses, credits, and temporary differences between the financial statement carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided on deferred tax assets if it is determined, within each taxing jurisdiction, that it is more likely than not that the asset will not be realized. The Company accounts for uncertain tax positions using a more likely than not recognition threshold. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. These tax positions are evaluated on a quarterly basis. The Company recognizes interest expense related to uncertain tax positions as Provision for income taxes. Penalties, if incurred, are recognized as a component of Selling, general and administrative (“SG&A”) expenses. The Company and its subsidiaries file a consolidated United States (“U.S.”) federal income tax return. State tax returns are filed on a combined or separate basis depending on the applicable laws in the jurisdictions where the tax returns are filed. The Company also files foreign tax returns on a separate company basis in the countries in which it operates. |
Derivative Financial Instruments | Derivative Financial Instruments The Company recognizes all derivative financial instruments in its consolidated financial statements at fair value . |
Revenue Recognition | Revenue Recognition The majority of the Company’s revenues consist of sales of various medical devices and products to large, multinational OEMs and their affiliated subsidiaries. The Company considers the customer’s purchase order, which in some cases is governed by a long-term agreement, and the Company’s corresponding sales order acknowledgment as the contract with the customer. The majority of contracts have an original expected duration of one year or less. Consideration payable to customers is included in the transaction price. In accordance with ASC 340-40-25-4, the Company expenses incremental costs of obtaining a contract when incurred because the amortization period is less than one year. The Company recognizes revenue from contracts with customers as performance obligations are satisfied when the customer obtains control of the products. Control is defined as the ability to direct the use of and obtain substantially all of the remaining benefits from the products. The customer obtains control of the products when title and risk of ownership transfers to them, which is primarily based upon shipping terms. Most of the Company’s revenues are recognized at the point in time when the products are shipped to customers. When a contract with a customer relates to products with no alternative use and the Company has an enforceable right to payment, including reasonable profit, for performance completed to date throughout the duration of the contract, revenue is recognized over time as control is transferred to the customer. When revenue is recognized over time, the Company uses an input measure to determine progress towards completion and total estimated costs at completion. Under this method, sales and gross profit are recognized generally as actual costs are incurred. Revenue is recognized net of sales tax, value-added taxes and other taxes. Performance Obligations The Company assesses whether promises are separate and distinct in the context of the contract. If promises are not separate and distinct, they are aggregated with other promises until they are separate and distinct, resulting in a performance obligation. The Company considers each shipment of an individual product included on a purchase order to be a separate performance obligation because the customer obtains economic benefit as each shipment occurs. Standard payment terms range from 30 to 90 days and may include a discount for early payment. The Company does not offer its customers a right of return. Rather, the Company warrants that each unit received by the customer will meet the agreed upon technical and quality specifications and requirements. If the units do not meet these requirements, the customer can return the non-compliant units as a corrective action under the warranty. The remedy offered to the customer is repair of the returned units or replacement if repair is not viable. Accordingly, the Company records a warranty reserve and any warranty activities are not considered to be a separate performance obligation. Contract Balances The timing of revenue recognition, billings and cash collections results in billed accounts receivable and less frequently, contract liabilities. Accounts receivable are recorded when the right to consideration becomes unconditional. Contract liabilities are recorded when customers pay or are billed in advance of the Company’s satisfaction of its performance obligations. Contract liabilities are classified as Accrued expenses and other current liabilities on the Consolidated Balance Sheets. For contracts with customers where revenue is recognized over time, the Company records a contract asset when revenue is earned but not yet billed associated with non-cancellable customer orders. Contract assets are presented as a current asset on the Consolidated Balance Sheets. Transaction Price Generally, the transaction price of the Company’s contracts consists of a unit price for each individual product included in the contract. The unit price can be fixed or variable based on the number of units ordered. In some instances, the transaction price also includes a rebate for meeting certain volume-based targets over a specified period of time. The transaction price of a contract is determined based on the unit price and the number of units ordered, reduced by the rebate expected to be earned on those units. Rebates are estimated based on the expected achievement of volume-based targets using the most likely amount method and are updated quarterly. Adjustments to these estimates are recognized in the period in which they are identified. When contracts with customers include consideration payable at the beginning of the contract, the transaction price is reduced at the later of when the Company recognizes revenue for the transfer of the related goods to the customer or when the Company pays or promises to pay the consideration. Volume discounts and rebates and other pricing reductions earned by customers are offset against their receivable balances. The transaction price is allocated to each performance obligation on a relative standalone selling price basis. As the majority of products sold to customers are manufactured to meet the specific requirements and technical specifications of that customer, the products are considered unique to that customer and the unit price stated in the contract is considered the standalone selling price. Contract Modifications |
Environmental Costs | Environmental Costs Environmental expenditures that relate to an existing condition caused by past operations and that do not provide future benefits are expensed as incurred. Liabilities are recorded when environmental assessments are made, the requirement for remedial efforts is probable and the amount of the liability can be reasonably estimated. Liabilities are recorded generally no later than the completion of feasibility studies. The Company has a process in place to monitor, identify, and assess how the current activities for known exposures are progressing against the recorded liabilities. The process is also designed to identify other potential remediation sites that are not presently known. |
Restructuring and Other Charges | Restructuring and Other Charges The Company continuously evaluates the business and identifies opportunities to realign its resources to better serve its customers and markets, improve operational efficiency and capabilities, and lower its operating costs or improve profitability. To realize the benefits associated with these opportunities, the Company undertakes restructuring-type activities to transform its business. The Company incurs costs associated with these activities, which primarily include exit and disposal costs and other costs directly related to the restructuring initiative. These actions may result in voluntary or involuntary employee termination benefits. Voluntary termination benefits are accrued when an employee accepts the related offer. Involuntary termination benefits are accrued upon the commitment to a termination plan and the benefit arrangement is communicated to affected employees, or when liabilities are determined to be probable and estimable, depending on the existence of a substantive plan for severance or termination. All other exit costs are expensed as incurred. The Company records exit and disposal costs (“restructuring charges”) as incurred in accordance with ASC 420, Exit or Disposal Cost Obligations , and are classified within Restructuring and other charges, while other costs directly related to the restructuring initiatives (“restructuring-related charges”) are classified within Cost of sales, Selling, general and administrative, and Research, development and engineering expenses in the Consolidated Statements of Operations. |
Research, Development and Engineering (RD&E) | Research, Development and Engineering (“RD&E”) |
Product Warranties | Product Warranties The Company allows customers to return defective or damaged products for credit, replacement, or repair. The Company warrants that its products will meet customer specifications and will be free from defects in materials and workmanship . The Company accrues its estimated exposure to warranty claims, through Cost of Sales, based upon experience and other specific information as it becomes available. The product warranty liability is classified as Accrued expenses and other current liabilities on the Consolidated Balance Sheets. Adjustments to pre-existing estimated exposure for warranties are made as changes to the obligations become reasonably estimable. The Company’s product warranty liability totaled $0.1 million as of December 31, 2023 and December 31, 2022. |
Stock-Based Compensation | Stock-Based Compensation The Company recognizes stock-based compensation expense for its compensation plans. These plans include stock options, restricted stock units (“RSUs”) and performance-based restricted stock units (“PRSUs”). For the Company’s PRSUs, in addition to service conditions, the ultimate number of shares to be earned depends on the achievement of targets based on market conditions, such as total shareholder return, or performance conditions based on the Company’s operating results. The Company records forfeitures of equity awards in the period in which they occur. The fair value of the stock-based compensation is determined at the grant date. The Company uses the Black-Scholes standard option pricing model (“Black-Scholes model”) to determine the fair value of stock options. The fair value of each RSU is determined based on the Company’s closing stock price on the date of grant. The fair value of each PRSU is determined based on either the Company’s closing stock price on the date of grant or through a Monte Carlo valuation model for those awards that include a market-based condition. In addition to the closing stock price on the date of grant, the determination of the fair value of awards using both the Black-Scholes and Monte Carlo valuation models is affected by other assumptions, including the following: Expected Term - The Company analyzes historical employee exercise and termination data to estimate the expected term assumption for stock options. For market-based awards, the term is commensurate with the performance period remaining as of the grant date. Risk-free Interest Rate - A risk-free rate is based on the U.S. Treasury rates in effect on the grant date for a maturity equal to or approximating the expected term of the award. Expected Volatility - For stock options, expected volatility is calculated using historical volatility based on the daily closing prices of the Company’s common stock over a period equal to the expected term. For market-based awards, a combination of historical and implied volatility for the Company and members of its peer group are used in developing the expected volatility assumption. Dividend Yield - The dividend yield assumption is based on the Company’s expected annual dividend yield on the grant date. The Company recognizes compensation expense over the required service or vesting period based on the fair value of the award on the date of grant. Certain executive stock-based awards contain market, performance and service conditions. Compensation expense for awards with market conditions is recognized over the service period and is not reversed if the market condition is not met. Compensation expense for awards with performance conditions is reassessed each reporting period and recognized based upon the probability that the performance targets will be achieved. All stock option awards granted under the Company’s compensation plans have an exercise price equal to the closing stock price on the date of grant, a ten-year contractual life and generally, vest annually over a three-year vesting term. RSUs typically vest in equal annual installments over a three The Company records deferred tax assets for awards that result in deductions on the Company’s income tax returns, based on the amount of stock-based compensation expense recognized and the statutory tax rate in the jurisdiction in which it will receive a deduction. Differences between the deferred tax assets recognized for financial reporting purposes and the actual tax deduction reported on the income tax return are recorded as a component of Provision for income taxes in the Consolidated Statements of Operations. Note 10, “Stock-Based Compensation,” contains additional information on the Company’s stock-based compensation. |
Defined Benefit Plans | Defined Benefit Plans The Company recognizes on its balance sheet as an asset or liability the overfunded or underfunded status of its defined benefit plans provided to its employees located in Mexico and Switzerland. This asset or liability is measured as the difference between the fair value of plan assets, if any, and the benefit obligation of those plans. For these plans, the benefit obligation is the projected benefit obligation, which is calculated based on actuarial computations of current and future benefits for employees. Actuarial gains or losses and prior service costs or credits that arise during the period, but are not included as components of net periodic benefit expense, are recognized as a component of AOCI on the Consolidated Balance Sheets. The Company records the service cost component of net benefit costs in Cost of sales and SG&A expenses. The interest cost component of net benefit costs is recorded in Interest expense and the remaining components of net benefit costs, amortization of net losses and expected return on plan assets, are recorded in Other (income) loss, net. |
Foreign Currency Translation and Remeasurement | Foreign Currency Translation and Remeasurement The Company translates all assets and liabilities of its foreign subsidiaries, where the U.S. dollar is not the functional currency, at the period-end exchange rate and translates income and expenses at the average exchange rates in effect during the period. The net effect of this translation is recorded in the consolidated financial statements as a component of AOCI. Translation adjustments are not adjusted for income taxes as they relate to permanent investments in the Company’s foreign subsidiaries. |
Earnings Per Share (EPS) | Earnings Per Share (“EPS”) Basic EPS is calculated using the weighted average number of shares outstanding during the period. Diluted EPS is calculated using the weighted average number of shares outstanding during the period plus, if dilutive, common stock equivalents outstanding during the period and stock issuable upon conversion of convertible debt instruments. The Company's common stock equivalents consist of shares issuable upon the release of RSUs and PRSUs and the incremental shares of common stock issuable upon the exercise of stock options. The dilutive effect of these common stock equivalents is reflected in diluted EPS by application of the treasury stock method. The dilutive effect of shares issuable upon conversion of convertible debt instruments are included in the calculation of diluted EPS under the if-converted method. Note 15, “Earnings Per Share,” contains additional information on the computation of the Company’s EPS. |
Comprehensive Income | Comprehensive Income The Company’s comprehensive income as reported in the Consolidated Statements of Comprehensive Income includes net income, foreign currency translation adjustments, the net change in cash flow hedges, net of tax, and defined benefit plan liability adjustments, net of tax. The Consolidated Statements of Comprehensive Income and Note 16, “Stockholders’ Equity,” contain additional information on the computation of the Company’s comprehensive income. |
Recently Accounting Pronouncements | Recent Accounting Pronouncements In the normal course of business, management evaluates all new Accounting Standards Updates (“ASU”) and other accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”), Securities and Exchange Commission (“SEC”), or other authoritative accounting bodies to determine the potential impact they may have on the Company’s Consolidated Financial Statements. Other than those discussed below, management does not expect any of the recently issued accounting pronouncements, which have not already been adopted, to have a material impact on the Company’s Consolidated Financial Statements. Accounting Guidance Not Yet Elected or Adopted In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280)-Improvements to Reportable Segment Disclosures . The ASU enhances disclosure of significant segment expenses by requiring disclosure of significant segment expenses regularly provided to the chief operating decision maker, extend certain annual disclosures to interim periods, and permits more than one measure of segment profit or loss to be reported under certain conditions. The amendments are effective for the Company in years beginning after December 15, 2023, and interim periods within years beginning after December 15, 2024. Early adoption of the ASU is permitted, including adoption in any interim period for which financial statements have not been issued. The Company is currently evaluating the impact that the adoption of this ASU will have on its consolidated financial statements. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740)-Improvements to Income Tax Disclosures. The ASU requires additional quantitative and qualitative income tax disclosures to allow readers of the consolidated financial statements to assess how the Company’s operations, related tax risks and tax planning affect its tax rate and prospects for future cash flows. For public business entities, the ASU is effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact that the adoption of this ASU will have on its consolidated financial statements. |
BUSINESS ACQUISITIONS (Tables)
BUSINESS ACQUISITIONS (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Business Combination and Asset Acquisition [Abstract] | |
Schedule of Summary of Final Allocation of Purchase Consideration | The following table summarizes the preliminary fair values of the assets acquired and liabilities assumed (in thousands): Fair value of net assets acquired Current assets $ 6,924 Inventory 5,376 Property, plant and equipment 3,436 Goodwill 20,989 Definite-lived intangible assets 9,200 Operating lease assets 2,072 Current liabilities (2,331) Operating lease liabilities (1,157) Fair value of net assets acquired $ 44,509 Fair value of net assets acquired Current assets $ 9,319 Property, plant and equipment 4,151 Goodwill 68,460 Definite-lived intangible assets 71,485 Operating lease assets 3,505 Other noncurrent assets 1,354 Current liabilities (4,370) Operating lease liabilities (3,258) Other noncurrent liabilities (9,377) Fair value of net assets acquired $ 141,269 The final purchase price allocation was as follows (in thousands): Fair value of net assets acquired Current assets (excluding inventory) $ 9,621 Inventory 11,270 Property, plant and equipment 17,977 Goodwill 78,392 Intangible assets 105,300 Operating lease assets 15,142 Other noncurrent assets 695 Current liabilities (11,143) Operating lease liabilities (12,044) Fair value of net assets acquired $ 215,210 |
Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination | The purchase price was allocated to intangible assets as follows (dollars in thousands): Definite-lived Intangible Assets Fair Value Assigned Weighted Average Amortization Period Weighted Average Discount Rate Customer lists $ 4,000 20.0 14.5% Technology 5,200 10.0 14.5% $ 9,200 The purchase price was allocated to intangible assets as follows (dollars in thousands): Definite-lived Intangible Assets Fair Value Assigned Weighted Average Amortization Period Customer lists $ 53,395 26.0 Technology 17,435 12.0 Tradenames 655 1.5 $ 71,485 The purchase price was allocated to intangible assets as follows (dollars in thousands): Definite-lived Intangible Assets Fair Value Assigned Weighted Average Amortization Period Customer lists $ 73,800 20.0 Technology 15,200 15.0 Tradenames 16,300 20.0 $ 105,300 |
Schedule of Business Acquisition, Pro Forma Information | The following table presents (in thousands) unaudited pro forma financial information, for the years shown, as if InNeuroCo, Aran and Oscor had been included in the Company’s financial results as of the beginning of fiscal year 2022, 2021 and 2020, respectively, through the date of acquisition (in thousands): 2023 2022 2021 Sales $ 1,615,606 $ 1,402,584 $ 1,291,600 Income from continuing operations 93,148 68,153 87,439 |
SUPPLEMENTAL CASH FLOW INFORM_2
SUPPLEMENTAL CASH FLOW INFORMATION (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Supplemental Cash Flow Elements [Abstract] | |
Schedule of Supplemental Cash Flow Information | The following represents supplemental cash flow information for the years ended December 31, 2023, 2022 and 2021 (in thousands): 2023 2022 2021 Non-cash investing and financing activities: Property, plant and equipment purchases included in accounts payable $ 21,044 $ 13,592 $ 5,556 Cash paid during the year for: Interest 37,701 35,804 24,740 Income taxes 30,351 11,165 19,649 |
INVENTORIES (Tables)
INVENTORIES (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Inventory Disclosure [Abstract] | |
Schedule of Inventory, Current | Inventories comprise the following (in thousands): December 31, 2023 2022 Raw materials $ 115,887 $ 98,640 Work-in-process 106,032 98,188 Finished goods 17,797 11,938 Total $ 239,716 $ 208,766 |
PROPERTY, PLANT AND EQUIPMENT_2
PROPERTY, PLANT AND EQUIPMENT, NET (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Property, Plant and Equipment [Abstract] | |
Schedule of Property, Plant and Equipment | PP&E comprises the following (in thousands): December 31, 2023 2022 Manufacturing machinery and equipment $ 436,834 $ 392,109 Buildings and building improvements 105,733 101,445 Information technology hardware and software 72,241 68,205 Leasehold improvements 90,510 87,616 Furniture and fixtures 18,089 17,614 Land and land improvements 13,358 13,173 Construction work in process 148,342 73,632 Other 1,537 1,478 886,644 755,272 Accumulated depreciation (478,690) (438,029) Total $ 407,954 $ 317,243 |
Schedule of Depreciation Expense | Depreciation expense for PP&E was as follows for the years ended December 31, 2023, 2022 and 2021 (in thousands): 2023 2022 2021 Depreciation expense $ 44,306 $ 42,617 $ 39,772 |
GOODWILL AND OTHER INTANGIBLE_2
GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Schedule of Goodwill | The changes in the carrying amount of goodwill by reportable segment during the years ended December 31, 2023 and 2022 was as follows (in thousands): Medical Non-Medical Total December 31, 2021 $ 907,704 $ 17,000 $ 924,704 Aran acquisition (Note 2) 68,460 — 68,460 Acquisition-related adjustments (Note 2) 505 — 505 Foreign currency translation (11,477) — (11,477) December 31, 2022 965,192 17,000 982,192 InNeuroCo acquisition (Note 2) 20,989 — 20,989 Foreign currency translation 7,826 — 7,826 December 31, 2023 $ 994,007 $ 17,000 $ 1,011,007 |
Schedule of Finite-Lived Intangible Assets | Intangible assets comprise the following (in thousands): Gross Accumulated Net December 31, 2023 Definite-lived: Purchased technology and patents $ 291,142 $ (196,388) $ 94,754 Customer lists 837,453 (253,267) 584,186 Amortizing tradenames and other 21,035 (7,117) 13,918 Total amortizing intangible assets $ 1,149,630 $ (456,772) $ 692,858 Indefinite-lived: Trademarks and tradenames $ 90,288 December 31, 2022 Definite-lived: Purchased technology and patents $ 283,929 $ (178,844) $ 105,085 Customer lists 825,634 (216,546) 609,088 Amortizing tradenames and other 21,028 (5,600) 15,428 Total amortizing intangible assets $ 1,130,591 $ (400,990) $ 729,601 Indefinite-lived: Trademarks and tradenames $ 90,288 |
Schedule of Indefinite-Lived Intangible Assets | Intangible assets comprise the following (in thousands): Gross Accumulated Net December 31, 2023 Definite-lived: Purchased technology and patents $ 291,142 $ (196,388) $ 94,754 Customer lists 837,453 (253,267) 584,186 Amortizing tradenames and other 21,035 (7,117) 13,918 Total amortizing intangible assets $ 1,149,630 $ (456,772) $ 692,858 Indefinite-lived: Trademarks and tradenames $ 90,288 December 31, 2022 Definite-lived: Purchased technology and patents $ 283,929 $ (178,844) $ 105,085 Customer lists 825,634 (216,546) 609,088 Amortizing tradenames and other 21,028 (5,600) 15,428 Total amortizing intangible assets $ 1,130,591 $ (400,990) $ 729,601 Indefinite-lived: Trademarks and tradenames $ 90,288 |
Schedule of Finite-Lived Intangible Assets, Amortization Expense | Aggregate intangible asset amortization expense comprises the following for the years ended December 31, 2023, 2022 and 2021 (in thousands): 2023 2022 2021 Cost of sales $ 16,260 $ 15,701 $ 13,090 SG&A 36,270 32,612 28,507 Restructuring and other charges 638 — — Total intangible asset amortization expense $ 53,168 $ 48,313 $ 41,597 |
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense | Estimated future intangible asset amortization expense based upon the carrying value as of December 31, 2023 is as follows (in thousands): 2024 2025 2026 2027 2028 After 2028 Amortization expense $ 52,298 $ 51,525 $ 49,844 $ 47,047 $ 44,246 $ 447,898 |
ACCRUED EXPENSES AND OTHER CU_2
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Accounts Payable and Accrued Liabilities [Abstract] | |
Schedule of Accrued Liabilities and Other Current Liabilities | Accrued expenses and other current liabilities comprise the following (in thousands): December 31, 2023 2022 Salaries and benefits $ 30,544 $ 33,084 Profit sharing and bonuses 36,114 15,800 Contingent consideration — 11,201 Contract liabilities 6,142 5,616 Short-term finance lease liabilities 1,894 1,093 Product warranties 84 77 Accrued interest 4,578 472 Other 8,732 6,156 Total $ 88,088 $ 73,499 |
DEBT (Tables)
DEBT (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Debt Disclosure [Abstract] | |
Schedule of Debt | Long-term debt comprises the following (in thousands): December 31, 2023 December 31, 2022 Principal Amount Discounts and Deferred Issuance Costs Net Carrying Amount Principal Amount Discounts and Deferred Issuance Costs Net Carrying Amount Senior Secured Credit Facilities: Revolving credit facilities $ 99,000 $ — $ 99,000 $ 140,300 $ — $ 140,300 Term loan A 375,000 (1,687) 373,313 455,313 (2,172) 453,141 Term loan B — — — 335,625 (3,805) 331,820 Convertible Senior Notes due 2028 500,000 (12,388) 487,612 — — — Total $ 974,000 $ (14,075) $ 959,925 $ 931,238 $ (5,977) $ 925,261 Current portion of long-term debt — (18,188) Long-term debt $ 959,925 $ 907,073 |
Schedule of Maturities of Long-term Debt | Contractual maturities under the Senior Secured Credit Facilities as of December 31, 2023 are as follows (in thousands): 2024 2025 2026 2027 2028 Future minimum principal payments $ — $ 10,000 $ 27,500 $ 30,000 $ 406,500 |
Schedule of Deferred Financing Costs | The change in deferred debt issuance costs related to the Company’s Revolving Credit Facility is as follows (in thousands): December 31, 2022 2,387 Financing costs incurred 579 Write-off of deferred debt issuance costs (260) Amortization during the period (540) December 31, 2023 $ 2,166 The change in debt discount and deferred debt issuance costs related to the Term Loan Facilities and 2028 Convertible Notes is as follows (in thousands): Deferred Debt Issuance Costs Debt Discount Total December 31, 2022 4,569 1,408 5,977 Financing costs incurred 1,602 13,750 15,352 Write-off of deferred debt issuance costs and unamortized discount (2,867) (1,391) (4,258) Amortization during the period (637) (2,359) (2,996) December 31, 2023 $ 2,667 $ 11,408 $ 14,075 |
STOCK-BASED COMPENSATION (Table
STOCK-BASED COMPENSATION (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Share-Based Payment Arrangement [Abstract] | |
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs | The classification of stock-based compensation expense in the accompanying Consolidated Statements of Operations was as follows (in thousands): Year Ended December 31, 2023 2022 2021 Cost of sales $ 3,709 $ 3,240 $ 3,365 SG&A 18,224 15,234 11,579 RD&E 1,237 1,099 969 Restructuring and other charges 113 1,450 272 Total stock-based compensation expense $ 23,283 $ 21,023 $ 16,185 Income tax benefit recognized for stock-based compensation arrangements $ 3,692 $ 2,908 $ 4,188 |
Schedule of Share-based Compensation, Stock Options, Activity | The following table summarizes stock option activity during the year ended December 31, 2023: Number of Weighted Weighted Aggregate Outstanding at December 31, 2022 240,622 $ 38.51 Exercised (82,533) 35.00 Outstanding at December 31, 2023 158,089 $ 40.35 2.9 $ 9.3 Vested and exercisable at December 31, 2023 158,089 $ 40.35 2.9 $ 9.3 |
Schedule Of Stock Option Exercise Information | The following table provides certain information relating to the exercise of stock options during 2023, 2022 and 2021 (in thousands): 2023 2022 2021 Intrinsic value $ 3,670 $ 370 $ 2,370 Cash received 2,303 150 743 Actual tax benefit for the tax deductions from the exercise of options 881 89 569 |
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity | The following table summarizes RSU activity during the year ended December 31, 2023: Time-Vested Weighted Nonvested at December 31, 2022 291,929 $ 77.58 Granted 231,604 75.77 Vested (117,587) 79.03 Forfeited (56,191) 72.98 Nonvested at December 31, 2023 349,755 $ 76.63 The following table summarizes PRSU activity during the year ended December 31, 2023: Performance- Weighted Nonvested at December 31, 2022 263,906 $ 90.29 Granted 105,757 74.32 Vested (24,427) 107.26 Forfeited (69,733) 82.72 Nonvested at December 31, 2023 275,503 $ 84.57 |
Schedule of Share-based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions | The weighted average fair value and assumptions used to value the TSR portion of the PRSUs granted are as follows: 2023 2022 2021 Weighted average fair value $ 74.29 $ 97.58 $ 85.16 Risk-free interest rate 3.79 % 1.58 % 0.19 % Expected volatility 46 % 42 % 41 % Expected life (in years) 3.0 3.9 3.0 Expected dividend yield — % — % — % |
RESTRUCTURING AND OTHER CHARG_2
RESTRUCTURING AND OTHER CHARGES (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Restructuring and Related Activities [Abstract] | |
Schedule of Restructuring and Related Charges | Restructuring and other charges comprise the following (in thousands): 2023 2022 2021 Restructuring charges $ 6,015 $ 4,920 $ 4,804 Acquisition and integration costs 3,444 10,075 2,544 Other general expenses 2,110 1,188 508 Total restructuring and other charges $ 11,569 $ 16,183 $ 7,856 The following table comprises restructuring and restructuring-related charges by classification in the accompanying Consolidated Statements of Operations (in thousands): 2023 2022 Restructuring charges: Restructuring and other charges $ 6,015 $ 4,920 Restructuring-related expenses (a) : Cost of sales 1,669 1,148 Selling, general and administrative 2,093 1,966 Research, development and engineering 667 1,231 Total restructuring and restructuring-related charges $ 10,444 $ 9,265 __________ (a) Restructuring-related expenses primarily include retention bonuses, consulting expenses and professional fees. Restructuring related expenses for 2021 were not material. |
Schedule of Changes in Restructuring Reserve | The following table summarizes the activity for restructuring reserves (in thousands): Operational Strategic reorganization and alignment Manufacturing alignment to support growth Total December 31, 2022 $ 232 $ 2,134 $ — $ 2,366 Charges incurred, net of reversals 844 1,259 3,912 6,015 Cash payments (1,055) (3,268) (687) (5,010) Non-cash adjustments — — (1,935) (1,935) December 31, 2023 $ 21 $ 125 $ 1,290 $ 1,436 |
INCOME TAXES (Tables)
INCOME TAXES (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Income Tax Disclosure [Abstract] | |
Schedule of Income before Income Tax, Domestic and Foreign | Income from continuing operations before income taxes for fiscal years 2023, 2022 and 2021 consisted of the following (in thousands): 2023 2022 2021 U.S. $ 31,001 $ 14,446 $ 48,293 International 76,293 61,512 52,770 Total income from continuing operations before income taxes $ 107,294 $ 75,958 $ 101,063 |
Schedule of Components of Income Tax Expense (Benefit) | The provision for income taxes from continuing operations for fiscal years 2023, 2022 and 2021 comprises the following (in thousands): 2023 2022 2021 Current: Federal $ 11,590 $ 20,455 $ 9,511 State 1,404 780 1,553 International 13,140 6,871 8,459 26,134 28,106 19,523 Deferred: Federal (7,451) (16,300) (8,665) State (168) 26 (393) International (1,871) (1,224) (2,422) (9,490) (17,498) (11,480) Total provision for income taxes $ 16,644 $ 10,608 $ 8,043 |
Schedule of Effective Income Tax Rate Reconciliation | The provision for income taxes from continuing operations differs from the U.S. statutory rate for fiscal years 2023, 2022 and 2021 due to the following: 2023 2022 2021 Statutory rate $ 22,531 21.0 % $ 15,951 21.0 % $ 21,223 21.0 % Federal tax credits (including R&D) (11,113) (10.4) (9,399) (12.4) (11,929) (11.8) Foreign rate differential (5,513) (5.1) (7,693) (10.1) (5,165) (5.1) Stock-based compensation 1,862 1.7 2,009 2.6 (1,084) (1.1) Uncertain tax positions (1,170) (1.1) 2,469 3.3 18 — State taxes, net of federal benefit 1,185 1.1 978 1.3 1,183 1.2 U.S. tax on foreign earnings, net of §250 deduction 6,090 5.7 5,225 6.9 1,913 1.9 Valuation allowance 1,737 1.6 (194) (0.3) 524 0.5 Other 1,035 1.0 1,262 1.7 1,360 1.4 Effective tax rate $ 16,644 15.5 % $ 10,608 14.0 % $ 8,043 8.0 % |
Schedule of Deferred Tax Assets and Liabilities | As of December 31, 2023 and December 31, 2022, the Company had a net deferred tax liability consisting of the following (in thousands): December 31, December 31, Research and development $ 27,957 $ 15,168 Operating lease liabilities 20,726 18,781 Tax credit carryforwards 8,989 10,110 Net operating loss carryforwards 7,814 9,121 Accrued expenses 7,516 7,113 Original issue discount from capped calls 7,288 — Stock-based compensation 5,154 4,230 Inventories 3,131 13,103 Gross deferred tax assets 88,575 77,626 Less valuation allowance (15,741) (16,649) Net deferred tax assets 72,834 60,977 Intangible assets (181,737) (188,976) Operating lease assets (20,851) (18,846) Property, plant and equipment (7,290) (6,789) Other (1,580) (790) Gross deferred tax liabilities (211,458) (215,401) Net deferred tax liability $ (138,624) $ (154,424) Presented as follows: Noncurrent deferred tax asset $ 7,001 $ 6,247 Noncurrent deferred tax liability (145,625) (160,671) Net deferred tax liability $ (138,624) $ (154,424) |
Schedule of Operating Loss and Tax Credit Carryforwards | As of December 31, 2023, the Company has the following carryforwards available (in millions): Jurisdiction Tax Gross Amount Deferred Tax Asset Valuation Allowance Begin to Expire U.S. State Net operating losses (a)(b) $ 89.6 $ 3.5 $ (3.3) 2024 International Net operating losses (a) 18.1 4.3 (4.1) 2024 U.S. Federal Foreign tax credits 4.9 4.9 (4.9) 2024 U.S. State R&D tax credits (b) 1.0 0.8 — 2035 U.S. State State tax credits (b) 3.8 3.0 (3.0) 2024 International R&D tax credits 0.3 0.3 — Indefinite __________ (a) Net operating losses (“NOLs”) are presented as pre-tax amounts. (b) U.S. State deferred tax assets and valuation allowance are presented net of federal benefit. |
Schedule of Income Tax Contingencies | Below is a summary of changes to the unrecognized tax benefit for the years ended December 31, 2023, 2022 and 2021 (in thousands): 2023 2022 2021 Balance, beginning of year $ 7,739 $ 5,537 $ 5,484 Additions based upon tax positions related to the current year 356 1,364 3,324 Additions (reductions) related to prior period tax returns (18) 838 (3,271) Reductions as a result of a lapse of applicable statute of limitations (1,607) — — Balance, end of year $ 6,470 $ 7,739 $ 5,537 |
LEASES (Tables)
LEASES (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Leases [Abstract] | |
Schedule of Lease Term, Discount Rate, Lease Costs and Supplemental Cash Flow Information | The components and classification of lease cost for the years ended December 31, 2023, 2022 and 2021 are as follows (in thousands): 2023 2022 2021 Finance lease cost: Amortization of lease assets $ 1,367 $ 1,080 $ 223 Interest on lease liabilities 321 317 59 Finance lease cost 1,688 1,397 282 Operating lease cost 14,057 13,927 10,729 Short-term lease cost (leases with initial term of 12 months or less) 324 342 137 Variable lease cost 3,041 3,026 2,619 Sublease income (904) (1,294) (1,392) Total lease cost $ 18,206 $ 17,398 $ 12,375 Cost of sales $ 13,542 $ 13,111 $ 9,642 SG&A 3,028 2,864 1,817 RD&E 929 1,106 857 Restructuring and other charges 386 — — Interest expense $ 321 $ 317 $ 59 Total lease cost $ 18,206 $ 17,398 $ 12,375 Supplemental cash flow information related to leases for the years ended December 31, 2023, 2022 and 2021 is as follows (in thousands): 2023 2022 2021 Cash paid for operating leases $ 13,892 $ 13,519 $ 10,808 Cash paid for interest on finance leases 321 317 59 Assets acquired under operating leases 17,911 15,777 32,466 Assets acquired under finance leases 4,210 1,882 8,154 The following table presents the weighted average remaining lease term and discount rate. December 31, December 31, Weighted-average remaining lease term - operating leases (in years) 9.2 7.5 Weighted-average remaining lease term - finance leases (in years) 7.7 10.0 Weighted-average discount rate - operating leases 5.5 % 3.9 % Weighted-average discount rate - finance leases 4.4 % 3.4 % |
Schedule of Operating Lease Liability Maturities | At December 31, 2023, the maturities of operating and finance lease liabilities were as follows (in thousands): Operating Leases Finance Leases 2024 $ 12,744 $ 2,411 2025 12,639 2,449 2026 12,580 2,011 2027 12,386 1,681 2028 11,851 1,296 Thereafter 42,683 4,516 Gross lease liabilities 104,883 14,364 Less: imputed interest (23,852) (2,082) Present value of lease liabilities 81,031 12,282 Less: current portion of lease liabilities (8,692) (1,894) Total long-term lease liabilities $ 72,339 $ 10,388 |
EARNINGS PER SHARE (Tables)
EARNINGS PER SHARE (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Earnings Per Share [Abstract] | |
Schedule of Earnings Per Share, Basic and Diluted | The following table sets forth a reconciliation of the information used in computing basic and diluted EPS for the years ended December 31, 2023, 2022 and 2021 (in thousands, except per share amounts): 2023 2022 2021 Numerator for basic and diluted EPS: Income from continuing operations $ 90,650 $ 65,350 $ 93,020 Income from discontinued operations — 1,027 3,788 Net income $ 90,650 $ 66,377 $ 96,808 Denominator for basic EPS: Weighted average shares outstanding 33,320 33,127 32,993 Effect of dilutive securities: Stock options, restricted stock and restricted stock units 438 230 265 Denominator for diluted EPS 33,758 33,357 33,258 Basic earnings per share: Income from continuing operations $ 2.72 $ 1.97 $ 2.82 Income from discontinued operations — 0.03 0.11 Basic earnings per share 2.72 2.00 2.93 Diluted earnings per share: Income from continuing operations $ 2.69 $ 1.96 $ 2.80 Income from discontinued operations — 0.03 0.11 Diluted earnings per share 2.69 1.99 2.91 |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share | The diluted weighted average share calculations do not include the following securities for the years ended December 31, 2023, 2022 and 2021, which are not dilutive to the EPS calculations or the performance criteria have not been met (in thousands): 2023 2022 2021 Time-vested stock options, restricted stock and restricted stock units 1 15 4 Performance-vested restricted stock units 84 152 92 |
STOCKHOLDERS' EQUITY (Tables)
STOCKHOLDERS' EQUITY (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Equity [Abstract] | |
Schedule of Changes in Number of Shares of Common Stock | The following table sets forth the changes in the number of shares of common stock for the years ended December 31: 2023 2022 Shares issued and outstanding at beginning of period 33,169,778 33,063,336 Stock options exercised, net of shares exchanged for payment 72,125 7,018 Vesting of RSUs, net of shares withheld to cover taxes 87,745 99,424 Shares issued and outstanding at end of period 33,329,648 33,169,778 |
Schedule of Accumulated Other Comprehensive Income (Loss) | Accumulated other comprehensive income comprises the following (in thousands): Defined Cash Foreign Total Tax Net-of-Tax December 31, 2021 $ (890) $ (2,291) $ 29,720 $ 26,539 $ 651 $ 27,190 Unrealized gain on cash flow hedges — 3,649 — 3,649 (766) 2,883 Realized gain on foreign currency hedges — (516) — (516) 108 (408) Realized loss on interest rate swap hedge — 918 — 918 (193) 725 Net defined benefit plan adjustments 544 — — 544 (35) 509 Foreign currency translation loss — — (25,570) (25,570) — (25,570) December 31, 2022 $ (346) $ 1,760 $ 4,150 $ 5,564 $ (235) $ 5,329 Unrealized gain on cash flow hedges — 7,008 — 7,008 (1,472) 5,536 Realized gain on foreign currency hedges — (5,353) — (5,353) 1,124 (4,229) Realized gain on interest rate swap hedge — (1,262) — (1,262) 265 (997) Net defined benefit plan adjustments 318 — — 318 (113) 205 Foreign currency translation gain — — 14,379 14,379 — 14,379 December 31, 2023 $ (28) $ 2,153 $ 18,529 $ 20,654 $ (431) $ 20,223 |
FINANCIAL INSTRUMENTS AND FAI_2
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Fair Value Disclosures [Abstract] | |
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis | The following tables provide information regarding assets and liabilities recorded at fair value on a recurring basis (in thousands): Fair Value Quoted Significant Significant December 31, 2023 Assets: Foreign currency hedging contracts $ 2,153 $ — $ 2,153 $ — Liabilities: Contingent consideration 876 — — 876 December 31, 2022 Assets: Interest rate swaps $ 1,262 $ — $ 1,262 $ — Assets: Foreign currency hedging contracts 521 — 521 — Liabilities: Foreign currency contracts 23 — 23 — Liabilities: Contingent consideration 11,756 — — 11,756 Notional Amount Maturity Pay Fixed Rate Receive Current Floating Rate Fair Value Balance Sheet Location $ 100,000 Jun 2023 2.1785 % 4.3869 % $ 1,262 Prepaid expenses and other current assets Information regarding outstanding foreign currency forward contracts designated as cash flow hedges as of December 31, 2023 is as follows (dollars in thousands): Notional Amount Maturity $/Foreign Currency Fair Value Balance Sheet Location $ 51,389 Dec 2024 1.0831 Euro $ 1,389 Prepaid expenses and other current assets 19,392 Dec 2024 0.0566 MXN Peso 182 Prepaid expenses and other current assets 19,201 Dec 2024 0.0248 UYU Peso 582 Prepaid expenses and other current assets Information regarding outstanding foreign currency forward contracts designated as cash flow hedges as of December 31, 2022 is as follows (dollars in thousands): Notional Amount Maturity $/Foreign Currency Fair Value Balance Sheet Location $ 37,175 Dec 2023 0.0489 MXN Peso $ 504 Prepaid expenses and other current assets 2,685 Mar 2023 0.0249 UYU Peso 17 Prepaid expenses and other current assets 17,309 Mar 2023 1.0751 Euro (23) Accrued expenses and other current liabilities |
Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) | The following table presents the impact of cash flow hedge derivative instruments on the Company’s Consolidated Statements of Operations and Consolidated Statements of Comprehensive Income for fiscal years 2023, 2022 and 2021 (in thousands): Gain (Loss) Recognized in OCI Gain (Loss) Reclassified from AOCI Derivative 2023 2022 2021 Location in Statement of Operations 2023 2022 2021 Interest rate swaps $ — $ 3,322 $ 642 Interest expense $ 1,262 $ (918) $ (3,406) Foreign exchange contracts 1,171 (2,226) (943) Sales (241) (2,073) (674) Foreign exchange contracts 5,666 2,225 399 Cost of sales 5,611 2,205 1,437 Foreign exchange contracts 171 328 (7) Operating expenses (17) 384 69 |
Schedule of Rollforward of Contingent Consideration | The following table presents the changes in the estimated fair values of the Company’s liabilities for contingent consideration measured using significant unobservable inputs (Level 3) for fiscal years 2023 and 2022 (in thousands): December 31, 2021 $ 2,415 Amount recorded for current year acquisitions 7,375 Fair value measurement adjustment 3,097 Payments (972) Foreign currency translation (159) December 31, 2022 11,756 Amount recorded for current year acquisition 876 Fair value measurement adjustment (736) Payments (11,177) Foreign currency translation 157 December 31, 2023 $ 876 |
Schedule of Equity Method Investments | Equity investments comprise the following (in thousands): December 31, December 31, Equity method investment $ 7,771 $ 8,252 Non-marketable equity securities 427 5,637 Total equity investments $ 8,198 $ 13,889 The components of Loss on equity investments, net for each period were as follows (in thousands): 2023 2022 2021 Equity method investment loss $ 481 $ 7,636 $ 3,057 Impairment charges 5,210 — 86 Total loss on equity investments, net $ 5,691 $ 7,636 $ 3,143 |
SEGMENT AND GEOGRAPHIC INFORM_2
SEGMENT AND GEOGRAPHIC INFORMATION (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Segment Reporting [Abstract] | |
Schedule of Segment Sales by Product Line | The following table presents sales by product line for the years ended December 31, 2023, 2022 and 2021 (in thousands): 2023 2022 2021 Segment sales by product line: Medical Cardio & Vascular $ 836,342 $ 699,469 $ 593,117 Cardiac Rhythm Management & Neuromodulation 610,577 532,580 502,288 Advanced Surgical, Orthopedics & Portable Medical 106,421 97,502 87,221 Total Medical 1,553,340 1,329,551 1,182,626 Non-Medical 43,333 46,545 38,453 Total sales $ 1,596,673 $ 1,376,096 $ 1,221,079 |
Schedule of Sales by Geographic Area | The following table presents sales by significant country for the years ended December 31, 2023, 2022 and 2021. In these tables, sales are allocated based on where the products are shipped (in thousands). 2023 2022 2021 Sales by geographic area: United States $ 897,429 $ 762,134 $ 671,502 Non-Domestic locations: Puerto Rico 108,421 114,078 110,162 Costa Rica 89,573 76,140 66,975 Rest of world 501,250 423,744 372,440 Total sales $ 1,596,673 $ 1,376,096 $ 1,221,079 The following table presents revenues by significant ship to location, which is defined as any country where 10% or more of a segment’s total revenues are shipped for the years ended December 31, 2023 and 2022. 2023 2022 Ship to Location Medical Non-Medical Medical Non-Medical United States 56% 62% 55% 67% Canada * 10% * * United Kingdom * * * 10% Rest of world 44% 28% 45% 23% |
Schedule of Revenue by Major Customers by Reporting Segments | The following table presents revenues by significant customers, which are defined as any customer who individually represents 10% or more of a segment’s total revenues for the years ended December 31, 2023 and 2022. 2023 2022 Customer Medical Non-Medical Medical Non-Medical Customer A 17% * 17% * Customer B 16% * 17% * Customer C 13% * 13% * Customer D * 19% * 30% All other customers 54% 81% 53% 70% __________ * Less than 10% of segment’s total revenues for the period. |
Schedule of Segment Income (Loss) from Operations | The following table presents income from continuing operations for the Company’s reportable segments for the years ended December 31, 2023, 2022 and 2021 (in thousands). 2023 2022 2021 Segment income from continuing operations: Medical $ 269,513 $ 205,877 $ 213,600 Non-Medical 3,182 7,571 8,022 Total segment income from continuing operations 272,695 213,448 221,622 Unallocated operating expenses (105,365) (92,121) (85,911) Operating income 167,330 121,327 135,711 Unallocated expenses, net (60,036) (45,369) (34,648) Income from continuing operations before income taxes $ 107,294 $ 75,958 $ 101,063 |
Schedule of Segment Depreciation and Amortization | The following table presents depreciation and amortization expense for the Company’s reportable segments for the years ended December 31, 2023, 2022 and 2021 (in thousands). 2023 2022 2021 Segment depreciation and amortization: Medical $ 93,242 $ 86,825 $ 75,366 Non-Medical 1,211 1,096 1,167 Total depreciation and amortization included in segment income from continuing operations 94,453 87,921 76,533 Unallocated depreciation and amortization 4,388 4,070 4,836 Total depreciation and amortization $ 98,841 $ 91,991 $ 81,369 |
Schedule of Long-Lived Tangible Assets and Identifiable Assets by Geographic Area | The following table presents total assets for the Company’s reportable segments as of December 31, 2023 and December 31, 2022 (in thousands). December 31, December 31, Identifiable assets: Medical $ 2,807,249 $ 2,652,357 Non-Medical 53,985 57,385 Total reportable segments 2,861,234 2,709,742 Unallocated assets 81,419 84,644 Total assets $ 2,942,653 $ 2,794,386 The following table presents PP&E by geographic area as of December 31, 2023 and December 31, 2022. In these tables, PP&E is aggregated based on the physical location of the tangible long-lived assets (in thousands). December 31, December 31, Long-lived tangible assets by geographic area: United States $ 234,246 $ 203,578 Ireland 118,965 61,356 Mexico 34,785 32,360 Rest of world 19,958 19,949 Total $ 407,954 $ 317,243 |
Schedule of Expenditures for Tangible Long-Lived Assets, Excluding Acquisitions | The following table presents capital expenditures for the Company’s reportable segments for the years ended December 31, 2023, 2022 and 2021 (in thousands). 2023 2022 2021 Expenditures for tangible long-lived assets: Medical $ 114,886 $ 69,687 $ 48,364 Non-Medical 707 360 628 Total reportable segments 115,593 70,047 48,992 Unallocated long-lived tangible assets 4,345 4,681 4,471 Total expenditures $ 119,938 $ 74,728 $ 53,463 |
REVENUE FROM CONTRACTS WITH C_2
REVENUE FROM CONTRACTS WITH CUSTOMERS (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Revenue from Contract with Customer [Abstract] | |
Schedules of Concentration of Risk by Reveune and Accounts Receivable | A significant portion of the Company’s sales for the years ended December 31, 2023, 2022 and 2021 and accounts receivable at December 31, 2023 and December 31, 2022 were to three customers as follows: Sales Accounts Receivable 2023 2022 2021 December 31, December 31, Customer A 17% 17% 18% 11% 14% Customer B 15% 16% 16% 8% 19% Customer C 13% 13% 13% 10% 11% 45% 46% 47% 29% 44% |
Schedule of Contract Assets and Contract Liabilities | The opening and closing balances of the Company’s contract assets and contract liabilities are as follows (in thousands): December 31, December 31, Contract assets $ 85,871 $ 71,927 Contract liabilities 6,142 5,616 |
DISCONTINUED OPERATIONS (Tables
DISCONTINUED OPERATIONS (Tables) | 12 Months Ended |
Dec. 31, 2023 | |
Discontinued Operations and Disposal Groups [Abstract] | |
Schedule of Discontinued Operations | Income from discontinued operations for the years ended December 31, 2022 and 2021 was as follows (in thousands): 2022 2021 Other income, net $ (1,323) $ (4,931) Provision for income taxes 296 1,143 Income from discontinued operations $ 1,027 $ 3,788 Cash flow information from discontinued operations for the years ended December 31, 2022 and 2021 was as follows (in thousands): 2022 2021 Income from discontinued operations $ 1,027 $ 3,788 Changes in operating assets and liabilities, net of acquisitions: Accrued expenses and other liabilities (1,323) (4,931) Income taxes payable 296 1,143 Net cash provided by operating activities $ — $ — |
SUMMARY OF SIGNIFICANT ACCOUN_3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 USD ($) segment customer | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | |
Schedule of Assets Useful Life [Line Items] | |||
Number of reportable segments | segment | 2 | ||
Number of customers | customer | 3 | ||
Sale of accounts receivable | $ 144.4 | ||
Factoring fee | 1.1 | ||
Accounts receivable derecognized | 139.4 | $ 120.7 | |
Costs associated with supplier financing arrangements | $ 1.8 | 0.9 | |
Description of payment terms | Standard payment terms range from 30 to 90 days and may include a discount for early payment. | ||
Product warranty | $ 0.1 | 0.1 | |
Net foreign currency transaction (gains ) losses | $ 1 | $ (1.1) | $ (0.1) |
Stock Options | |||
Schedule of Assets Useful Life [Line Items] | |||
Contractual life | 10 years | ||
Award vesting period | 3 years | ||
Restricted Stock And Unit Awards | Director | |||
Schedule of Assets Useful Life [Line Items] | |||
Award vesting period | 1 year | ||
Minimum | Restricted Stock And Unit Awards | |||
Schedule of Assets Useful Life [Line Items] | |||
Award vesting period | 3 years | ||
Minimum | Patents | |||
Schedule of Assets Useful Life [Line Items] | |||
Intangible asset, useful life | 5 years | ||
Minimum | Customer lists | |||
Schedule of Assets Useful Life [Line Items] | |||
Intangible asset, useful life | 7 years | ||
Minimum | Other intangible assets | |||
Schedule of Assets Useful Life [Line Items] | |||
Intangible asset, useful life | 1 year | ||
Maximum | Restricted Stock And Unit Awards | |||
Schedule of Assets Useful Life [Line Items] | |||
Award vesting period | 4 years | ||
Maximum | Performance-Vested | |||
Schedule of Assets Useful Life [Line Items] | |||
Award vesting period | 3 years | ||
Maximum | Patents | |||
Schedule of Assets Useful Life [Line Items] | |||
Intangible asset, useful life | 20 years | ||
Maximum | Customer lists | |||
Schedule of Assets Useful Life [Line Items] | |||
Intangible asset, useful life | 20 years | ||
Maximum | Other intangible assets | |||
Schedule of Assets Useful Life [Line Items] | |||
Intangible asset, useful life | 20 years | ||
Buildings and building improvements | Minimum | |||
Schedule of Assets Useful Life [Line Items] | |||
Property, plant and equipment, useful life | 12 years | ||
Buildings and building improvements | Maximum | |||
Schedule of Assets Useful Life [Line Items] | |||
Property, plant and equipment, useful life | 30 years | ||
Manufacturing machinery and equipment | Minimum | |||
Schedule of Assets Useful Life [Line Items] | |||
Property, plant and equipment, useful life | 3 years | ||
Manufacturing machinery and equipment | Maximum | |||
Schedule of Assets Useful Life [Line Items] | |||
Property, plant and equipment, useful life | 10 years | ||
Office equipment | Minimum | |||
Schedule of Assets Useful Life [Line Items] | |||
Property, plant and equipment, useful life | 3 years | ||
Office equipment | Maximum | |||
Schedule of Assets Useful Life [Line Items] | |||
Property, plant and equipment, useful life | 10 years |
BUSINESS ACQUISITIONS (Narrativ
BUSINESS ACQUISITIONS (Narrative) (Details) $ in Thousands, € in Millions | 3 Months Ended | 12 Months Ended | ||||||
Oct. 01, 2023 USD ($) | Apr. 06, 2022 USD ($) | Dec. 01, 2021 USD ($) | Dec. 31, 2023 USD ($) $ / € | Dec. 31, 2023 USD ($) $ / € | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | Apr. 06, 2022 EUR (€) | |
Business Acquisition [Line Items] | ||||||||
Contingent consideration | $ 900 | |||||||
Acquisitions, net of cash acquired | $ 43,602 | $ 126,636 | $ 217,978 | |||||
Acquisition-related adjustments | 505 | |||||||
Contingent consideration fair value adjustment | (736) | 3,097 | 133 | |||||
Proceeds from contingent consideration | 0 | 1,319 | 0 | |||||
Acquisition related costs | 700 | 6,900 | 2,000 | |||||
InNeuroCo | ||||||||
Business Acquisition [Line Items] | ||||||||
Consideration transferred | 44,500 | |||||||
Cash paid | 43,600 | |||||||
Contingent consideration | 900 | $ 900 | 900 | |||||
Revenue-based payments (up to) | $ 13,500 | |||||||
Inventory increase (decrease) | 600 | |||||||
Favorable lease adjustment | 700 | |||||||
Acquisition-related adjustments | $ 2,200 | |||||||
Sales related to acquisition | 5,200 | |||||||
Earnings or loss of acquisition | $ 0 | |||||||
InNeuroCo | Measurement Input, Price Volatility | ||||||||
Business Acquisition [Line Items] | ||||||||
Weighted average measurement input | 0.15 | 0.15 | ||||||
InNeuroCo | Discount rate | ||||||||
Business Acquisition [Line Items] | ||||||||
Weighted average measurement input | 0.14 | 0.14 | ||||||
InNeuroCo | Customer lists | Measurement Input, Annual Attrition Rate | Valuation, Income Approach | ||||||||
Business Acquisition [Line Items] | ||||||||
Measurement input | $ / € | 0.050 | 0.050 | ||||||
InNeuroCo | Technology | Measurement Input, Royalty Rate | Valuation, Income Approach | Minimum | ||||||||
Business Acquisition [Line Items] | ||||||||
Measurement input | $ / € | 0.050 | 0.050 | ||||||
Aran Acquisition | ||||||||
Business Acquisition [Line Items] | ||||||||
Consideration transferred | $ 141,300 | |||||||
Cash paid | 133,900 | $ 10,900 | ||||||
Contingent consideration | 7,400 | |||||||
Revenue-based payments (up to) | $ 10,900 | € 10 | ||||||
Percentage of business acquired | 100% | 100% | ||||||
Acquisitions, net of cash acquired | $ 129,300 | |||||||
Sales related to acquisition | 15,100 | |||||||
Earnings or loss of acquisition | $ 0 | |||||||
Oscor Inc | ||||||||
Business Acquisition [Line Items] | ||||||||
Consideration transferred | $ 215,200 | |||||||
Inventory increase (decrease) | (900) | |||||||
Percentage of business acquired | 100% | |||||||
Acquisition-related adjustments | $ 5,200 | 500 | ||||||
Adjustment, current liabilities | 2,300 | |||||||
Adjustment in current assets | 2,500 | |||||||
Contingent consideration receivable | $ 1,400 | |||||||
Contingent consideration fair value adjustment | 100 | |||||||
Proceeds from contingent consideration | 1,300 | |||||||
Sales related to acquisition | 4,700 | |||||||
Earnings or loss of acquisition | $ 0 |
BUSINESS ACQUISITIONS (Allocati
BUSINESS ACQUISITIONS (Allocation Of The Provisional Purchase Price ) (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Oct. 01, 2023 | Dec. 31, 2022 | Apr. 06, 2022 | Dec. 31, 2021 | Dec. 01, 2021 |
Fair value of net assets acquired | ||||||
Goodwill | $ 1,011,007 | $ 982,192 | $ 924,704 | |||
InNeuroCo | ||||||
Fair value of net assets acquired | ||||||
Current assets | $ 6,924 | |||||
Inventory | 5,376 | |||||
Property, plant and equipment | 3,436 | |||||
Goodwill | 20,989 | |||||
Definite-lived intangible assets | 9,200 | |||||
Operating lease assets | 2,072 | |||||
Current liabilities | (2,331) | |||||
Operating lease liabilities | (1,157) | |||||
Fair value of net assets acquired | $ 44,509 | |||||
Aran Acquisition | ||||||
Fair value of net assets acquired | ||||||
Current assets | $ 9,319 | |||||
Property, plant and equipment | 4,151 | |||||
Goodwill | 68,460 | |||||
Definite-lived intangible assets | 71,485 | |||||
Operating lease assets | 3,505 | |||||
Other noncurrent assets | 1,354 | |||||
Current liabilities | (4,370) | |||||
Operating lease liabilities | (3,258) | |||||
Other noncurrent liabilities | (9,377) | |||||
Fair value of net assets acquired | $ 141,269 | |||||
Oscor Inc | ||||||
Fair value of net assets acquired | ||||||
Current assets | $ 9,621 | |||||
Inventory | 11,270 | |||||
Property, plant and equipment | 17,977 | |||||
Goodwill | 78,392 | |||||
Intangible assets | 105,300 | |||||
Operating lease assets | 15,142 | |||||
Other noncurrent assets | 695 | |||||
Current liabilities | (11,143) | |||||
Operating lease liabilities | (12,044) | |||||
Fair value of net assets acquired | $ 215,210 |
BUSINESS ACQUISITIONS ( Pro For
BUSINESS ACQUISITIONS ( Pro Forma Information) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Business Combination, Separately Recognized Transactions [Line Items] | |||
Sales | $ 1,615,606 | $ 1,402,584 | $ 1,291,600 |
Income from continuing operations | $ 93,148 | $ 68,153 | $ 87,439 |
BUSINESS ACQUISITIONS ( Schedul
BUSINESS ACQUISITIONS ( Schedule of Finite-Lived Intangible Assets Acquired) (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2021 | |
InNeuroCo | ||
Business Combination, Separately Recognized Transactions [Line Items] | ||
Fair Value Assigned | $ 9,200 | |
InNeuroCo | Customer lists | ||
Business Combination, Separately Recognized Transactions [Line Items] | ||
Fair Value Assigned | $ 4,000 | |
Weighted Average Amortization Period (Years) | 20 years | |
Weighted Average Discount Rate | 14.50% | |
InNeuroCo | Technology | ||
Business Combination, Separately Recognized Transactions [Line Items] | ||
Fair Value Assigned | $ 5,200 | |
Weighted Average Amortization Period (Years) | 10 years | |
Weighted Average Discount Rate | 14.50% | |
Aran Acquisition | ||
Business Combination, Separately Recognized Transactions [Line Items] | ||
Fair Value Assigned | $ 71,485 | |
Aran Acquisition | Customer lists | ||
Business Combination, Separately Recognized Transactions [Line Items] | ||
Fair Value Assigned | $ 53,395 | |
Weighted Average Amortization Period (Years) | 26 years | |
Aran Acquisition | Technology | ||
Business Combination, Separately Recognized Transactions [Line Items] | ||
Fair Value Assigned | $ 17,435 | |
Weighted Average Amortization Period (Years) | 12 years | |
Aran Acquisition | Tradenames | ||
Business Combination, Separately Recognized Transactions [Line Items] | ||
Fair Value Assigned | $ 655 | |
Weighted Average Amortization Period (Years) | 1 year 6 months | |
Oscor Inc | ||
Business Combination, Separately Recognized Transactions [Line Items] | ||
Fair Value Assigned | $ 105,300 | |
Oscor Inc | Customer lists | ||
Business Combination, Separately Recognized Transactions [Line Items] | ||
Fair Value Assigned | $ 73,800 | |
Weighted Average Amortization Period (Years) | 20 years | |
Oscor Inc | Technology | ||
Business Combination, Separately Recognized Transactions [Line Items] | ||
Fair Value Assigned | $ 15,200 | |
Weighted Average Amortization Period (Years) | 15 years | |
Oscor Inc | Tradenames | ||
Business Combination, Separately Recognized Transactions [Line Items] | ||
Fair Value Assigned | $ 16,300 | |
Weighted Average Amortization Period (Years) | 20 years |
SUPPLEMENTAL CASH FLOW INFORM_3
SUPPLEMENTAL CASH FLOW INFORMATION (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Non-cash investing and financing activities: | |||
Property, plant and equipment purchases included in accounts payable | $ 21,044 | $ 13,592 | $ 5,556 |
Cash paid during the year for: | |||
Interest | 37,701 | 35,804 | 24,740 |
Income taxes | $ 30,351 | $ 11,165 | $ 19,649 |
INVENTORIES (Details)
INVENTORIES (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Inventory Disclosure [Abstract] | ||
Raw materials | $ 115,887 | $ 98,640 |
Work-in-process | 106,032 | 98,188 |
Finished goods | 17,797 | 11,938 |
Total | $ 239,716 | $ 208,766 |
PROPERTY, PLANT AND EQUIPMENT_3
PROPERTY, PLANT AND EQUIPMENT, NET (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment, gross | $ 886,644 | $ 755,272 |
Accumulated depreciation | (478,690) | (438,029) |
Total | 407,954 | 317,243 |
Manufacturing machinery and equipment | ||
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment, gross | 436,834 | 392,109 |
Buildings and building improvements | ||
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment, gross | 105,733 | 101,445 |
Information technology hardware and software | ||
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment, gross | 72,241 | 68,205 |
Leasehold improvements | ||
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment, gross | 90,510 | 87,616 |
Furniture and fixtures | ||
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment, gross | 18,089 | 17,614 |
Land and land improvements | ||
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment, gross | 13,358 | 13,173 |
Construction work in process | ||
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment, gross | 148,342 | 73,632 |
Other | ||
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment, gross | $ 1,537 | $ 1,478 |
PROPERTY, PLANT AND EQUIPMENT_4
PROPERTY, PLANT AND EQUIPMENT, NET (Depreciation Expense) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Property, Plant and Equipment [Abstract] | |||
Depreciation expense | $ 44,306 | $ 42,617 | $ 39,772 |
GOODWILL AND OTHER INTANGIBLE_3
GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Schedule of Goodwill) (Details) | 12 Months Ended | |
Dec. 31, 2023 USD ($) | Dec. 31, 2022 USD ($) | |
Goodwill [Roll Forward] | ||
Opening goodwill | $ 982,192,000 | $ 924,704,000 |
Acquisition | 20,989,000 | 68,460,000 |
Acquisition-related adjustments | 505,000 | |
Foreign currency translation | 7,826,000 | (11,477,000) |
Closing goodwill | 1,011,007,000 | 982,192,000 |
Medical | ||
Goodwill [Roll Forward] | ||
Opening goodwill | 965,192,000 | 907,704,000 |
Acquisition | 20,989,000 | 68,460,000 |
Acquisition-related adjustments | 505,000 | |
Foreign currency translation | 7,826,000 | (11,477,000) |
Closing goodwill | 994,007,000 | 965,192,000 |
Accumulated impairment loss | 0 | |
Non-Medical | ||
Goodwill [Roll Forward] | ||
Opening goodwill | 17,000,000 | 17,000,000 |
Acquisition | 0 | 0 |
Acquisition-related adjustments | 0 | |
Foreign currency translation | 0 | 0 |
Closing goodwill | 17,000,000 | $ 17,000,000 |
Accumulated impairment loss | $ 0 |
GOODWILL AND OTHER INTANGIBLE_4
GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Narrative) (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 |
Indefinite-lived Intangible Assets [Line Items] | |||
Finite-lived intangible asset | $ 692,858 | $ 729,601 | |
Trademarks and tradenames | |||
Indefinite-lived Intangible Assets [Line Items] | |||
Indefinite-lived intangible assets (excluding goodwill) | $ 90,288 | 90,288 | |
Lake Region Medical | Trademarks and tradenames | |||
Indefinite-lived Intangible Assets [Line Items] | |||
Indefinite-lived intangible assets (excluding goodwill) | $ 70,000 | $ 20,300 |
GOODWILL AND OTHER INTANGIBLE_5
GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Schedule of Definite-Lived and Indefinite-Lived Intangible Assets, Major Class) (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | $ 1,149,630 | $ 1,130,591 |
Accumulated Amortization | (456,772) | (400,990) |
Net Carrying Amount | 692,858 | 729,601 |
Trademarks and tradenames | ||
Indefinite-lived Intangible Assets [Line Items] | ||
Indefinite-lived intangible assets (excluding goodwill) | 90,288 | 90,288 |
Purchased technology and patents | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | 291,142 | 283,929 |
Accumulated Amortization | (196,388) | (178,844) |
Net Carrying Amount | 94,754 | 105,085 |
Customer lists | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | 837,453 | 825,634 |
Accumulated Amortization | (253,267) | (216,546) |
Net Carrying Amount | 584,186 | 609,088 |
Amortizing tradenames and other | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | 21,035 | 21,028 |
Accumulated Amortization | (7,117) | (5,600) |
Net Carrying Amount | $ 13,918 | $ 15,428 |
GOODWILL AND OTHER INTANGIBLE_6
GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Amortization Expense by categories) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Finite-Lived Intangible Assets [Line Items] | |||
Total intangible asset amortization expense | $ 53,168 | $ 48,313 | $ 41,597 |
Cost of sales | |||
Finite-Lived Intangible Assets [Line Items] | |||
Total intangible asset amortization expense | 16,260 | 15,701 | 13,090 |
SG&A | |||
Finite-Lived Intangible Assets [Line Items] | |||
Total intangible asset amortization expense | 36,270 | 32,612 | 28,507 |
Restructuring and other charges | |||
Finite-Lived Intangible Assets [Line Items] | |||
Total intangible asset amortization expense | $ 638 | $ 0 | $ 0 |
GOODWILL AND OTHER INTANGIBLE_7
GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Future Amortization Expense) (Details) $ in Thousands | Dec. 31, 2023 USD ($) |
Goodwill and Intangible Assets Disclosure [Abstract] | |
2024 | $ 52,298 |
2025 | 51,525 |
2026 | 49,844 |
2027 | 47,047 |
2028 | 44,246 |
After 2028 | $ 447,898 |
ACCRUED EXPENSES AND OTHER CU_3
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Accounts Payable and Accrued Liabilities [Abstract] | ||
Salaries and benefits | $ 30,544 | $ 33,084 |
Profit sharing and bonuses | 36,114 | 15,800 |
Contingent consideration | 0 | 11,201 |
Contract liabilities | 6,142 | 5,616 |
Short-term finance lease liabilities | 1,894 | 1,093 |
Product warranties | 84 | 77 |
Accrued interest | 4,578 | 472 |
Other | 8,732 | 6,156 |
Total | $ 88,088 | $ 73,499 |
DEBT (Schedule of Long-Term Deb
DEBT (Schedule of Long-Term Debt) (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Feb. 28, 2023 | Dec. 31, 2022 |
Debt Instrument [Line Items] | |||
Principal Amount | $ 974,000 | $ 931,238 | |
Discounts and Deferred Issuance Costs | (14,075) | (5,977) | |
Net Carrying Amount | 959,925 | 925,261 | |
Current portion of long-term debt | 0 | (18,188) | |
Long-term debt | 959,925 | 907,073 | |
Line of Credit | Revolving Credit Facility | |||
Debt Instrument [Line Items] | |||
Principal Amount | 99,000 | 140,300 | |
Discounts and Deferred Issuance Costs | 0 | 0 | |
Net Carrying Amount | 99,000 | 140,300 | |
Loans Payable | Secured Debt | Term Loan A (TLA) Facility | |||
Debt Instrument [Line Items] | |||
Principal Amount | 375,000 | 455,313 | |
Discounts and Deferred Issuance Costs | (1,687) | (2,172) | |
Net Carrying Amount | 373,313 | 453,141 | |
Loans Payable | Secured Debt | Term Loan B (TLB) Facility | |||
Debt Instrument [Line Items] | |||
Principal Amount | 0 | 335,625 | |
Discounts and Deferred Issuance Costs | 0 | (3,805) | |
Net Carrying Amount | 0 | 331,820 | |
Convertible Debt | 2028 Convertible Senior Notes | |||
Debt Instrument [Line Items] | |||
Net Carrying Amount | $ 65,000 | ||
Convertible Debt | Secured Debt | 2028 Convertible Senior Notes | |||
Debt Instrument [Line Items] | |||
Principal Amount | 500,000 | 0 | |
Discounts and Deferred Issuance Costs | (12,388) | 0 | |
Net Carrying Amount | $ 487,612 | $ 0 |
DEBT (Senior Secured Credit Fac
DEBT (Senior Secured Credit Facilities) (Details) - USD ($) | Feb. 15, 2023 | Sep. 02, 2021 | Feb. 14, 2023 | Jan. 30, 2023 |
Secured Debt | Term Loan A (TLA) Facility | ||||
Debt Instrument [Line Items] | ||||
Debt instrument term | 5 years | |||
Secured Debt | Term Loan B (TLB) Facility | ||||
Debt Instrument [Line Items] | ||||
Debt instrument term | 7 years | |||
Discount percent | 0.50% | |||
Revolving Credit Facility | Line of Credit | ||||
Debt Instrument [Line Items] | ||||
Debt instrument term | 5 years | |||
Credit facility maximum borrowing capacity | $ 500,000,000 | $ 400,000,000 | $ 400,000,000 | $ 600,000,000 |
Increase in maximum borrowing capacity | $ 100,000,000 | |||
Sublimit percentage | 50% | |||
Revolving Credit Facility | Line of Credit | Adjusted Term Secured Overnight Financing Rate (SOFT) | ||||
Debt Instrument [Line Items] | ||||
Spread on variable rate | 0.10% |
DEBT (Revolving Credit Facility
DEBT (Revolving Credit Facility) (Details) $ in Millions | 12 Months Ended |
Dec. 31, 2023 USD ($) | |
Revolving Credit Facility | Line of Credit | |
Debt Instrument [Line Items] | |
Remaining borrowing capacity | $ 397.5 |
Outstanding amount | $ 99 |
Unused capacity commitment fee | 0.18% |
Weighted average interest rate | 7.08% |
Revolving Credit Facility | Line of Credit | Minimum | |
Debt Instrument [Line Items] | |
Unused capacity commitment fee | 0.15% |
Revolving Credit Facility | Line of Credit | Maximum | |
Debt Instrument [Line Items] | |
Unused capacity commitment fee | 0.25% |
Standby Letters of Credit | |
Debt Instrument [Line Items] | |
Outstanding standby letters of credit | $ 3.5 |
DEBT (Term Loan Facilities) (De
DEBT (Term Loan Facilities) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Feb. 15, 2023 | Dec. 31, 2022 | |
Debt Instrument [Line Items] | |||
Unamortized debt issuance costs | $ 14,075 | $ 5,977 | |
Line of Credit | Revolving Credit Facility | |||
Debt Instrument [Line Items] | |||
Weighted average interest rate | 7.08% | ||
Debt issuance costs | $ 1,000 | ||
Unamortized debt issuance costs | $ 0 | $ 0 | |
Term Loan A (TLA) Facility | Secured Debt | |||
Debt Instrument [Line Items] | |||
Weighted average interest rate | 6.96% | ||
Revolving Credit Facility And Term Loan A (TLA) Faility | Secured Debt | |||
Debt Instrument [Line Items] | |||
Unamortized debt issuance costs | $ 3,800 | ||
Write off of debt issuance cost | 600 | ||
Term Loan B (TLB) Facility | Secured Debt | |||
Debt Instrument [Line Items] | |||
Write off of debt issuance cost | $ 3,900 |
DEBT (Covenants) (Details)
DEBT (Covenants) (Details) $ / shares in Units, shares in Millions | 1 Months Ended | 12 Months Ended | |||||
Feb. 03, 2023 | Sep. 01, 2021 $ / € | Feb. 28, 2023 USD ($) d $ / shares shares | Dec. 31, 2023 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | Jan. 31, 2023 $ / shares | |
Debt Instrument [Line Items] | |||||||
Long-term debt | $ 959,925,000 | $ 925,261,000 | |||||
Proceeds from issuance of convertible notes, net of discount | 486,250,000 | 0 | $ 0 | ||||
Conversion premium on share price (in dollars per share) | $ / shares | $ 65.81 | ||||||
Original issue discount from capped calls | $ 7,288,000 | $ 0 | |||||
Capped Call Options | |||||||
Debt Instrument [Line Items] | |||||||
Capped call (in shares) | shares | 5.7 | ||||||
Capped Call Options | |||||||
Debt Instrument [Line Items] | |||||||
Conversion price (in dollars per share) | $ / shares | $ 108.59 | ||||||
Capped call (in shares) | shares | 5.7 | ||||||
Original issue discount from capped calls | $ 8,800,000 | ||||||
Derivative, cost of hedge | 35,000,000 | ||||||
2028 Convertible Senior Notes | Convertible Debt | |||||||
Debt Instrument [Line Items] | |||||||
Debt principal payments | 500,000,000 | ||||||
Long-term debt | $ 65,000,000 | ||||||
Stated interest rate | 2.125% | ||||||
Proceeds from issuance of convertible notes, net of discount | $ 485,000,000 | ||||||
Conversion price (in dollars per share) | $ / shares | $ 87.20 | ||||||
Conversion premium interest rate | 0.325 | ||||||
Trading days | d | 20 | ||||||
Consecutive trading days | d | 30 | ||||||
Percentage of stock price | 130% | ||||||
Redemption price, percentage | 100% | ||||||
Number of preceding days | 2 days | ||||||
Effective interest rate | 2.76% | ||||||
Percent of holders to declare debt and interest immediately payable | 25% | ||||||
Initial conversion rate | 0.0114681 | ||||||
2028 Convertible Senior Notes | Convertible Debt | Measurement Period | |||||||
Debt Instrument [Line Items] | |||||||
Trading days | d | 5 | ||||||
Consecutive trading days | d | 10 | ||||||
Percentage of stock price | 98% | ||||||
Revolving Credit Facility | Term Loan A (TLA) Facility | Secured Debt | |||||||
Debt Instrument [Line Items] | |||||||
Net leverage ratio incremental increase option | 5 | ||||||
Revolving Credit Facility | Term Loan A (TLA) Facility | Secured Debt | Maximum | |||||||
Debt Instrument [Line Items] | |||||||
Net leverage ratio incremental increase option | 5.50 | ||||||
Revolving Credit Facility | ITGRTerm Loan A T L A Facility | Secured Debt | |||||||
Debt Instrument [Line Items] | |||||||
Interest expense ratio | $ / € | 2.50 |
DEBT (Long-term Debt Maturity S
DEBT (Long-term Debt Maturity Schedule) (Details) $ in Thousands | Dec. 31, 2023 USD ($) |
Debt Disclosure [Abstract] | |
2024 | $ 0 |
2025 | 10,000 |
2026 | 27,500 |
2027 | 30,000 |
2028 | $ 406,500 |
DEBT (Deferred Financing Fees)
DEBT (Deferred Financing Fees) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Deferred Finance Costs [Roll Forward] | |||
Total, Beginning Balance | $ 5,977 | ||
Total, Amortization during the period | (8,054) | $ (2,036) | $ (6,954) |
Total, Ending Balance | 14,075 | 5,977 | |
Revolving Credit Facility | |||
Deferred Finance Costs [Roll Forward] | |||
Debt issuance costs, Beginning Balance | 2,387 | ||
Financing costs incurred | 579 | ||
Write-off of debt issuance costs and unamortized discount | (260) | ||
Amortization during the period | (540) | ||
Debt issuance costs, Ending Balance | 2,166 | 2,387 | |
Term Loan And Senior Notes | |||
Deferred Finance Costs [Roll Forward] | |||
Debt issuance costs, Beginning Balance | 4,569 | ||
Financing costs incurred | 1,602 | ||
Write-off of debt issuance costs and unamortized discount | (2,867) | ||
Amortization during the period | (637) | ||
Debt issuance costs, Ending Balance | 2,667 | 4,569 | |
Total, Beginning Balance | 5,977 | ||
Total, Financing costs incurred | 15,352 | ||
Total, Write-off of deferred debt issuance costs and unamortized discount | (4,258) | ||
Total, Amortization during the period | (2,996) | ||
Total, Ending Balance | 14,075 | 5,977 | |
Term Loan B (TLB) Facility | |||
Deferred Finance Costs [Roll Forward] | |||
Debt Discount , Beginning Balance | 1,408 | ||
Debt Discount, financing costs incurred | 13,750 | ||
Debt Discount, Write-off of deferred debt issuance costs and unamortized discount | (1,391) | ||
Debt Discount, Amortization during the period | (2,359) | ||
Debt Discount, Ending Balance | $ 11,408 | $ 1,408 |
BENEFIT PLANS (Savings Plan Nar
BENEFIT PLANS (Savings Plan Narrative) (Details) - USD ($) | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Defined Contribution And Benefit Plan Disclosure [Line Items] | |||
Net costs recognized | $ 9,900,000 | $ 8,800,000 | $ 7,900,000 |
Maximum | |||
Defined Contribution And Benefit Plan Disclosure [Line Items] | |||
Employer matching contribution (in dollars per share) | $ 0.50 | ||
Employer matching contribution, percentage of employees' gross pay | 6% |
BENEFIT PLANS (Defined Benefit
BENEFIT PLANS (Defined Benefit Plans Narrative) (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Retirement Benefits [Abstract] | |||
Aggregated projected benefit obligation | $ 2.9 | $ 2.5 | |
Net periodic pension cost | 0.6 | $ 0.1 | $ 0.5 |
Expected future benefit payments first five years | 1.3 | ||
Expected future benefit payments next five years | $ 2.7 |
STOCK-BASED COMPENSATION (Narra
STOCK-BASED COMPENSATION (Narratives) (Details) - USD ($) | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Number of shares authorized (in shares) | 1,450,000 | ||
Number of shares available for grant (in shares) | 1,088,383 | ||
Stock Options | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Grants in period (in shares) | 0 | 0 | 0 |
Closing stock price (in dollars per share) | $ 99.08 | ||
Total unrecognized compensation cost | $ 0 | ||
Restricted Stock and Restricted Stock Units | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Total unrecognized compensation cost | $ 15,000,000 | ||
Period for recognition | 1 year 9 months 18 days | ||
Fair value of shares vested | $ 9,100,000 | $ 10,700,000 | $ 12,900,000 |
Granted (in dollars per share) | $ 79.03 | $ 75.87 | $ 81.98 |
Performance-Vested | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Total unrecognized compensation cost | $ 10,200,000 | ||
Period for recognition | 1 year 7 months 6 days | ||
Fair value of shares vested | $ 1,800,000 | $ 3,100,000 | |
Granted (in dollars per share) | $ 74.32 | $ 90.84 | $ 85.16 |
Performance period (over) | 3 years | ||
Performance period | 5 years | ||
Illiquidity discount percent | 11.23% | 9.25% | 8.19% |
STOCK-BASED COMPENSATION (Compo
STOCK-BASED COMPENSATION (Components of Stock-Based Compensation Expense) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | |||
Total stock-based compensation expense | $ 23,283 | $ 21,023 | $ 16,185 |
Income tax benefit recognized for stock-based compensation arrangements | 3,692 | 2,908 | 4,188 |
Cost of sales | |||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | |||
Total stock-based compensation expense | 3,709 | 3,240 | 3,365 |
SG&A | |||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | |||
Total stock-based compensation expense | 18,224 | 15,234 | 11,579 |
RD&E | |||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | |||
Total stock-based compensation expense | 1,237 | 1,099 | 969 |
Restructuring and other charges | |||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | |||
Total stock-based compensation expense | $ 113 | $ 1,450 | $ 272 |
STOCK-BASED COMPENSATION (Stock
STOCK-BASED COMPENSATION (Stock Option Activity) (Details) $ / shares in Units, $ in Millions | 12 Months Ended |
Dec. 31, 2023 USD ($) $ / shares shares | |
Number of Stock Options | |
Beginning balance (in shares) | shares | 240,622 |
Exercised (in shares) | shares | (82,533) |
Ending balance (in shares) | shares | 158,089 |
Vested and exercisable, Number of Stock Options (in shares) | shares | 158,089 |
Weighted Average Exercise Price | |
Beginning balance (in dollars per share) | $ / shares | $ 38.51 |
Exercised (in dollars per share) | $ / shares | 35 |
Ending balance (in dollars per share) | $ / shares | 40.35 |
Vested and exercisable, Weighted Average Exercise Price (in dollars per share) | $ / shares | $ 40.35 |
Weighted Average Remaining Contractual Term and Aggregate Intrinsic Value | |
Outstanding, Weighted Average Remaining Contractual Term (in years) | 2 years 10 months 24 days |
Vested and exercisable , Weighted Average Remaining Contractual Term (in years) | 2 years 10 months 24 days |
Outstanding, Aggregate Intrinsic Value | $ | $ 9.3 |
Vested and exercisable , Aggregate Intrinsic Value | $ | $ 9.3 |
STOCK-BASED COMPENSATION (Exerc
STOCK-BASED COMPENSATION (Exercise of Stock Option) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Share-Based Payment Arrangement [Abstract] | |||
Intrinsic value | $ 3,670 | $ 370 | $ 2,370 |
Cash received | 2,303 | 150 | 743 |
Actual tax benefit for the tax deductions from the exercise of options | $ 881 | $ 89 | $ 569 |
STOCK-BASED COMPENSATION (Restr
STOCK-BASED COMPENSATION (Restricted Stock and Restricted Stock Units) (Details) | 12 Months Ended |
Dec. 31, 2023 $ / shares shares | |
Time-Vested | |
Time-Vested and Performance-Vested Activity | |
Beginning balance (in shares) | shares | 291,929 |
Granted (in shares) | shares | 231,604 |
Vested (in shares) | shares | (117,587) |
Forfeited (in shares) | shares | (56,191) |
Ending balance (in shares) | shares | 349,755 |
Weighted Average Grant Date Fair Value | |
Beginning balance (in dollars per share) | $ / shares | $ 77.58 |
Granted (in dollars per share) | $ / shares | 75.77 |
Vested (in dollars per share) | $ / shares | 79.03 |
Forfeited (in dollars per share) | $ / shares | 72.98 |
Ending balance (in dollars per share) | $ / shares | $ 76.63 |
Performance-Vested | |
Time-Vested and Performance-Vested Activity | |
Beginning balance (in shares) | shares | 263,906 |
Granted (in shares) | shares | 105,757 |
Vested (in shares) | shares | (24,427) |
Forfeited (in shares) | shares | (69,733) |
Ending balance (in shares) | shares | 275,503 |
Weighted Average Grant Date Fair Value | |
Beginning balance (in dollars per share) | $ / shares | $ 90.29 |
Granted (in dollars per share) | $ / shares | 74.32 |
Vested (in dollars per share) | $ / shares | 107.26 |
Forfeited (in dollars per share) | $ / shares | 82.72 |
Ending balance (in dollars per share) | $ / shares | $ 84.57 |
STOCK-BASED COMPENSATION (Weigh
STOCK-BASED COMPENSATION (Weighted-Average Fair Value and Assumptions) (Details) - Performance-Vested - $ / shares | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Weighted average fair value (in dollars per share) | $ 74.29 | $ 97.58 | $ 85.16 |
Risk-free interest rate | 3.79% | 1.58% | 0.19% |
Expected volatility | 46% | 42% | 41% |
Expected life (in years) | 3 years | 3 years 10 months 24 days | 3 years |
Expected dividend yield | 0% | 0% | 0% |
RESTRUCTURING AND OTHER CHARG_3
RESTRUCTURING AND OTHER CHARGES (Schedule of Restructuring And Other Charges Components) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Restructuring and Related Activities [Abstract] | |||
Restructuring charges | $ 6,015 | $ 4,920 | $ 4,804 |
Acquisition and integration costs | 3,444 | 10,075 | 2,544 |
Other general expenses | 2,110 | 1,188 | 508 |
Total restructuring and other charges | $ 11,569 | $ 16,183 | $ 7,856 |
RESTRUCTURING AND OTHER CHARG_4
RESTRUCTURING AND OTHER CHARGES (Narrative) (Details) $ in Thousands | 3 Months Ended | 12 Months Ended | ||
Dec. 31, 2023 USD ($) manufacturing_facility | Dec. 31, 2023 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | |
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring charges | $ 6,015 | $ 4,920 | $ 4,804 | |
Acquisition and integration costs | 3,444 | 10,075 | 2,544 | |
Asset impairment | $ 2,000 | |||
Number of manufacturing facilities | manufacturing_facility | 1 | |||
Oscor And Aran Acquisitions | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Acquisition and integration costs | 3,400 | 10,100 | 2,400 | |
Fair value reduction adjustment for acquisition-related contingent consideration liability | 3,100 | |||
InoMec Ltd | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Fair value reduction adjustment for acquisition-related contingent consideration liability | (700) | 300 | $ 100 | |
Strategic reorganization and alignment | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring-related charges incurred | $ 1,700 | 1,700 | ||
Restructuring charges | 1,259 | |||
Employee Severance | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring charges | $ 1,500 | |||
2021 SRA Initiatives | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring-related charges incurred | 5,700 | 5,700 | ||
2021 SRA Initiatives | Minimum | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Expected costs | 6,000 | 6,000 | ||
2021 SRA Initiatives | Maximum | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Expected costs | 7,000 | 7,000 | ||
Research and Product Development Alignment | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring-related charges incurred | 3,600 | 3,600 | ||
Research and Product Development Alignment | Minimum | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Expected costs | 6,000 | 6,000 | ||
Research and Product Development Alignment | Maximum | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Expected costs | 8,000 | 8,000 | ||
Manufactoring Alignment To Support Growth | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring-related charges incurred | 1,200 | 1,200 | ||
Manufactoring Alignment To Support Growth | Minimum | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Expected costs | 2,000 | 2,000 | ||
Manufactoring Alignment To Support Growth | Maximum | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Expected costs | 3,000 | 3,000 | ||
Employee Severance | 2022 OE Initiatives | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring-related charges incurred | 7,100 | 7,100 | ||
Employee Severance | 2022 OE Initiatives | Minimum | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Expected costs | 10,000 | 10,000 | ||
Employee Severance | 2022 OE Initiatives | Maximum | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Expected costs | 12,000 | 12,000 | ||
Employee Severance | 2021 OE Initiatives | ||||
Restructuring Cost and Reserve [Line Items] | ||||
Restructuring-related charges incurred | $ 4,900 | $ 4,900 |
RESTRUCTURING AND OTHER CHARG_5
RESTRUCTURING AND OTHER CHARGES (Schedule of Restructuring Restructuring-Related Costs) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Restructuring Charges [Abstract] | |||
Restructuring charges | $ 6,015 | $ 4,920 | $ 4,804 |
Total restructuring and restructuring-related charges | 10,444 | 9,265 | |
Cost of sales | |||
Restructuring Charges [Abstract] | |||
Total restructuring and restructuring-related charges | 1,669 | 1,148 | |
Selling, general and administrative | |||
Restructuring Charges [Abstract] | |||
Total restructuring and restructuring-related charges | 2,093 | 1,966 | |
Research, development and engineering | |||
Restructuring Charges [Abstract] | |||
Total restructuring and restructuring-related charges | $ 667 | $ 1,231 |
RESTRUCTURING AND OTHER CHARG_6
RESTRUCTURING AND OTHER CHARGES (Schedule of Restructuring Reserve By Type of Cost) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Restructuring Reserve [Roll Forward] | |||
Beginning balance | $ 2,366 | ||
Charges incurred, net of reversals | 6,015 | $ 4,920 | $ 4,804 |
Cash payments | (5,010) | ||
Non-cash adjustments | (1,935) | ||
Ending balance | 1,436 | 2,366 | |
Operational excellence initiatives | |||
Restructuring Reserve [Roll Forward] | |||
Beginning balance | 232 | ||
Charges incurred, net of reversals | 844 | ||
Cash payments | (1,055) | ||
Non-cash adjustments | 0 | ||
Ending balance | 21 | 232 | |
Strategic reorganization and alignment | |||
Restructuring Reserve [Roll Forward] | |||
Beginning balance | 2,134 | ||
Charges incurred, net of reversals | 1,259 | ||
Cash payments | (3,268) | ||
Non-cash adjustments | 0 | ||
Ending balance | 125 | 2,134 | |
Manufacturing alignment to support growth | |||
Restructuring Reserve [Roll Forward] | |||
Beginning balance | 0 | ||
Charges incurred, net of reversals | 3,912 | ||
Cash payments | (687) | ||
Non-cash adjustments | (1,935) | ||
Ending balance | $ 1,290 | $ 0 |
INCOME TAXES (Income Before Inc
INCOME TAXES (Income Before Income Tax Domestic And Foreign) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Income Tax Disclosure [Line Items] | |||
Income (loss) from continuing operations before income taxes | $ 107,294 | $ 75,958 | $ 101,063 |
U.S. | |||
Income Tax Disclosure [Line Items] | |||
Income (loss) from continuing operations before income taxes | 31,001 | 14,446 | 48,293 |
International | |||
Income Tax Disclosure [Line Items] | |||
Income (loss) from continuing operations before income taxes | $ 76,293 | $ 61,512 | $ 52,770 |
INCOME TAXES (Provision Benefit
INCOME TAXES (Provision Benefit of Income Taxes) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Current: | |||
Federal | $ 11,590 | $ 20,455 | $ 9,511 |
State | 1,404 | 780 | 1,553 |
International | 13,140 | 6,871 | 8,459 |
Total | 26,134 | 28,106 | 19,523 |
Deferred: | |||
Federal | (7,451) | (16,300) | (8,665) |
State | (168) | 26 | (393) |
International | (1,871) | (1,224) | (2,422) |
Total | (9,490) | (17,498) | (11,480) |
Total provision for income taxes | $ 16,644 | $ 10,608 | $ 8,043 |
INCOME TAXES (Effect Tax Rate R
INCOME TAXES (Effect Tax Rate Reconciliation) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Effective Income Tax Rate Reconciliation, Amount [Abstract] | |||
Statutory rate | $ 22,531 | $ 15,951 | $ 21,223 |
Federal tax credits (including R&D) | (11,113) | (9,399) | (11,929) |
Foreign rate differential | (5,513) | (7,693) | (5,165) |
Stock-based compensation | 1,862 | 2,009 | (1,084) |
Uncertain tax positions | (1,170) | 2,469 | 18 |
State taxes, net of federal benefit | 1,185 | 978 | 1,183 |
U.S. tax on foreign earnings, net of §250 deduction | 6,090 | 5,225 | 1,913 |
Valuation allowance | 1,737 | (194) | 524 |
Other | 1,035 | 1,262 | 1,360 |
Total provision for income taxes | $ 16,644 | $ 10,608 | $ 8,043 |
Effective Income Tax Rate Reconciliation, Percent [Abstract] | |||
Statutory rate | 21% | 21% | 21% |
Federal tax credits (including R&D) | (10.40%) | (12.40%) | (11.80%) |
Foreign rate differential | (5.10%) | (10.10%) | (5.10%) |
Stock-based compensation | 1.70% | 2.60% | (1.10%) |
Uncertain tax positions | (1.10%) | 3.30% | 0% |
State taxes, net of federal benefit | 1.10% | 1.30% | 1.20% |
U.S. tax on foreign earnings, net of §250 deduction | 5.70% | 6.90% | 1.90% |
Valuation allowance | 1.60% | (0.30%) | 0.50% |
Other | 1% | 1.70% | 1.40% |
Effective tax rate | 15.50% | 14% | 8% |
INCOME TAXES (Deferred Tax Asse
INCOME TAXES (Deferred Tax Assets and Liabilities) (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Components of Deferred Tax Assets and Liabilities [Abstract] | ||
Research and development | $ 27,957 | $ 15,168 |
Operating lease liabilities | 20,726 | 18,781 |
Tax credit carryforwards | 8,989 | 10,110 |
Net operating loss carryforwards | 7,814 | 9,121 |
Accrued expenses | 7,516 | 7,113 |
Original issue discount from capped calls | 7,288 | 0 |
Stock-based compensation | 5,154 | 4,230 |
Inventories | 3,131 | 13,103 |
Gross deferred tax assets | 88,575 | 77,626 |
Less valuation allowance | (15,741) | (16,649) |
Net deferred tax assets | 72,834 | 60,977 |
Intangible assets | (181,737) | (188,976) |
Operating lease assets | (20,851) | (18,846) |
Property, plant and equipment | (7,290) | (6,789) |
Other | (1,580) | (790) |
Gross deferred tax liabilities | (211,458) | (215,401) |
Net deferred tax liability | (138,624) | (154,424) |
Noncurrent deferred tax asset | 7,001 | 6,247 |
Noncurrent deferred tax liability | $ (145,625) | $ (160,671) |
INCOME TAXES (Income Tax Carry
INCOME TAXES (Income Tax Carry Forward) (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Operating Loss Carryforwards [Line Items] | ||
Deferred Tax Asset | $ 7,814 | $ 9,121 |
U.S. State | ||
Operating Loss Carryforwards [Line Items] | ||
Net operating loss | 89,600 | |
Deferred Tax Asset | 3,500 | |
Valuation Allowance | (3,300) | |
U.S. State | R&D tax credits(b) | ||
Operating Loss Carryforwards [Line Items] | ||
Tax credit | 1,000 | |
Deferred Tax Assets, Tax credit | 800 | |
Valuation Allowance | 0 | |
U.S. State | State tax credits(b) | ||
Operating Loss Carryforwards [Line Items] | ||
Tax credit | 3,800 | |
Deferred Tax Assets, Tax credit | 3,000 | |
Valuation Allowance | (3,000) | |
International | ||
Operating Loss Carryforwards [Line Items] | ||
Net operating loss | 18,100 | |
Deferred Tax Asset | 4,300 | |
Valuation Allowance | (4,100) | |
International | R&D tax credits(b) | ||
Operating Loss Carryforwards [Line Items] | ||
Tax credit | 300 | |
Deferred Tax Assets, Tax credit | 300 | |
Valuation Allowance | 0 | |
U.S. Federal | Foreign tax credits | ||
Operating Loss Carryforwards [Line Items] | ||
Tax credit | 4,900 | |
Deferred Tax Assets, Tax credit | 4,900 | |
Valuation Allowance | $ (4,900) |
INCOME TAXES (Unrecognized Tax
INCOME TAXES (Unrecognized Tax Benefits) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] | |||
Balance, beginning of year | $ 7,739 | $ 5,537 | $ 5,484 |
Additions based upon tax positions related to the current year | 356 | 1,364 | 3,324 |
Additions (reductions) related to prior period tax returns | (18) | 838 | (3,271) |
Reductions as a result of a lapse of applicable statute of limitations | (1,607) | 0 | 0 |
Balance, end of year | $ 6,470 | $ 7,739 | $ 5,537 |
INCOME TAXES (Narrative) (Detai
INCOME TAXES (Narrative) (Details) - USD ($) | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 |
Income Tax Disclosure [Abstract] | |||
Reasonably possible reduction within next 12 months | $ 600,000 | ||
Unrecognized tax benefit | 6,400,000 | ||
Unrecognized tax benefits, accrued interest | 300,000 | $ 400,000 | |
Income tax penalties | 0 | 0 | |
Interest and penalties on unrecognized tax benefits | $ 800,000 | $ 500,000 | $ 0 |
COMMITMENTS AND CONTINGENCIES (
COMMITMENTS AND CONTINGENCIES (Narrative) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Gain Contingencies [Line Items] | |||
Loss contingency damages sought | $ 300 | ||
Drawn down from the escrow | 200 | ||
Anticipated future costs remaining | 100 | ||
Accrued environmental loss contingencies, current | $ 100 | ||
Environmental Loss Contingency, Current, Statement of Financial Position [Extensible Enumeration] | Accrued Liabilities, Current | ||
Expenses related to license agreements | $ 1,178,384 | $ 1,017,090 | $ 884,109 |
Self insurance reserve | 7,700 | 6,300 | |
Royalty | |||
Gain Contingencies [Line Items] | |||
Expenses related to license agreements | $ 1,800 | $ 1,700 | $ 1,300 |
LEASES (Schedule of Lease Costs
LEASES (Schedule of Lease Costs) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Lessor, Lease, Description [Line Items] | |||
Amortization of lease assets | $ 1,367 | $ 1,080 | $ 223 |
Interest on lease liabilities | 321 | 317 | 59 |
Finance lease cost | 1,688 | 1,397 | 282 |
Operating lease cost | 14,057 | 13,927 | 10,729 |
Short-term lease cost (leases with initial term of 12 months or less) | 324 | 342 | 137 |
Variable lease cost | 3,041 | 3,026 | 2,619 |
Sublease income | (904) | (1,294) | (1,392) |
Total lease cost | 18,206 | 17,398 | 12,375 |
Cost of sales | |||
Lessor, Lease, Description [Line Items] | |||
Total lease cost | 13,542 | 13,111 | 9,642 |
SG&A | |||
Lessor, Lease, Description [Line Items] | |||
Total lease cost | 3,028 | 2,864 | 1,817 |
RD&E | |||
Lessor, Lease, Description [Line Items] | |||
Total lease cost | 929 | 1,106 | 857 |
Restructuring and other charges | |||
Lessor, Lease, Description [Line Items] | |||
Total lease cost | 386 | 0 | |
Interest expense | |||
Lessor, Lease, Description [Line Items] | |||
Total lease cost | $ 321 | $ 317 | $ 59 |
LEASES (Schedule of Operating L
LEASES (Schedule of Operating Lease Liability Maturities) (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Operating Leases | ||
2024 | $ 12,744 | |
2025 | 12,639 | |
2026 | 12,580 | |
2027 | 12,386 | |
2028 | 11,851 | |
Thereafter | 42,683 | |
Gross lease liabilities | 104,883 | |
Less: imputed interest | (23,852) | |
Present value of lease liabilities | $ 81,031 | |
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] | Accrued Liabilities, Current | Accrued Liabilities, Current |
Less: current portion of lease liabilities | $ (8,692) | $ (10,362) |
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] | Other Liabilities, Noncurrent | Other Liabilities, Noncurrent |
Operating lease liabilities | $ 72,339 | $ 64,049 |
Finance Leases | ||
2024 | 2,411 | |
2025 | 2,449 | |
2026 | 2,011 | |
2027 | 1,681 | |
2028 | 1,296 | |
Thereafter | 4,516 | |
Gross lease liabilities | 14,364 | |
Less: imputed interest | (2,082) | |
Present value of lease liabilities | 12,282 | |
Less: current portion of lease liabilities | (1,894) | (1,093) |
Total long-term lease liabilities | $ 10,388 | $ 8,006 |
LEASES (Lease Term and Discount
LEASES (Lease Term and Discount Rate) (Details) | Dec. 31, 2023 | Dec. 31, 2022 |
Leases [Abstract] | ||
Weighted-average remaining lease term - operating leases (in years) | 9 years 2 months 12 days | 7 years 6 months |
Weighted-average remaining lease term - finance leases (in years) | 7 years 8 months 12 days | 10 years |
Weighted-average discount rate - operating leases | 5.50% | 3.90% |
Weighted-average discount rate - finance leases | 4.40% | 3.40% |
LEASES (Schedule of Operating_2
LEASES (Schedule of Operating Lease Supplemental Cash Flow Information) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Leases [Abstract] | |||
Cash paid for operating leases | $ 13,892 | $ 13,519 | $ 10,808 |
Cash paid for interest on finance leases | 321 | 317 | 59 |
Assets acquired under operating leases | 17,911 | 15,777 | 32,466 |
Assets acquired under finance leases | $ 4,210 | $ 1,882 | $ 8,154 |
EARNINGS PER SHARE (Details)
EARNINGS PER SHARE (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Numerator for basic and diluted EPS: | |||
Income from continuing operations | $ 90,650 | $ 65,350 | $ 93,020 |
Income from discontinued operations | 0 | 1,027 | 3,788 |
Net income | $ 90,650 | $ 66,377 | $ 96,808 |
Denominator for basic EPS: | |||
Weighted average shares outstanding (in shares) | 33,320 | 33,127 | 32,993 |
Effect of dilutive securities stock options, restricted stock and restricted stock units (in shares) | 438 | 230 | 265 |
Denominator for diluted EPS (in shares) | 33,758 | 33,357 | 33,258 |
Basic earnings per share: | |||
Income from continuing operations (in dollars per share) | $ 2.72 | $ 1.97 | $ 2.82 |
Income from discontinued operations (in dollars per share) | 0 | 0.03 | 0.11 |
Basic earnings per share (in dollars per share) | 2.72 | 2 | 2.93 |
Diluted earnings per share: | |||
Income from continuing operations (in dollars per share) | 2.69 | 1.96 | 2.80 |
Income from discontinued operations (in dollars per share) | 0 | 0.03 | 0.11 |
Diluted earnings per share (in dollars per share) | $ 2.69 | $ 1.99 | $ 2.91 |
EARNINGS PER SHARE (Antidilutiv
EARNINGS PER SHARE (Antidilutive Securities) (Details) - $ / shares shares in Thousands | 12 Months Ended | |||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Feb. 28, 2023 | |
Capped Call Options | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Capped call (in shares) | 5,700 | |||
Strike price (in dollars per share) | $ 108.59 | |||
Time-vested stock options, restricted stock and restricted stock units | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Securities excluded from calculation of earnings per share (in shares) | 1 | 15 | 4 | |
Performance-vested restricted stock units | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Securities excluded from calculation of earnings per share (in shares) | 84 | 152 | 92 |
STOCKHOLDERS' EQUITY (Schedule
STOCKHOLDERS' EQUITY (Schedule of Changes in Number of Shares of Common Stock) (Details) - shares | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||
Shares issued and outstanding at beginning of period (in shares) | 33,169,778 | |
Shares issued and outstanding at end of period (in shares) | 33,329,648 | 33,169,778 |
Common Stock | ||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||
Shares issued and outstanding at beginning of period (in shares) | 33,169,778 | 33,063,336 |
Stock options exercised, net of shares exchanged for payment (in shares) | 72,125 | 7,018 |
Shares issued and outstanding at end of period (in shares) | 33,329,648 | 33,169,778 |
RSUs | Common Stock | ||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||
Vesting of RSUs, net of shares withheld to cover taxes (in shares) | 87,745 | 99,424 |
STOCKHOLDERS' EQUITY (Schedul_2
STOCKHOLDERS' EQUITY (Schedule of Accumulated Other Comprehensive Income) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Accumulated Other Comprehensive Income [Roll Forward] | |||
Total stockholders’ equity, beginning balance | $ 1,417,456 | $ 1,354,697 | $ 1,271,055 |
Net-of-Tax Amount | 310 | 3,200 | 2,105 |
Total stockholders’ equity, ending balance | 1,519,042 | 1,417,456 | 1,354,697 |
Defined Benefit Plan Liability | |||
Accumulated Other Comprehensive Income [Roll Forward] | |||
Total stockholders’ equity, beginning balance | (346) | (890) | |
Total Pre-Tax Amount | (318) | (544) | |
Tax | (113) | (35) | |
Net-of-Tax Amount | (205) | (509) | |
Total stockholders’ equity, ending balance | (28) | (346) | (890) |
Cash Flow Hedges | |||
Accumulated Other Comprehensive Income [Roll Forward] | |||
Total stockholders’ equity, beginning balance | 1,760 | (2,291) | |
Total Pre-Tax Amount | (7,008) | (3,649) | |
Tax | (1,472) | (766) | |
Net-of-Tax Amount | (5,536) | (2,883) | |
Total stockholders’ equity, ending balance | 2,153 | 1,760 | (2,291) |
Cash Flow Hedges | Foreign currency hedges | |||
Accumulated Other Comprehensive Income [Roll Forward] | |||
Total Pre-Tax Amount | 5,353 | 516 | |
Tax | 1,124 | 108 | |
Net-of-Tax Amount | 4,229 | 408 | |
Cash Flow Hedges | Interest rate swaps | |||
Accumulated Other Comprehensive Income [Roll Forward] | |||
Total Pre-Tax Amount | 1,262 | (918) | |
Tax | 265 | (193) | |
Net-of-Tax Amount | 997 | (725) | |
Foreign Currency Translation Adjustment | |||
Accumulated Other Comprehensive Income [Roll Forward] | |||
Total stockholders’ equity, beginning balance | 4,150 | 29,720 | |
Total Pre-Tax Amount | (14,379) | 25,570 | |
Tax | 0 | 0 | |
Net-of-Tax Amount | (14,379) | 25,570 | |
Total stockholders’ equity, ending balance | 18,529 | 4,150 | 29,720 |
Total Pre-Tax Amount | |||
Accumulated Other Comprehensive Income [Roll Forward] | |||
Total stockholders’ equity, beginning balance | 5,564 | 26,539 | |
Total stockholders’ equity, ending balance | 20,654 | 5,564 | 26,539 |
Tax | |||
Accumulated Other Comprehensive Income [Roll Forward] | |||
Total stockholders’ equity, beginning balance | (235) | 651 | |
Total stockholders’ equity, ending balance | (431) | (235) | 651 |
Net-of-Tax Amount | |||
Accumulated Other Comprehensive Income [Roll Forward] | |||
Total stockholders’ equity, beginning balance | 5,329 | 27,190 | 52,692 |
Total stockholders’ equity, ending balance | $ 20,223 | $ 5,329 | $ 27,190 |
FINANCIAL INSTRUMENTS AND FAI_3
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Assets and Liabilities Recorded at Fair Value on a Recurring Basis) (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Oct. 01, 2023 | Dec. 31, 2022 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Liabilities: Contingent consideration | $ 900 | ||
Fair Value, Recurring | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Assets: Foreign currency hedging contracts | $ 2,153 | $ 521 | |
Liabilities: Contingent consideration | 876 | 11,756 | |
Assets: Interest rate swap | 1,262 | ||
Liabilities: Foreign currency hedging contracts | 23 | ||
Fair Value, Recurring | Quoted Prices in Active Markets (Level 1) | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Assets: Foreign currency hedging contracts | 0 | 0 | |
Liabilities: Contingent consideration | 0 | 0 | |
Assets: Interest rate swap | 0 | ||
Liabilities: Foreign currency hedging contracts | 0 | ||
Fair Value, Recurring | Significant Other Observable Inputs (Level 2) | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Assets: Foreign currency hedging contracts | 2,153 | 521 | |
Liabilities: Contingent consideration | 0 | 0 | |
Assets: Interest rate swap | 1,262 | ||
Liabilities: Foreign currency hedging contracts | 23 | ||
Fair Value, Recurring | Significant Unobservable Inputs (Level 3) | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Assets: Foreign currency hedging contracts | 0 | 0 | |
Liabilities: Contingent consideration | $ 876 | 11,756 | |
Assets: Interest rate swap | 0 | ||
Liabilities: Foreign currency hedging contracts | $ 0 |
FINANCIAL INSTRUMENTS AND FAI_4
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of Interest Rate Swaps) (Details) - Designated as Hedging Instrument - Interest Rate Swap Maturing June 2023 - Prepaid expenses and other current assets | Dec. 31, 2023 USD ($) |
Derivatives, Fair Value [Line Items] | |
Notional Amount | $ 100,000,000 |
Pay Fixed Rate | 2.1785% |
Receive Current Floating Rate | 4.3869% |
Fair Value | $ 1,262,000 |
FINANCIAL INSTRUMENTS AND FAI_5
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of Foreign Currency Contracts) (Details) - Designated as Hedging Instrument $ in Thousands | Dec. 31, 2023 USD ($) $ / € $ / $ | Dec. 31, 2022 USD ($) $ / $ $ / € $ / $ |
Prepaid expenses and other current assets | Forex Contract Maturing December 2024 | ||
Derivatives, Fair Value [Line Items] | ||
Notional Amount | $ 51,389 | |
$/Foreign currency (in dollars per foreign currency) | $ / € | 1.0831 | |
Fair Value | $ 1,389 | |
Prepaid expenses and other current assets | Forex Contract Maturing December 2024 | ||
Derivatives, Fair Value [Line Items] | ||
Notional Amount | $ 19,392 | |
$/Foreign currency (in dollars per foreign currency) | $ / $ | 0.0566 | |
Fair Value | $ 182 | |
Prepaid expenses and other current assets | Forex Contract Maturing December 2024 | ||
Derivatives, Fair Value [Line Items] | ||
Notional Amount | $ 19,201 | |
$/Foreign currency (in dollars per foreign currency) | $ / € | 0.0248 | |
Fair Value | $ 582 | |
Prepaid expenses and other current assets | Forex Contract Maturing December 2023 | ||
Derivatives, Fair Value [Line Items] | ||
Notional Amount | $ 37,175 | |
$/Foreign currency (in dollars per foreign currency) | $ / $ | 0.0489 | |
Fair Value | $ 504 | |
Prepaid expenses and other current assets | Forex Contract Maturing March 2023 | ||
Derivatives, Fair Value [Line Items] | ||
Notional Amount | $ 2,685 | |
$/Foreign currency (in dollars per foreign currency) | $ / € | 0.0249 | |
Fair Value | $ 17 | |
Accrued Expenses And Other Current Liabilities | Forex Contract Maturing March 2023 | ||
Derivatives, Fair Value [Line Items] | ||
Notional Amount | $ 17,309 | |
$/Foreign currency (in dollars per foreign currency) | $ / $ | 1.0751 | |
Fair Value | $ (23) |
FINANCIAL INSTRUMENTS AND FAI_6
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of Derivative Instruments with Hedge Accounting Designation) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Interest expense | |||
Derivative Instruments and Hedging Activities Disclosures [Line Items] | |||
Gain (Loss) Reclassified from AOCI | $ 1,262 | $ (918) | $ (3,406) |
Interest expense | Interest rate swaps | |||
Derivative Instruments and Hedging Activities Disclosures [Line Items] | |||
Gain (Loss) Recognized in OCI | 0 | 3,322 | 642 |
Sales | |||
Derivative Instruments and Hedging Activities Disclosures [Line Items] | |||
Gain (Loss) Reclassified from AOCI | (241) | (2,073) | (674) |
Sales | Foreign exchange contracts | |||
Derivative Instruments and Hedging Activities Disclosures [Line Items] | |||
Gain (Loss) Recognized in OCI | 1,171 | (2,226) | (943) |
Cost of sales | |||
Derivative Instruments and Hedging Activities Disclosures [Line Items] | |||
Gain (Loss) Reclassified from AOCI | 5,611 | 2,205 | 1,437 |
Cost of sales | Foreign exchange contracts | |||
Derivative Instruments and Hedging Activities Disclosures [Line Items] | |||
Gain (Loss) Recognized in OCI | 5,666 | 2,225 | 399 |
Operating expenses | |||
Derivative Instruments and Hedging Activities Disclosures [Line Items] | |||
Gain (Loss) Reclassified from AOCI | (17) | 384 | 69 |
Operating expenses | Foreign exchange contracts | |||
Derivative Instruments and Hedging Activities Disclosures [Line Items] | |||
Gain (Loss) Recognized in OCI | $ 171 | $ 328 | $ (7) |
FINANCIAL INSTRUMENTS AND FAI_7
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Narratives) (Details) - USD ($) | 3 Months Ended | 12 Months Ended | |||||
Oct. 01, 2023 | Apr. 06, 2022 | Dec. 31, 2023 | Dec. 31, 2021 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |||||||
Reclassification of net losses from accumulated OCI to income, estimated net amount to be transferred | $ 2,200,000 | ||||||
Contingent consideration liability, current | $ 0 | 0 | $ 11,201,000 | ||||
Contingent consideration | $ 900,000 | ||||||
Non-marketable securities impairment | 5,200,000 | $ 100,000 | |||||
Non-marketable securities fair value | 200,000 | $ 0 | 200,000 | $ 0 | |||
Equity method investment, return of capital | 300,000 | 2,200,000 | |||||
2028 Convertible Senior Notes | Significant Other Observable Inputs (Level 2) | Convertible Debt | |||||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |||||||
Fair value | $ 635,000,000 | $ 635,000,000 | |||||
Chinese Venture Capital Fund | |||||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |||||||
Percentage of ownership interest | 7.50% | 7.50% | |||||
Fair Value, Recurring | |||||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |||||||
Contingent consideration | $ 876,000 | $ 876,000 | 11,756,000 | ||||
Fair Value, Recurring | Significant Other Observable Inputs (Level 2) | |||||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |||||||
Contingent consideration | 0 | 0 | 0 | ||||
US BioDesign LLC | |||||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |||||||
Cash paid | 500,000 | ||||||
Fair value increase (reduction) adjustment for acquisition-related contingent consideration liability | (600,000) | ||||||
US BioDesign LLC | Fair Value, Recurring | |||||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |||||||
Contingent consideration | 0 | 0 | 0 | ||||
InoMec Ltd | |||||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |||||||
Contingent consideration liability, noncurrent | 900,000 | 900,000 | 600,000 | ||||
Contingent consideration liability, current | 11,200,000 | ||||||
Contingent consideration | 900,000 | 900,000 | |||||
Cash paid | 300,000 | 500,000 | |||||
Fair value increase (reduction) adjustment for acquisition-related contingent consideration liability | (700,000) | 300,000 | 100,000 | ||||
InoMec Ltd | Fair Value, Recurring | |||||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |||||||
Contingent consideration | 0 | 0 | 1,100,000 | ||||
Aran Acquisition | |||||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |||||||
Contingent consideration liability, current | 10,700,000 | ||||||
Contingent consideration | $ 7,400,000 | ||||||
Cash paid | $ 133,900,000 | 10,900,000 | |||||
Fair value increase (reduction) adjustment for acquisition-related contingent consideration liability | 3,400,000 | ||||||
InNeuroCo | |||||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |||||||
Contingent consideration | 900,000 | 900,000 | 900,000 | ||||
Cash paid | $ 43,600,000 | ||||||
Foreign Exchange Contract | Not Designated as Hedging Instrument | |||||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |||||||
Notional amount | $ 23,000,000 | 23,000,000 | 12,000,000 | ||||
Foreign exchange contracts | Not Designated as Hedging Instrument | |||||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | |||||||
Gain recognized in OCI | $ 400,000 | $ 2,600,000 | $ 400,000 |
FINANCIAL INSTRUMENTS AND FAI_8
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Estimated Fair Values for Contingent Consideration) (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||
Balance at beginning of period | $ 11,756 | $ 2,415 |
Amount recorded for current year acquisitions | $ 876 | $ 7,375 |
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] | Restructuring And Other Charges, Net | Restructuring And Other Charges, Net |
Fair value measurement adjustment | $ (736) | $ 3,097 |
Payments | (11,177) | (972) |
Foreign currency translation | 157 | (159) |
Balance at end of period | $ 876 | $ 11,756 |
FINANCIAL INSTRUMENTS AND FAI_9
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Equity Method Investments) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Fair Value Disclosures [Abstract] | |||
Equity method investment | $ 7,771 | $ 8,252 | |
Non-marketable equity securities | 427 | 5,637 | |
Total equity investments | 8,198 | 13,889 | |
Equity method investment loss | 481 | 7,636 | $ 3,057 |
Impairment charges | 5,210 | 0 | 86 |
Total loss on equity investments, net | $ 5,691 | $ 7,636 | $ 3,143 |
SEGMENT AND GEOGRAPHIC INFORM_3
SEGMENT AND GEOGRAPHIC INFORMATION (Narrative) (Details) | 12 Months Ended |
Dec. 31, 2023 segment | |
Segment Reporting [Abstract] | |
Number of reportable segments | 2 |
SEGMENT AND GEOGRAPHIC INFORM_4
SEGMENT AND GEOGRAPHIC INFORMATION (Sales by Product Lines) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Segment Reporting, Revenue Reconciling Item [Line Items] | |||
Sales | $ 1,596,673 | $ 1,376,096 | $ 1,221,079 |
Medical | |||
Segment Reporting, Revenue Reconciling Item [Line Items] | |||
Sales | 1,553,340 | 1,329,551 | 1,182,626 |
Medical | Cardio & Vascular | |||
Segment Reporting, Revenue Reconciling Item [Line Items] | |||
Sales | 836,342 | 699,469 | 593,117 |
Medical | Cardiac Rhythm Management & Neuromodulation | |||
Segment Reporting, Revenue Reconciling Item [Line Items] | |||
Sales | 610,577 | 532,580 | 502,288 |
Medical | Advanced Surgical, Orthopedics & Portable Medical | |||
Segment Reporting, Revenue Reconciling Item [Line Items] | |||
Sales | 106,421 | 97,502 | 87,221 |
Non-Medical | |||
Segment Reporting, Revenue Reconciling Item [Line Items] | |||
Sales | $ 43,333 | $ 46,545 | $ 38,453 |
SEGMENT AND GEOGRAPHIC INFORM_5
SEGMENT AND GEOGRAPHIC INFORMATION (Sales by Geographic Information) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Segment Reporting, Revenue Reconciling Item [Line Items] | |||
Total sales | $ 1,596,673 | $ 1,376,096 | $ 1,221,079 |
U.S. | |||
Segment Reporting, Revenue Reconciling Item [Line Items] | |||
Total sales | 897,429 | 762,134 | 671,502 |
PUERTO RICO | |||
Segment Reporting, Revenue Reconciling Item [Line Items] | |||
Total sales | 108,421 | 114,078 | 110,162 |
Costa Rica | |||
Segment Reporting, Revenue Reconciling Item [Line Items] | |||
Total sales | 89,573 | 76,140 | 66,975 |
Rest of world | |||
Segment Reporting, Revenue Reconciling Item [Line Items] | |||
Total sales | $ 501,250 | $ 423,744 | $ 372,440 |
SEGMENT AND GEOGRAPHIC INFORM_6
SEGMENT AND GEOGRAPHIC INFORMATION (Significant Customers) (Details) - Customer Concentration Risk - Sales | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Customer A | |||
Revenue, Major Customer [Line Items] | |||
Concentration risk percentage | 17% | 17% | 18% |
Customer B | |||
Revenue, Major Customer [Line Items] | |||
Concentration risk percentage | 15% | 16% | 16% |
Customer C | |||
Revenue, Major Customer [Line Items] | |||
Concentration risk percentage | 13% | 13% | 13% |
Medical | Customer A | |||
Revenue, Major Customer [Line Items] | |||
Concentration risk percentage | 17% | 17% | |
Medical | Customer B | |||
Revenue, Major Customer [Line Items] | |||
Concentration risk percentage | 16% | 17% | |
Medical | Customer C | |||
Revenue, Major Customer [Line Items] | |||
Concentration risk percentage | 13% | 13% | |
Medical | All other customers | |||
Revenue, Major Customer [Line Items] | |||
Concentration risk percentage | 54% | 53% | |
Non-Medical | Customer D | |||
Revenue, Major Customer [Line Items] | |||
Concentration risk percentage | 19% | 30% | |
Non-Medical | All other customers | |||
Revenue, Major Customer [Line Items] | |||
Concentration risk percentage | 81% | 70% |
SEGMENT AND GEOGRAPHIC INFORM_7
SEGMENT AND GEOGRAPHIC INFORMATION (Schedule of Revenue by Ship To Location) (Details) - Sales - Geographic Concentration Risk | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
United States | Medical | ||
Segment Reporting Information [Line Items] | ||
Concentration risk percentage | 56% | 55% |
United States | Non-Medical | ||
Segment Reporting Information [Line Items] | ||
Concentration risk percentage | 62% | 67% |
Canada | Non-Medical | ||
Segment Reporting Information [Line Items] | ||
Concentration risk percentage | 10% | |
United Kingdom | Non-Medical | ||
Segment Reporting Information [Line Items] | ||
Concentration risk percentage | 10% | |
Rest of world | Medical | ||
Segment Reporting Information [Line Items] | ||
Concentration risk percentage | 44% | 45% |
Rest of world | Non-Medical | ||
Segment Reporting Information [Line Items] | ||
Concentration risk percentage | 28% | 23% |
SEGMENT AND GEOGRAPHIC INFORM_8
SEGMENT AND GEOGRAPHIC INFORMATION (Reconciliation of Segment Information) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Segment Reporting Information [Line Items] | |||
Operating income as reported | $ 167,330 | $ 121,327 | $ 135,711 |
Unallocated expenses, net | (60,036) | (45,369) | (34,648) |
Income from continuing operations before income taxes | 107,294 | 75,958 | 101,063 |
Depreciation and amortization | 98,841 | 91,991 | 81,369 |
Identifiable assets | 2,942,653 | 2,794,386 | |
Expenditures for tangible long-lived assets | 119,938 | 74,728 | 53,463 |
Operating Segments | |||
Segment Reporting Information [Line Items] | |||
Operating income as reported | 272,695 | 213,448 | 221,622 |
Depreciation and amortization | 94,453 | 87,921 | 76,533 |
Identifiable assets | 2,861,234 | 2,709,742 | |
Expenditures for tangible long-lived assets | 115,593 | 70,047 | 48,992 |
Operating Segments | Medical | |||
Segment Reporting Information [Line Items] | |||
Operating income as reported | 269,513 | 205,877 | 213,600 |
Depreciation and amortization | 93,242 | 86,825 | 75,366 |
Identifiable assets | 2,807,249 | 2,652,357 | |
Expenditures for tangible long-lived assets | 114,886 | 69,687 | 48,364 |
Operating Segments | Non-Medical | |||
Segment Reporting Information [Line Items] | |||
Operating income as reported | 3,182 | 7,571 | 8,022 |
Depreciation and amortization | 1,211 | 1,096 | 1,167 |
Identifiable assets | 53,985 | 57,385 | |
Expenditures for tangible long-lived assets | 707 | 360 | 628 |
Unallocated operating expenses | |||
Segment Reporting Information [Line Items] | |||
Operating income as reported | (105,365) | (92,121) | (85,911) |
Depreciation and amortization | 4,388 | 4,070 | 4,836 |
Identifiable assets | 81,419 | 84,644 | |
Expenditures for tangible long-lived assets | $ 4,345 | $ 4,681 | $ 4,471 |
SEGMENT AND GEOGRAPHIC INFORM_9
SEGMENT AND GEOGRAPHIC INFORMATION (Long lived Tangible Assets by Region) (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Segment Reporting, Asset Reconciling Item [Line Items] | ||
Long-lived tangible assets | $ 407,954 | $ 317,243 |
United States | ||
Segment Reporting, Asset Reconciling Item [Line Items] | ||
Long-lived tangible assets | 234,246 | 203,578 |
Ireland | ||
Segment Reporting, Asset Reconciling Item [Line Items] | ||
Long-lived tangible assets | 118,965 | 61,356 |
Mexico | ||
Segment Reporting, Asset Reconciling Item [Line Items] | ||
Long-lived tangible assets | 34,785 | 32,360 |
Rest of world | ||
Segment Reporting, Asset Reconciling Item [Line Items] | ||
Long-lived tangible assets | $ 19,958 | $ 19,949 |
REVENUE FROM CONTRACTS WITH C_3
REVENUE FROM CONTRACTS WITH CUSTOMERS (Schedules of Concentration of Risk by Revenue and Accounts Receivable) (Details) | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Disaggregation of Revenue [Line Items] | |||
Percent of revenue from contract with customer compared to total revenue | 31% | 30% | |
Sales | Customer Concentration Risk | Top Customers | |||
Disaggregation of Revenue [Line Items] | |||
Concentration risk percentage | 45% | 46% | 47% |
Sales | Customer Concentration Risk | Customer A | |||
Disaggregation of Revenue [Line Items] | |||
Concentration risk percentage | 17% | 17% | 18% |
Sales | Customer Concentration Risk | Customer B | |||
Disaggregation of Revenue [Line Items] | |||
Concentration risk percentage | 15% | 16% | 16% |
Sales | Customer Concentration Risk | Customer C | |||
Disaggregation of Revenue [Line Items] | |||
Concentration risk percentage | 13% | 13% | 13% |
Accounts Receivable | Customer Concentration Risk | Top Customers | |||
Disaggregation of Revenue [Line Items] | |||
Concentration risk percentage | 29% | 44% | |
Accounts Receivable | Customer Concentration Risk | Customer A | |||
Disaggregation of Revenue [Line Items] | |||
Concentration risk percentage | 11% | 14% | |
Accounts Receivable | Customer Concentration Risk | Customer B | |||
Disaggregation of Revenue [Line Items] | |||
Concentration risk percentage | 8% | 19% | |
Accounts Receivable | Customer Concentration Risk | Customer C | |||
Disaggregation of Revenue [Line Items] | |||
Concentration risk percentage | 10% | 11% |
REVENUE FROM CONTRACTS WITH C_4
REVENUE FROM CONTRACTS WITH CUSTOMERS (Schedule of Contract Assets and Contract Liabilities) (Details) - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
Revenue from Contract with Customer [Abstract] | ||
Contract assets | $ 85,871 | $ 71,927 |
Contract liabilities | $ 6,142 | $ 5,616 |
REVENUE FROM CONTRACTS WITH C_5
REVENUE FROM CONTRACTS WITH CUSTOMERS - Narrative (Details) - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Revenue from Contract with Customer [Abstract] | ||
Increase in contract assets due to amendments of a contract | $ 13.9 | |
Contract with customer, liability, revenue recognized | $ 3.6 | $ 2.7 |
DISCONTINUED OPERATIONS (AS&O B
DISCONTINUED OPERATIONS (AS&O Business Narrative) (Details) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||
Discontinued Operation, Gain on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration] | Income from discontinued operations before income taxes | Income from discontinued operations before income taxes | |
Discontinued Operations, disposed-by-sale | AS&O Product Line | |||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||
Discontinued operation, gain on disposal of discontinued operation, net of tax | $ 0 | $ 1.3 | $ 4.9 |
DISCONTINUED OPERATIONS (Income
DISCONTINUED OPERATIONS (Income from Discontinued Operations) (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||
Provision for income taxes | $ 0 | $ 296 | $ 1,143 |
Income from discontinued operations | $ 0 | 1,027 | 3,788 |
AS&O Product Line | Discontinued Operations, Held-for-sale | |||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | |||
Other income, net | (1,323) | (4,931) | |
Provision for income taxes | 296 | 1,143 | |
Income from discontinued operations | $ 1,027 | $ 3,788 |
DISCONTINUED OPERATIONS (Cash F
DISCONTINUED OPERATIONS (Cash Flow Information from Discontinued Operations) (Details) - AS&O Product Line - Discontinued Operations, Held-for-sale - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2022 | Dec. 31, 2021 | |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||
Income from discontinued operations | $ 1,027 | $ 3,788 |
Changes in operating assets and liabilities, net of acquisitions: | ||
Accrued expenses and other liabilities | (1,323) | (4,931) |
Income taxes payable | 296 | 1,143 |
Net cash provided by operating activities | $ 0 | $ 0 |
SUBSEQUENT EVENTS (Details)
SUBSEQUENT EVENTS (Details) - USD ($) $ in Millions | Jan. 05, 2024 | Oct. 01, 2023 |
Subsequent Event [Line Items] | ||
Liabilities: Contingent consideration | $ 0.9 | |
Subsequent Event | Pulse Technologies | ||
Subsequent Event [Line Items] | ||
Percentage of business acquired | 100% | |
Consideration transferred | $ 138.2 | |
Liabilities: Contingent consideration | $ 20 |
Schedule II - Valuation and Q_2
Schedule II - Valuation and Qualifying Accounts (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Provision for credit losses | |||
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] | |||
Balance at beginning of period | $ 338 | $ 132 | $ 155 |
Charged to Costs & Expenses | 74 | 48 | 20 |
Charged to Other Accounts- Describe | 1 | 163 | 0 |
Deductions | (42) | (5) | (43) |
Balance at end of period | 371 | 338 | 132 |
Valuation allowance for deferred tax assets | |||
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] | |||
Balance at beginning of period | 16,649 | 19,456 | 20,739 |
Charged to Costs & Expenses | 3,267 | (684) | (941) |
Charged to Other Accounts- Describe | (14) | (131) | 26 |
Deductions | (4,161) | (1,992) | (368) |
Balance at end of period | $ 15,741 | $ 16,649 | $ 19,456 |